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Abstract: miRNAs as potential tools for ‘miR’-aculuous CHO cell phenotypes in 
Bioprocessing systems 
Chinese Hamster Ovary (CHO) cells are the biopharmaceutical industry’s “mini 
biofactories” for the production of complex, post-translationally modified therapeutic 
proteins. In order to address the ever-growing market need for these recombinant 
proteins, various genetic engineering tools have been employed. Here, we describe 
genetic approaches to improve CHO cell culture longevity, with a view to increasing 
overall process yield via the manipulation of two miRNAs: Let-7a and miR-7. 
Previous miRNA profiling studies in our laboratory and in the published literature 
helped in the identification of these miRNAs, which have shown to be disregulated in 
various tumor types and are key regulators of the cell cycle. Therefore, this stimulated 
the interest of our research group to manipulate these miRNAs in CHO cells with a 
view to positively impact bioprocess-relevant CHO cell phenotypes. 
In the first approach, we used a Let-7 sponge decoy vector to deplete endogenous Let-
7 levels with a view to increasing culture longevity and productivity of CHO-K1 
SEAP expressing cells. Despite let-7 having a recognised role in deregulated cell 
growth no improvement was observed in stable, sponge-transfected clones. Out of a 
panel of 40 clones, we observed only two with improved cellular viability in 24 well 
plate format, however, the results were not reproduced in a 5 mL scale-up batch 
study. In the second approach, we targeted a previously verified miRNA for improved 
CHO cell growth and productivity i.e. miR-7, using a bacterial genome-editing tool, 
CRISPR-Cas9. A considerable amount of optimisation work was performed to 
establish the CRISPR system for use in the lab, initially using eGFP as model target 
gene in CHO cells. Finally we designed single guide RNAs to target Cas9 to the miR-
7a-5p genomic locus to disrupt miR-7 in order to enhance growth of a CHO-K1 cell 
line producing an IgG-1. We estimated ~ 40% targeting efficiency of miRNAs using 
this approach. After an extensive screen, one stable clone was identified with what 
appeared to be a heterozygous deletion of one miR-7a copy. We demonstrate that 
CRISPR-Cas9 can be successfully used to target miRNA loci in the CHO genome but 
that functional knockout may be more difficult compared to protein coding genes. 
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1.1 Chinese Hamster Ovary cells – major “biofactories” for the production of 
biopharmaceuticals 
 
Chinese hamster ovary (CHO) cells are the ‘primary workhorse’ of the 
biopharmaceutical industry with more than two-third (~ 70%) of current recombinant 
therapeutic products on the market produced in CHO cells. Owing to the inherent 
ability of CHO cells to produce human-like post-translational modifications and 
glycosylation patterns in the final protein product, they have earned the status of 
being the primary host choice for the production of recombinant therapeutic products 
(Jayapal et al. 2007a). CHO cells are favoured host for producing many recombinant 
therapeutic proteins over microbial counterparts, which lack the ability of to produce 
recombinant proteins with desired glycosylation patterns that are both compatible and 
bioactive in humans. The FDA approval of the first recombinant protein produced 
using CHO i.e. recombinant tissue plasminogen activator (r-tPA), (Activase 
commercially) in 1987 by Genentech, was the ‘launchpad’ for the manufacture of 
other CHO-based therapeutics. By 2011 there were 19 newly FDA approved 
biopharmaceuticals in the United States (US) and European Union (EU) combined 
(Table 1.1 outlines list of some selected FDA/EU approved biologics in CHO) 
(Walsh 2011 and Walsh 2012). Of these 19 new recombinant products, 14 were 
produced using CHO expression systems (Walsh 2012). Globally, the current annual 
sales of recombinant therapeutics reported is ~ US $120 billion, of which US $70 
billion sales per annum constituted by biologics produced using CHO cells. This 
emphasises how greatly the biotechnology industry depends upon CHO cells. 
Moreover, CHO cells will provide a large contribution to the development of 
biotechnology industry in future to meet the predicted US $150 billion world annual 
sales of biologics in 2015 (Jayapal et al. 2007a). 
The growth of biopharmaceuticals has overtaken the growth of small molecule 
therapeutics. Monoclonal antibodies (mAbs) dominate the biologics market currently 
(Figure 1.1) in comparison to other recombinant therapeutic products. According to 
Business Communications Company’s (BCC) research predictions the global sales of 
mAbs in 2016 will increase to US $58 billion by 2016 from US $44.6 billion in 2011 
(BCC research 2012).  
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Figure 1.1: Biologics market distribution 2011 data. Data adapted from Aggarwal, S Nature 
Biotechnol. 29(12) 1083-1089, 2011. 
 
 
Table 1.1: Recombinant therapeutics products produced using CHO cells as expression systems 
(Jayapal et al. 2007b, Animal Cell Technology Industrial Platform 2012 & 2013). 
Biologics  Type Therapeutic 
Application 
Company Approved 
Zaltrap 
(aflibercept) 
Fusion Protein consisting of 
VEGF receptors 1 and 2 
binding domains fused to an 
IgG Fc. 
Metastatic 
colorectal 
cancer 
Regeneron 
/Sanofi-aventis 
2013 (EU) 
2012 (USA) 
Rixubis Recombinant coagulation 
factor IX 
Hemophilia B Baxter 2013 (USA) 
Perjeta 
(pertuzumab) 
Humanized mAb specific for 
HER2 
Breast Cancer Roche 
(Genentech) 
2013 (EU) 
2012 (USA) 
Ovaleap 
(follitropin alfa) 
Biosimilar recombinant 
human follicle stimulating 
hormone. 
Infertility 
/subfertility 
Teva 2013 (EU) 
NovoEight 
(turoctocog alfa) 
Modified factor VIII Haemo-philia A Novo 2013 (EU & USA) 
Gazyva 
(obinutuzumab) 
Humanized, glycol-engineered 
mAb specific for CD20 
expressed on B lymphocytes. 
Chronic 
lymphocytic 
leukemia 
Roche 
(Genentech) 
2013 (USA) 
Yervoy Human mAb binds to Melanoma Bristol-Myers 2011 (EU & USA) 
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(Ipilimumab) cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4, 
a negative regulator of T-cell 
activation) 
Squibb (BMS) 
Nulojix 
(belatacept) 
Fusion protein consisting of 
extracellular domain of human 
CTLA-4 fused to IgG Fc. 
Prophylaxis of 
organ rejection 
following 
kidney 
transplant 
BMS 2011 (EU & USA) 
Eylea (aflibercept) Fusion protein consisting of 
extracellular ligand binding 
domains of VEGF receptor 
fused to IgG Fc 
Neovascular 
(wet) age-
related macular 
de-generation 
Regeneron 2011 (EU & USA) 
Adcetris 
(brentuximabveodti
n) 
Chimeric mAb conjugate 
specific for human CD 30 
(expressed on the surface of 
lymphoma cells) 
Lymphoma Seattle genetics 2011 (USA) 
Prolia (denosumab) Human mAb specific for 
Receptor activator of nuclear 
factor kappa-B ligand 
(RANK) ligand 
Osteoporo-sis in 
post-
menopausal 
women 
Amgen 2010 (EU & USA) 
Lumizyme 
(alglucosidas-e 
alfa) 
Recombinant human acid-alfa-
glucosidase 
Pompe disease 
(glycogen 
storage disease 
type III) 
Genzyme 2010 (US) 
Elonva 
(corifollitrop-in 
alfa) 
Modified recombinant human 
follicle stimulating hormone  
Controlled 
ovarian 
stimulation 
N.V Organon 2010 (EU) 
Stelara 
(usetekinumab) 
Humanized mAb for 
interleukin (IL)-12/23 
Psoriasis Centocor/Johnson 
& Johnson (J&J 
2009 (EU & USA) 
Abseamed 
(epoeietin-alfa) 
Hormone 
Red blood cell progenitor 
Anaemia Medice 
Arzneimittel 
Putter 
2007 (EU) 
Vectibix 
(panitumuma-b) 
Humanized mAb 
Epidermal growth factor 
(EGF) receptor 
Colorectal 
cancer 
Amgen 2006 (USA) 
2007 (EU) 
Proxinium 
(catumaxom-ab) 
Humanized mAb 
Epithelial cell adhesion 
molecule (EpCAM) target 
Head and Neck 
cancer 
Viventia Biotech 2005 (EU & USA) 
Aldurazyme Enzyme alfa-L-iduronidase  Mucopolysacch Genzyme 2003 (EU & USA) 
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(iduronidase) aridosis type I 
(MPS-I) 
/Biomarin 
Opgenra 
(eptotermin alfa 
Osteogenic protein 1 Alternative to 
autograft 
Stryker Biotech 2002 (EU) 
2001 (USA) 
Herceptin 
(trastuzumab) 
Chimeric mAb for human 
epidermal growth factor 2 
(HER2) receptor 
Breast cancer Genentech 2000 (EU) 
1998 (USA) 
Epogen/ Procrit Cytokine/receptor 
antagonist/growth factor 
Anaemia Genentech 1989 (USA) 
Activase (alteplase) Enzyme for tPA as target Acute 
myocardial 
infection 
Genentech 2002 (EU) 
1987 (USA) 
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Therefore, in order to meet the ever growing global biologics market demand, the 
production process for biologics using the well-accepted CHO cell line still needs to 
be optimized. Over the past two decades, product titres have been improved 
considerably. This is mainly attributed to medium development as well as optimized 
feed strategies and approximately 20-fold due to improved vector expression systems 
and producer clone isolation process. However, the advent of complex therapeutics 
such as antibody fragments, fusion proteins and others, has presented new challenges 
to the current process of bio-manufacturing recombinant proteins using CHO cell 
systems. Therefore, there is still an issue to be addressed in the area of optimization of 
biologics production process (Hacker, De Jesus and Wurm 2009, De Jesus and Wurm 
2011, Butler and Meneses-Acosta 2012) 
In the past, there have been various approaches to augment CHO cell performance 
both at the bioprocess engineering level such as using biphasic mode of CHO cell 
cultivation and at the molecular biology level i.e. single and/or multi-gene, vector 
engineering and other approaches to establish a robust and stable CHO cell line. In 
terms of manipulating the bioprocess and maintaining a stable ‘happy’ 
microenvironment, critical process parameters (CPPs) such as pH, temperature, 
osmolality, dissolved oxygen (D.O), feed supplement are monitored and regulated 
accordingly (Kaufmann et al. 1999, Yoon, Song and Lee 2003, Fox et al. 2004, 
Kumar et al. 2008). For instance, specific productivity in the CHO cell culture 
production processes has been enhanced by using serum-free media (Butler 2005a). 
The combined use of hyper-osmolality and/or a low temperature strategy with the 
chemical supplementation of histone deacetylase inhibitors such as sodium butyrate 
or valproic acid have also been employed to boost specific productivity (Matasci et al. 
2009, Kantardjieff et al. 2010a, Sunley and Butler 2010). 
At the genetic engineering level, single and/or multi-gene targeting strategies to target 
various genes in CHO cells with a view to improve specific productivity include cell 
engineering through anti-apoptosis (Kim and Lee 2000a, Sauerwald, Oyler and 
Betenbaugh 2003, Sung et al. 2007), autophagy (Hwang and Lee 2009), cell-cycle 
engineering (Mazur et al. 1998a, Astley and Al-Rubeai 2008). Various protein-based 
engineering approaches such as chaperone (Hwang, Chung and Lee 2003, Chung et 
al. 2004a, Mohan et al. 2007), unfolded protein response-based (UPR) (Tigges and 
Fussenegger 2006), secretion (Florin et al. 2009), metabolic engineering (Zhang et al. 
2006, Wlaschin and Hu 2007) and glycosylation engineering (Ferrara et al. 2006) 
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have also been explored. One of the other important genetic engineering approaches is 
vector engineering (Wurm 2004, Davies et al. 2013). Most of these approaches have 
been discussed in separate sections later.  
Glycosylation plays a central role in controlling the composition of glycans, which 
enhance the pharmacological properties of therapeutic recombinant protein products. 
For example, the effector function of an antibody i.e. antibody-dependent cell 
cytotoxicity (ADCC), in the case of the major blockbuster drug HerceptinTM, has been 
elevated by reducing the core fucosylation of the biantennary-glycan on the Fc region 
of antibody. The maintenance and manipulation of the CPPs to cater for a ‘happy’ 
culture environment for CHO cells is required since CPPs could impact on the 
recombinant protein quality, which in turn could seriously impact the bioactivity 
profile of these biological molecules. Therefore, engineering CHO cells as well as the 
bioprocess can result in increased volumetric or specific productivity of the 
therapeutic protein products with desired pharmacological properties (Zanghi et al. 
1998, Yang and Butler 2000, Okazaki et al. 2004). 
 
1.2 CHO-mics’ 
 
1.2.1 Genomics  
 
The success story of CHO cells, so far, has also been further enhanced by the 
publication of ‘omics data for mouse (Mus musculus- as a reference sequence), 
Chinese hamster (Cricetulus griseus) and CHO cells (Xu et al. 2011, Lewis et al. 
2013). Owing to the importance of CHO cell lines in the biotechnology industry, there 
has been a lot of focus on generating CHO genome data. For instance, in an effort of 
extracting maximal genomic data information, Xu et al. (2011) published the genomic 
sequence of CHO-K1 parental cell line and assembled 2.45 Gb of genomic sequence 
predicting 24,383 genes. They connected most of the assembled scaffolds with 21 
chromosomes in order to unravel their chromosomal genes locations. Moreover, they 
reported that the homologs of most human glycosylation-associated genes are present 
in the CHO-K1 genome, 141 (~ 53 %) of which are not expressed during exponential 
growth phase. Such information of the glycosylation-associated genes could augment 
the process of glyco-engineering in CHO cells. With more than 350 therapeutic 
products, mainly monoclonal antibodies to be produced with CHO cells as hosts, 
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currently in the pipeline for pre-clinical trial (Reichert 2012 and 2013), the need for 
the availability of CHO-K1 genomic sequence remains an objective of prime 
importance. The potential of CHO-mics’ is yet to be fully realized.  
 
1.2.2 Other Omics tools  
1.2.2.1 CHO-based Transcriptomics 
In last decade, a considreable amount of CHO transcriptomic data has been explored. 
For instance, Birzele et al. (2010) performed CHO expression profiling and identified 
13,375 CHO genes and more than 6000 transcripts were predicted to be full-length 
and covered 95 % of the corresponding mouse orthologs. However, only a part of this 
data (non-annotated) has been deposited in the National Center for Biotechnology 
Information’s (NCBI) database. The limited annotation and availability of the 
assembled CHO genomic sequences data deposited and released in public databases 
continues to be a challenge (Birzele et al. 2010, Becker et al. 2011). In order to 
address the issue of limited publicly available CHO genome data, Becker et al. (2011) 
made use of a diverse set of cDNA sequences i.e. ~ 29000 transcripts from CHO cell 
lines. The researchers assembled and compared these transcripts to M.musculus to 
study the distinction between different isoforms in these two species. The researchers 
generated 13,187 CHO cell line transcripts with functional annotations, classified 
them into isogroups (possible genes) and isotigs (splice variants) (Becker et al. 2011). 
The utilization of Omics tools assisting in the development of rCHO cell line process 
have been reviewed in great detail by (Gupta and Lee 2007, Kim, Kim and Lee 2012). 
Detailed detection of the global changes in DNA/RNA, metabolites, protein and the 
desired glycosylation patterns is now possible with recent advances in Omics based 
tools. The impact of these global changes could provide a better understanding of the 
molecular mechanisms associated with particular CHO cell phenotypes, observed 
under certain environmental conditions. For instance, the perturbations on specific 
productivity (q) and specific growth rate (µ) with the addition of chemicals such as 
NaBu, DMSO, zinc sulphate, cytochalasin, tunicamycin and growth factors have been 
investigated in many studies (Van Dyk et al. 2003, Hayduk and Lee 2005, Li et al. 
2006, Joon et al. 2008, Kantardjieff et al. 2010b). However, due to the lack of 
sufficient CHO genome sequence information, as mentioned above, non-CHO 
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specific DNA arrays for mouse and rat have been used for comparative transcriptomic 
analysis, which are useful but not ideal for CHO transcriptome analyses. But there are 
reports wherein DNA microarrays have been successfully utilised to study rCHO cells 
under q enhancing conditions such as low culture temperature (Kaufmann et al. 
1999), NaBu treatment (Joon et al. 2008) and high osmotic condition (Shen et al. 
2010). Similar studies focused on the enhancement of µ and/or high q by studying 
different transcripts expressed across other rCHO cell lines have also been performed 
(Nissom et al. 2006, Wong et al. 2006, Doolan et al. 2008, Doolan et al. 2010). CHO-
specific analysis tools could yield more accurate and reliable differential expression 
information, which could also augment the reliable identification of CHO-specific 
proteins associated with certain genes (Meleady et al. 2012). In another effort, 
Courtes et al., (2013) performed a translatome analysis by probing for 13 K annotated 
CHO-specific genes using high resolution and streamlined profiling technology. The 
researchers successfully identified key genes, which are potential key players for 
cellular growth, namely: heterogenous nuclear ribonucleoproteins, protein regulator 
of cytokinesis 1, glucose-6-phosphate dehydrogenase, UTP6 small subunit 
processome and RuvB-like protein 1 (Courtes et al. 2013). In a recent study, CHO 
RNA-Seq data was utilised from sequencing efforts by Vishwanathan et al. (2015) to 
study the transcriptomic data to provide physiological insights related CHO cell 
performance during production processes. The researchers assembled and annotated 
set of RNA-Seq data to identify genes involved in major functional pathways such as 
metabolism, glycolysis and glycosylation (Vishwanathan et al. 2015). 
1.2.2.2 CHO-based ProteOmics 
Transcriptomic data is often integrated with proteomic data, thus allowing for better 
understanding of the molecular mechanisms driving certain types of rCHO cells 
phenotypes. For example, an approach such as two-dimensional gel electrophoresis 
(2D-DIGE) combined with mass spectroscopy (MS) has been widely used to identify 
proteins modified under specific conditions in rCHO cells (Lee, Harrington and 
Bailey 1996). Proteomic approaches to monitor global protein changes caused by 
overexpressing and/or down regulation of an effector protein, for example, 
overexpressing B-cell lymphoma-extra large (Bcl-xL) (Carlage et al. 2009, Baik and 
Lee 2010) or E2F Transcription factor-1 (E2F-1) (Lee et al. 1996) in recombinant 
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CHO cells have been performed with a view to impact cell growth positively. A 
number of proteomic studies in rCHO cells have been carried out in order to identify 
differentially expressed proteins during hyperosmotic pressure (Lee et al. 2003), 
apoptosis induction (Baik and Lee 2010), culture in serum-free media with optimized 
hydrolysates mixtures (Kim et al. 2011a).  
1.2.2.3 CHO-based Metabolomics 
Another crucial Omics based tool attracting attention is metabolite profiling in rCHO 
cell cultures. Metabolomics can aid in media development and process feeding 
strategies. 100-fold product titre enhancement, in the last few decades, is largely 
attributed to the type of media used and feeding strategies. Metabolomics studies are 
performed with a combination of tools such as liquid chromatography-MS or nuclear 
magnetic resonance (NMR to monitor extracellular or intracellular metabolite flux for 
media development with view to, for example, reduce the likelihood of early onset of 
apoptosis in rCHO cell culture (Bradley et al. 2010, Goudar et al. 2010). For instance 
Chong et al. (2010) reported that malate accumulation in the medium could prevent 
rCHO attaining high cell densities. This revelation and subsequent overexpression of 
malate dehydrogenase II led to significant growth enhancement in integral viable cell 
counts (Chong et al. 2010). 
1.2.2.4 CHO-based Glycomics 
Post-translational modifications regulating recombinant therapeutic protein function 
also play a key role in affecting cell phenotype. Engineering approaches have also 
diversified into the field of glycosylational engineering for the improvement. For 
example, most mAbs possess complex glycoforms with fucosylated bi-antennary 
glycans with trimannosyl core capped by an N-acteylgalactosamine (GlcNAc), 
galactose and N-acteylneuraminic (Neu5Ac) residue on each branch. Many other 
glycoforms found to be afucosylated, have terminal or bisecting GlcNAc, with 5-9 
mannose residues for enhanced ADCC (Mimura et al. 2007), while enhanced 
sialylation of recombinant EPO through addition of two extra glycan sites resulted in 
enhanced serum half-life of the recombinant protein (Kiss et al. 2010).  
These Omics tools, when combined, could also allow for the identification of 
differentially expressed genes and enzymatic reactions when a parental cell-line 
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transitions from being a non-producer to producer cell-line (Dietmair et al. 2012). In a 
nutshell, the integration of various ’Omics data could provide for system biology 
levels insights into the underlying complexity inherent in CHO cell physiology and 
shed light on targets for metabolic engineering intervention (Figure 1.2). 
 
Figure 1.2 represents a system biology mapping with the genome, transcriptome and proteome of 
CHO cell-lines mapped to all metabolic pathways in the Kyoto Encyclopedia of Genes and 
Genomes (KEGG). Image was sourced from a review by (Kildegaard et al. 2013). 
 
1.3 Improving CHO cell productivity 
1.3.1 Stable GOI integration – An uphill task 
Generating a therapeutic protein producing cell line starts with the process of stably 
transfecting the cell line with the gene encoding the protein of interest. Most of the 
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cell lines exhibit variations in expression of proteins and more often these variations 
are associated with the genetically engineered cell-lines in contrast to parental cell-
lines (Browne and Al-Rubeai 2007a). In genetically engineered cells, random 
integration of the recombinant GOI gives rise to variable expression patterns due to 
‘positional’ effects and present a serious bottleneck both in terms of time (i.e. by 
forcing extensive screening of large number of clones) and resources during 
recombinant CHO cell line generation. This increased heterogeneity is particularly 
due to the fact that only 0.1 % of the genome is considered ‘hot-spot’ or 
‘transcriptionally active’ (Little 1993), therefore the decreasing the frequency of GOI 
insertion into such a rare transcriptionally active zone of the genome.  
1.3.2 Selection and Amplification Systems for CHO cell line development 
In the biopharmaceutical sector, mostly mutant CHO cell lines are utilised for 
biologics production processes following the GOI transfection into the cells. Table 
1.3.2a provides a list of selected commercially available CHO cell lines. These CHO 
cell lines are either dihyrdofolate reductase negative (DHFR- mutated or deleted 
versions of the DHFR gene) or glutamine synthase negative (GS-) (Liu et al. 2010b). 
The DHFR and GS gene-based selection and amplification systems are the two most 
commonly employed during the CHO cell line development. The methodologies of 
these two systems have been described in detail in a review from Camire (2000). The 
selection of positive transfectants is attained through the introduction of GOI along 
with a copy of DHFR or GS gene that complements the auxotrophy. Medium used for 
GS and DHFR-based are medium without glutamine and hypoxanthine supplements, 
respectively. Cells are further isolated with stringent selection through addition of 
methotrexate (MTX) or methionine sulfoximine (MSX) selective agents in increasing 
concentrations. The advantage of using GS-based system for gene amplification is 
that the high-producer clones can be produced within 3 months in comparison to 
DHFR-based system, which takes 5-6 months. Moreover with the GS-based system, 
another advantage is that little optimisation is needed when supplementing the culture 
media with glutamine (Butler 2005b).  
There are alternative approaches to these selection methods including geneticin 
(G418), hygromycin B (HygB), zeocin, blasticidin or puromycin genes conferring 
resistance to these selective antibiotic reagents in culture (Butler 2005a). Li et al. 
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(2010) reviewed and presented a list of selection markers used in the Table 1.3.2b. 
 
 
 
Table 1.3.2a: List of selected commercial CHO cell-lines used for research and industrial 
purposes. 
Commercial CHO cell lines Source 
CHO-DXB11 or CHO-DUK-XB11 or CHO-
DUKX 
CHO-K1 strain mutagenized to generate this 
DHFR deficient cell-line 
CHO-K1 Parental CHO cell-line 
CHO DP12  Co-expresses light and heavy chains of murine 
6G4.2.5 mAb (American Type Culture Collection 
(ATCC)-HB-11722). 
CHO DG44 Parental CHO cell-line (ATCC) mutagenized to 
cause deletions in both the DHFR alleles. 
CHO-S CHO cell-line adapted to serum-free culture 
conditions and produces high levels of 
recombinant protein. 
 
Table 1.3.2b: Selected list of Selection Markers used for CHO cell-based Gene Selection and 
Amplification process.  
Selectable Marker Selective Reagent 
Metabolic selectable marker (most commonly 
utilized) 
 
Dihydrofolate reductase (DHFR) Methotrexate (MTX) 
Glutamine synthase (GS) Methionine sulfoximine (MSX) 
Antibiotic selectable marker  
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Puromycin acetyltransferase Puromycin 
Blasticidin deaminase Blasticidin S 
Histidinol dehydrogenase Histidinol 
Hygromycin phosphotransferase Hygromycin B 
Zeocin resistance gene Zeocin 
Bleomycin resistance gene Bleomycin 
Aminoglycoside phosphotransferase Geneticin (G418) 
 
1.3.3 Automated systems for the isolation of CHO clones 
The process of selecting clones for large-scale production is done more efficiently via 
high-throughput cell screening techniques, reviewed in great details in (Browne and 
Al-Rubeai 2007b, Kim, Kim and Lee 2012), and includes FACS, the ClonePixTM 
system (Genetix), the Cell XpressTM, the CellCelectorTM system (Aviso) and the 
Laser-Enabled Analysis and Processing (LEAPTM) system (Cyntellect). All these 
advanced technologies allow for the selection of clones with high GOI expression 
levels, whose performances are further tested in serum-free suspension fed-batch 
cultures.  
1.3.4 Vector Engineering 
An area of optimization for increased product yield include vector engineering, which 
facilitates rCHO cell line development by modulating transcriptional activity via 
insertion of various DNA elements into a vector. These techniques are discussed 
further in Section 1.3.4 and 1.4 in more detail. The surroundings around the 
chromosome exert strong influences on the promoter (e.g. CpG islands are CG rich 
DNA regions wherein gene promoters are often located) that could potentially affect 
GOI expression. CpG islands are epigenetic regulatory hotspots for methylation (West 
and Fraser 2005). The availability of the CHO genomic sequence should facilitate the 
identification and pre-tagging of transcriptionally active zones using site-specific 
integration techniques. Recombinase-mediated cassette exchange utilizes Cre & Flp 
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recombinases recognizing loxP and FRT sequences and artificial-chromosome 
engineering (ACE) system are examples of this (Huang et al. 2007a, Kennard et al. 
2009, Kameyama et al. 2010).  
1.3.4.1 Remodeling chromatin in anActive-state  
In the quest to generate a stable hyper-producer cell-line, other techniques to remodel 
chromatin in an active state for increased stable transgene expression and increasing 
the gene copy number, have also been entertained (Figure 1.3). These techniques 
include transposable elements (Ley et al. 2013), trans- and cis- genetic elements such 
as scaffold/matrix attachment regions (S/MARs), and ubiquitous chromatin opening 
elements (UCOEs). Other techniques and strategies that allow for selection marker 
attenuation offer greater probability of isolating high-producer clones from low-
producers. For example, AU-rich elements (ARE) and murine ornithine 
decarboxylase (MODC) PEST regions combo-use for mRNA and protein 
destabilization, respectively have yielded positive results by reducing the selection 
marker during MTX amplification. Moreover, when both ARE and MODC PEST 
used with MTX selection system, the specific productivity increased from 14-fold to 
27-fold (Ng, Wang and Yap 2007). In a similar attempt to reduce the selectable 
marker gene expression downstream, an attenuated internal-ribosome entry site 
(IRES) element as a substitute for ARE, has also been employed for high recombinant 
protein product titers in CHO cells (Ng et al. 2012). 
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Figure 1.3 outlines vector-engineering approaches to address the issue of low-production capacity 
of CHO cells by stable and sustained expression of transgenes using IRES, MARs, UCOEs and 
other cis-trans chromatin remodeling techniques. Image reproduced from a review by (Lai, Yang 
and Ng 2013). 
1.3.4.2 CHO Promoters for high transcriptional activity 
The choice of promoter used is crucial in terms of achieving consistently high 
expression of heterologous genes within CHO cells. The most commonly employed 
promoters in vector expression systems in mammalian cells include cytomegalovirus 
(CMV) and simian viral 40 (SV40) promoters for ensuring high transcriptional rates 
(Spenger et al. 2004). Moreover, human elongation factor 1α (EF1α) is also a strong 
promoter for gene expression in mammalian cells (Deer and Allison 2004, Rita Costa 
et al. 2010). However, there are issues associated with the use of some the virus-based 
constitutive promoters since the over-expression of the GOI could lead to permanent 
cell-stress and could even lead to gene silencing as a common host response, which 
can lead to heterogeneity in expression patterns within a cell population (Kim et al. 
2011b). Such unwanted effects can be prevented with the use of endogenous 
promoters derived from house keeping genes such as CHO-derived elongation factor-
1 (CHEF-1) promoter. CHEF-1 has been reported to maintain high expression levels 
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for a multitude of genes in different CHO cell-lines (Deer and Allison 2004). 
Additionally, native CHO promoters such as s100a6 (calcyclin), which is a cold-
shock responsive promoter reported to be an excellent alternative choice to inducible 
promoter systems (that require addition of chemicals to the media). Calcylin promoter 
has been reported to induce 3-4 fold increase basal productivity in CHO cells (upon 
temperature shift to 33 °C) in comparison to SV40 promoter (Thaisuchat et al. 2011). 
1.4 Bioprocess-relevant CHO cell engineering 
1.4.1 Cell Cycle pathway engineering 
The use of small chemical molecules as selective cell cycle inhibitors can mediate a 
complete and sustained G0/G1 growth phase arrest without impacting the G2/M phase 
by directly targeting cyclin dependent kinases (CDK 4/6) (Du et al. 2014). This 
approach works even better than the commonly employed physical parameter 
manipulation approaches such as low temperature and hyper-osmolality. Chemical 
perturbations (NaBu) to induce cell cycle arrest and eventually enhancing specific 
productivity (Sunley and Butler 2010) have also been explored by researchers. Using 
a selective inhibitor to induce growth arrest has been utilized to optimize growth, q 
(i.e. increased q to 110 pg/cell/day (Du et al. 2014)) and glycosylation profile (i.e. 
decreased mannose content (Du et al. 2014)) across different rCHO cell lines. Similar 
studies with cell-cycle mediators such as p27KIP1 and p21CIP1 have been performed in 
the past to induce rCHO-K1 SEAP cell growth arrest with the aim to achieve high q 
(Fussenegger, Mazur and Bailey 1997, Mazur et al. 1998b, Meents et al. 2002b). 
1.4.2 Apoptosis pathway engineering  
Apoptotic signals within cells are mediated by caspase-cascade signalling system. 
Therefore, the suppression or by-pass of caspase activation can be a fruitful strategy 
to positively influence and/or enhance rCHO cell growth. Overexpression of anti-
apoptotic proteins such as those from the B-cell lymphoma-2 (Bcl-2) family proteins- 
Bcl2, Bcl-xL and Myeloid cell luekemia-1 (Mcl-1) and the suppression of pro-
apoptotic Bcl-2 associated x protein (Bax-like) proteins (Bax, Bcl-2 antagonist killer 
protein (Bak) and Bcl-2 ovarian killer protein (Bok)) have been reported to result in 
increased recombinant protein production (Kim and Lee 2000b, Meents et al. 2002a, 
Chiang and Sisk 2005) For instance, Majors et al. (2009) observed that Mcl-1 
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overexpression in CHO cells led to a significant 90 % improved cell viability for 14 
days. This improved viability was coupled with 20-30 % increase in antibody 
production (Majors et al. 2009). Moreover, Cost et al. (2010) used CHO cell lines 
with two important Bcl-2 family proteins deleted, resulting in significant higher cell 
densities in large-scale culture (Cost et al. 2010a). Combinatorial strategies of anti-
apoptosis and secretion engineering have been reported to yield a CHO cell line that 
expresses X-box binding protein-1 (XBP-1), which is a potent stimulator of promoters 
of secretory pathway genes leading to increased protein synthesis (as a result 
enhancing q, however, reported to reduce cell viability too) and x-linked inhibitor of 
apoptosis (XIAP) protein (whose overexpression can alleviate the negative impact of 
XBP-1) to inhibit apoptosis. This resulted in 60 % increased production titres (Shaffer 
et al. 2004, Becker et al. 2010). RNA-interference technology has also been employed 
in providing resistance to apoptosis in rCHO cells.  Lim et al. (2006) has reported an 
enhancement in cellular viability and productivity of CHO cells using small hairpin 
RNA (shRNA) technology to knockdown Bax and Bak of the Bcl-2 protein family.  
1.4.3 Secretion engineering 
Cell line engineering approaches have also been employed for the enhancement of 
protein secretion since protein productivity by rCHO cells is often hindered by a 
problem in the saturated secretory pathway. Soluble N-ethylmaleimide-sensitive 
factor attachment protein receptors (SNAREs) play a central role in vesicle trafficking 
(Jahn and Scheller 2006, Toonen and Verhage 2003). Syl1/Munc18 (SM) proteins are 
essential key regulators of SNARE-mediated fusion event. In secretion engineering in 
rCHO cells components associated with the secretary pathway i.e. SNAREs 
synaptosome-associated protein of 23kDa (SNAP-23) and vesicle-associated 
membrane protein 8 (VAMP8) and SM proteins (Syl 1 and Munc18c) were 
introduced in an effort to successfully elevate q (Peng and Fussenegger 2009, Peng, 
Abellan and Fussenegger 2011). In another study, researchers used phosphorylation-
resistant ceramide transfer protein (CERT) along with XBP-1 (overexpressed) in 
rCHO cells. CERT is involved in the trafficking of ceramide from endoplasmic 
reticulum (ER) to Golgi. A 35 % increase in specific productivity of t-PA (qt-PA) was 
observed in rCHO cells (Rahimpour et al. 2013).  
1.4.4 Chaperone engineering 
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Enhancing q as well as efficiently producing an authentic therapeutic protein is 
compromised by several processes including transcription, translation and proper 
protein folding. The repercussions of any over-expression strategy could potentially 
compromise the protein folding machinery resulting in increased production of 
misfolded proteins. Misfolded proteins in turn could cause potentially cytotoxic 
protein aggregation. However, mammalian cells are equipped with molecular 
chaperones in the ER to ensure newly synthesized proteins are correctly folded 
(Schröder, Schäfer and Friedl 2002, McClellan et al. 2005, Tartaglia et al. 2007). 
rCHO cells overexpressing protein disulphide isomerase (PDI) enhanced q in a 
product-specific manner.  For example, rCHO cells producing antibody have 
benefitted from chaperone engineering, however, in the case of rCHO cells producing 
thrombopoietin (TPO), interleukin-15 (IL-15), or a tumour necrosis factor receptor: Fc 
fusion protein, similar improvements could not be achieved (Davis et al. 2000, Borth 
et al. 2005, Mohan et al. 2007). On the other hand, CHO cell engineered to 
overexpress PDI isoforms e.g. endoplasmic reticulum protein 27 (ERp27) and its co-
overexpression with calnexin/calreticulin showed improved TPO production (Hwang, 
Chung and Lee 2003, Chung et al. 2004b). Numerous other reports have suggested 
mixed views on the benefits of PDI overexpression as an engineering target with 
different cell lines and various expression systems.  
1.4.5 Unfolded protein response machinery engineering 
The primary signalling network induced in response to the build-up of misfolded 
and/or unfolded proteins in ER is the UPR. UPR activation is due to elevated 
transcriptional rates of the genes encoding ER-resident chaperones, with the likes of 
endoplasmin and PDI associated with improved recombinant productivity in CHO 
(Smales et al. 2004). However, ER-stress (due to overexpression of therapeutic 
proteins and/or bioprocess related insults) in CHO could potentially compromise the 
overall productivity of therapeutic proteins since ~ 30 % of newly synthesized 
proteins can be degraded due to improper protein folding (Schubert et al. 2000, 
Schröder and Kaufman 2005, Yewdell and Nicchitta 2006, Chakrabarti, Chen and 
Varner 2011). Studies have reported that UPR activation is dynamically regulated 
during the production phase of cell culture. In this regard, rCHO engineering has been 
focused on the engineering of ER-localized quality control proteins. For example, the 
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activating transcription factor (ATF4) improved the specific IgG production rate by 
2.4-fold and DNA-damage inducible protein 34 (GADD34) have been reported to 
enhance the q to 28 pg/cell/day of anti-thrombin III (AT-III) in rCHO cells (Omasa et 
al. 2008, Ohya et al. 2008). In another study, the widely explored XBP-1s (spliced 
form of XBP-1) overexpression resulted in 2.5-fold increase in q for various 
therapeutic proteins such as mAbs, EPO, interferon-gamma (Ku et al. 2010). 
1.4.6 Metabolic engineering 
The two major carbon and energy (C & E) source for CHO cell that are absolutely 
vital for their growth are glucose and glutamine. However, the utilisation of a mole of 
glucose and glutamine concomitantly results in the accumulation of a mole of lactate 
and 2 moles of ammonia, respectively, as by-products. The accumulation of such by-
products has been reported to have negative impact on CHO cell growth profile, and 
consequently to the quality and quantity of the recombinant proteins produced 
(Ozturk, Riley and Palsson 1992, Lao and Toth 1997, Zeng, Deckwer and Hu 1998). 
In order to address these issues, rCHO have been engineered to efficiently utilize 
metabolites at the same time reducing waste by-product accumulation in the culture. 
For example, the catalytic enzyme lactate dehydrogenase (LDH) (responsible for 
glucose to pyruvate to lactate conversion) has been genetically manipulated in 
hybridoma and CHO cells to reduce the specific production of lactate in culture (Chen 
et al. 2001, Jeong et al. 2001). The small interfering RNA (siRNA)-mediated 
suppression of LDH-A (subunit of LDH) resulted in 45-79 % reduced lactate 
production without impairing the cellular growth rate and human TPO (hTPO) 
production (Kim and Lee 2007). In an alternative method, CHO cells engineered with 
overexpression of fructose-specific transporter (GLUT-5) have been observed to 
utilize fructose as the alternate C & E source, hence, causing reduced lactate 
production (Wlaschin and Hu 2007).  
1.5 Genome-editing technology 
Genome editing tools such as the use of endonucleases to cause functional knockouts 
of unwanted genes in the CHO genome is a topical area of exploration. Tools such as 
chemical nucleases, zinc-finger nucleases (ZFNs), mega-nucleases and transcription 
activators like effector nucleases (TALENs) and bacterial CRISPR-Cas9 (clustered 
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regularly interspaced short palindromic repeats-Cas9) systems offer exciting new 
opportunities in terms of genome engineering for CHO cell line developmental 
purposes. The best known of these nucleases-based technologies to cause a functional 
knockout in virtually any genome of plants, animals and bacteria are ZFNs, TALENs 
and CRISPR-Cas9 system. In the following sections mainly these nucleases will be 
discussed. 
1.5.1 ZFNs and TALENs 
Complex genome modifications at single nucleotide resolution have been the biggest 
goal of scientists working in applied genetics, including gene therapy, synthetic 
biology, drug development and biotechnology. In the past, genome editing was 
achieved by traditional chemical mutangenesis (Eeken and Sobels 1983, Solnica-
Krezel, Schier and Driever 1994) and transposon-mediated mutagenesis methods 
(Marx 1982, Spradling and Rubin 1982). These methods were intrinsically limited 
since they lacked specificity. In the past two decade methods such as homologous 
recombination (HR) based specific gene targeting (Gaj, Gersbach and Barbas 2013), 
φC31-mediated integration systems (Groth et al. 2004) and ZFNs (Bibikova et al. 
2002, Bibikova et al. 2003) began to surface. However, the use of these techniques 
were limited by several factors, including the low efficiency at which the genetically 
engineered constructs were introduced to target a specific chromosomal locus, time-
consuming engineering of these constructs and offsite-targeting issues (Gaj, Gersbach 
and Barbas 2013). An alternative solution for these techniques emerged in the form 
RNAi technology, which provided researchers with a rapid, inexpensive and high-
throughput solution to gene knockdown. However, it was acknowledged that RNAi 
knockdown of genes is incomplete, varies between experiments and laboratories 
performing research using this technology. Moreover, there were reports of 
unpredictable off-target effects and only temporary inhibition of gene function, hence, 
limiting the practical application of RNAi technology (Gaj, Gersbach and Barbas 
2013). Better genetic tools to address the aforementioned issues, came to light in the 
form of chimeric nucleases i.e. ZFNs and TALENs which are composed of a 
programmable, sequence-specific DNA-binding motif linked to a non-specific DNA 
cleavage domain. Both these chimeric nucleases have been used to introduce broad 
range of genetic modifications. Both these chimeric nuclease-based techniques work 
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by inducing double-strand DNA breaks (DSBs) that stimulate error-prone non-
homologous end joining (NHEJ), as well as HR repair mechanisms, hence resulting in 
a mutated DNA locus. NHEJ is the frequent repair mechanism employed by 
mammalian cells, in contrast to HR, which occurs at a several orders of magnitude 
lower frequency than NHEJ (Barnes 2001, van den Bosch, Lohman and Pastink 2002, 
Lieber 2010). ZFNs and TALENs discovery and application made a revolutionary 
contribution to the genome-editing field and this rightly earned them the status of 
Method of the Year in 2011 by Nature Methods (Kim and Kim 2014a). 
A ZFN has a modular structure comprising two main domains: a Cys2-His2 tandem 
array of zinc finger protein (ZFP) domain (most common in eukaryotes) (Tupler, 
Perini and Green 2001) and a FokI type II restriction enzyme-derived nuclease 
domain (Figure 1.5.1 (A) and (B)). ZFPs can be used to replace the DNA-binding 
domain of FokI in order to create a ZFN. There is an absolute requirement for two 
ZFN monomers in order to form an active nuclease to cleave the target DNA. 
Therefore, the two monomer domains (separated by 5-7 bp spacers) of FokI must 
dimerize for this active configuration enhancing ZFNs specificity (Kim, Cha and 
Chandrasegaran 1996, Bitinaite et al. 1998). The sequence specificity of ZFNs is 
dictated by the ZFPs and each finger recognizes a 3-bp sequence, therefore, 3-6 
zinc fingers are used to generate a single synthetic ZFN that targets a 9-18 bp DNA 
target sequence (Wolfe, Nekludova and Pabo 2000, Liu et al. 1997). They have been 
widely employed in the CHO cell engineering, for example, Cost et al. performed Bak 
and Bax knockouts using ZFN technology to increase CHO cells resistance to 
apoptosis (Cost et al. 2010a).  
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Figure 1.5.1 Structure of zinc-finger and transcription activator-like effectors nucleases. (A) (Top 
Left) Customized zinc-finger protein in complex with target DNA (grey). (B) (Bottom Left) ZFN 
dimer bound to target DNA. ZFN sites consist of two zinc-finger binding sites separated by 5-7 
bp spacer sequence recognized by FokI cleavage domain. Custom designed ZF proteins recognize 
unique ‘left’ and ‘right’ half-sites. (C) (Top Right) TALE protein in complex with the target 
DNA. (Bottom Right) TALEN dimer bound to target DNA. TALEN target sites consist of two 
TALE binding sites separated by a spacer sequence of variable length of 12-20 bp. Custom 
designed TALEs recognize unique ‘left’ and ‘right’ half-sites. Image reproduced from a review 
by (Gaj, Gersbach and Barbas 2013). 
 
Moreover, their utilization by Fan et al. (2012) to generate GS knockout CHO cells in 
order to study the impact of GS selection efficiency in cell line generation has been 
one of the greatest applications of this genome-editing tool (Fan et al. 2012). In the 
biomedical field ZFNs have been designed as drugs against human-immunodeficiency 
virus (HIV) and currently being tested for phase 2 clinical trials. However, ZFNs have 
limitations. This is due to the fact that the construction of ZFN protein with high 
selectivity is a costly, laborious and time-consuming task (Bibikova et al. 2002, 
Bibikova et al. 2003, Urnov et al. 2010, Cradick et al. 2011), requiring very specific 
expertise. 
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Similar to ZFNs, another alternative platform for genetic engineering was discovered 
in the form of second-generation artificial TALENs. TALENs differ from ZFNs only 
in that in TALENs DNA-binding domain is not zinc finger domain, instead multiple 
33-35 amino-acid-repeat domains that recognize a single base pair. The construction 
and production of these nucleases is more easier and efficient than the ZFNs. TALEs 
were first discovered in bacteria Xanthomonas oryzae pv. oryzae (Xoo) and 
Xanthomonas oryzae pv. oryzicola (Xooc) (Zhang et al. 2014). These pathovars are 
bacteria invasion strategies to infect plant (Bonas, Stall and Staskawicz 1989). Owing 
to their similarity with eukaryotic transcription factors, they are termed transcription 
activator-like effectors. These are comprised of a group of key effector proteins, 
which contain N- and C- termini and a central domain for specific DNA binding that 
varies with 5-30 (average 17.5) tandem monomer repeats. TALENs specificity is 
determined by two hypervariable amino acids known as the repeat-variable di-
residues (RVDs) (Boch and Bonas 2010, Miller et al. 2011a)  (Figure 1.6.1 (C) and 
(D)). The length of DNA sequence recognized by TALENs is usually 17-18 bp, 
however, for artificial TALENs is 14-20 bp. Similar to ZFNs, TALENs also have a 
FokI component to them, which works in a dimeric fashion, and thus makes it 
necessary to design a pair of TALENs to effect a DSB. 
Artificial TALEN-mediated genome editing was optimized to be a rapid, efficient and 
specific method for genome modifications (Cermak et al. 2011, Bedell et al. 2012, 
Garg et al. 2012, Sung et al. 2013, Zu et al. 2013). TALEN-based genetic 
manipulation could be used for the insertion of exogenous sequences (e.g. FRT/loxP 
sequences) in CHO cells genome for instance with a view to enhance cell growth and 
protein productivity. Moreover, TALENs have been utilized in the construction of 
transgenic animals, for in-vivo gene therapy and treatment of diseases such as sickle 
cell anaemia and neurodegenerative disorders (Hsu and Zhang 2012, Schiffer et al. 
2012, Sun et al. 2012). However, before considering TALEN application in other 
areas of clinical research, factors such as specificity and efficiency of RVDs, off-
target effects and structural stability of its repeat modules must be heeded. Moreover, 
the delivery method chosen and cytotoxicity of TALEs require detailed examination, 
as well as the fact that these are derived from plant pathogens, therefore, immune 
responses in clinical treatment are among other concerns (Schiffer et al. 2012). 
TALENs are a great tool to have in the genome-editing toolbox, however, due to the 
	 36	
labour and time invested to construct these, limits their practical applicability (Wei et 
al. 2013). 
1.5.2 CRISPR-Cas system for genome engineering 
The latest tool that provides greater specificity and efficiency, with reduced off-target 
effects and decreased cytotoxicity when applied to mammalian cells, is the bacterial 
CRISPR-Cas9 system (Cong et al. 2013, Mali et al. 2013b).  
1.5.2.1 Types of CRISPR-Cas systems 
CRISPR-associated (cas) genes constitute a natural adaptive-immunity response in 
bacteria upon invasion of viruses and other parasites in order to protect the bacteria 
from infection (Gasiunas et al. 2012). In CRISPR-Cas system, CRISPR repeat-spacer 
arrays are transcribed into long primary transcripts, which are further processed into a 
set of short CRISPR RNAs (crRNAs) that are composed of a conserved repeat 
fragment and a variable spacer sequence (referred to as the guide RNA) 
complementary to the sequence of the invading nucleic acid (Carte et al. 2008, Hale et 
al. 2009). The cas genes are also present in the vicinity of CRISPR arrays (Jansen et 
al. 2002, Makarova et al. 2006). The combination of crRNAs and the Cas proteins 
results in the formation of an effector complex that recognizes the complementary 
sequence of the invasive species using the guide RNA functional specificity, inducing 
sequence-specific cleavage and hence, rendering the foreign species harmless by 
preventing the proliferation and propagation of foreign nucleic acids (Jore et al. 2011) 
(Figure 1.5.2.1). 
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There are various distinct forms of CRISPR-Cas systems. They only differ in the Cas 
nucleoprotein type required to induce specific DNA cleavage (Wiedenheft, Sternberg 
and Doudna 2012). The type I-E system as noticed in E.coli has a crRNA located in a 
multi-subunit, which binds to complementary DNA sequence and degrades the target 
DNA using the Cas3 nuclease (Beloglazova et al. 2011, Sinkunas et al. 2011). In 
certain types of bacteria such as Sulfobulus solfataricus and Pyrococcus furiosus i.e. 
in type III CRISPR-Cas system, the crRNA recognizes and cleave synthetic RNA in-
vitro, however, the type III CRISPR-Cas system of Staphylococcus epidermis targets 
DNA in-vivo (Marraffini and Sontheimer 2008, Hale et al. 2012). The type II 
CRISPR-Cas system of S.thermophilus has four cas (i.e. cas9, cas1, cas2 and csn2) 
genes. The DNA disruption is accomplished by Cas9 protein (Makarova et al. 2011). 
Very recently, a novel class II CRISPR-Cas system has been described in literature. 
Figure 1.5.2.1 Bacterial 
CRISPR-Cas9 mechanism 
of action to degrade foreign 
parasite’s and/or virus’s 
nucleic acids, and 
consequently rendering 
them harmless. 
Image reproduced from 
(Nemudryi et al. 2014). 
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This CRISPR-Cas system uses a class II effector protein, Cpf1- a single RNA-guided 
endonuclease lacking trans-activating RNA (tracrRNA) (Shmakov et al. 2015). 
1.5.2.2. CRISPR-Cas9 System and its application 
The type II CRISPR-Cas9 system of S.pyogenes is one of the better-characterized 
genome editing CRISPR-Cas systems (Magadán et al. 2012). In this CRISPR-Cas 
type, the crRNA array encodes the guide RNAs and a required auxiliary tracrRNA. 
The tracrRNA facilitates processing of the crRNA array into discrete units (Garneau 
et al. 2010, Gasiunas et al. 2012). Each crRNA unit contains a 20 nt guide sequence 
that guides Cas9 to cleave the DNA target in a site-specific manner. In addition to 
these key components of the CRISPR-Cas9 genome editing machinery, there is an 
absolute requirement that the target site must immediately precede a 5- NGG 
protospacer-adjacent motif (PAM) sequence (N can be any nucleotide of the four A, 
C, G, T) (Jinek et al. 2012). The Cas9 nuclease uses the conserved HNH and RuvC 
nuclease (Sapranauskas et al. 2011, Cho et al. 2013, Ran et al. 2013) domains in order 
to induce double strand breaks (DSBs) in the DNA. The RuvC catalytic domain can 
be mutated to yield a mutated version of Cas9 i.e. Cas9 nickase that performs single-
strand breaks in DNA that can be employed to reduce off-target effects  
(Sapranauskas et al. 2011, Cho et al. 2013, Ran et al. 2013). Lately, studies have been 
conducted to design chimeric RNAs that contain both crRNA and tracrRNA fused 
together as a unit i.e. single guide RNA (sgRNA) (Figure 1.5.2.2.a), which can 
be customized to target 17 nt, 18 nt, 19 nt or 20 nt sequences in a gene (Chang et al. 
2013, Cong et al. 2013, Dicarlo et al. 2013, Mali et al. 2013b). These customized 
small chimeric sgRNA are combined into a plasmid vector that also contains codon-
optimized Cas9 nuclease for the heterologous expression of all these elements from a 
single expression construct (Cho et al. 2013, Cong et al. 2013, Jinek et al. 2013, Mali 
et al. 2013b).  
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CRISPR-Cas9 system works through the guide RNA sequence that guides the Cas9 
nuclease to the complementary target sequence. Once bound, the Cas9 performs site-
specific cleavage to cause DSBs. This is followed by the cell natural DNA repair 
system deployment to repair the DSBs in the DNA via NHEJ or HR. Since NHEJ 
occurs at frequencies several orders of magnitude more than HR, it is the most likely 
method of repair (Sedivy and Sharp 1989). NHEJ is an imperfect repair process that 
gives rise to mutations (e.g. indels, mismatch repair) at the site of DSBs during repair, 
potentially disturbing the reading-frame of a protein-coding gene and leading to pre-
mature STOP codon formation, hence, rendering it functionless (Perez et al. 2008, 
Santiago et al. 2008, Galetto, Duchateau and Pâques 2009, Miller et al. 2011b) 
Figure 1.5.2.2.a shows a single 
chimeric sgRNA to induce DSBs 
in target loci (Green sequence). 
Single sgRNA construct consists 
of a guide RNA scafflod to guide 
the Cas9 nuclease to the target 
DNA site adjacent to the short 
PAM (NGG in Sea Green) site at 
3’ of the protospacer. 
Image source: Addgene.org 
Figure 1.5.2.2.b shows the 
employment of the cell’s natural 
DNA repair system upon DSBs 
break in the target DNA by 
nucleases. The Left side of the image 
shows error-prone NHEJ leading to 
frame shift mutations, while the 
Right side of the image shows the 
less-frequent HR-mediated repair 
and, in the presence of donor DNA 
Image source: www.neb.com 
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(Figure 1.5.2.2.b). Moreover, the use of CRISPR-Cas9 system opens up a vast array 
of opportunities since the introduction of a DSB at a given locus increases the 
frequency of HR by several orders of magnitude. Therefore, if CRISPR-Cas9 
targeting is combined with donor DNA with homology to the nucleotide sequence at 
the break/cleavage site, then homology directed repair (HDR) takes place as a repair 
mechanism with the insertion of the donor DNA (Yang et al. 2013). With such great 
opportunities to genetically modify the sequence of virtually any gene, the CRISPR-
Cas9 system has wide applications in gene engineering. For example, development of 
isogenic human stem cells (Horii et al. 2013), exploiting HDR for precise genetic 
manipulation to correct mutant cell phenotype (Schwank et al. 2013), the study of the 
functional relationships between large groups of genes (Shalem et al. 2014, Wang and 
Quake 2014) and screening for the active regions of a genome in living cells (Chen et 
al. 2013) can be conducted via this technology.  
In regard to the biopharmaceutical industry, CRISPR-Cas9 systems have been 
employed to engineer CHO cells and have been reported lately by several groups 
(Ronda et al. 2014, Bachu, Bergareche and Chasin 2015, Grav et al. 2015, Lee et al. 
2015). Ronda et al. (2014) genetically manipulated CHO cells using the CRISPR-
Cas9 system to enhance protein quality by designing sgRNA to target COSMC (a 
C1GALT1C1 encoding C1GALT1-specific chaperone 1-essential for correct O-
glycosylation (Wang et al. 2010) and FUT8 (the α1,6-fucosyltransferase-catalyzing 
the addition of fucose on IgG antibodies that could reduce ADCC). The researchers 
achieved 47.3 % indel frequency in the COSMC gene, while a combination of 
CRISPR-Cas9 system with a lectin selection application attained 99.7 % indel 
frequency in the FUT8 gene. These results demonstrate how efficient and convenient 
the CRISPR-Cas9 technology is for targeting genes in CHO cells to improve their 
characteristics. Generating a stable CHO cell line that expresses the therapeutic 
protein gene invariably and/or generating a stable CHO cell line that has multiple 
knockouts of unwanted genes is challenging but desirable. Previously, ZFNs were 
used to achieve knock out of multiple undesirable genes, however, only sequentially 
(Cost et al. 2010b, Grav et al. 2015). Moreover, the time, labor and cost of generating 
these knockouts were exorbitant. For this purpose, the CRISPR-Cas9 systems can 
offer advantages in terms of designing highly efficient and effective multiplex sgRNA 
units, which can target several parts of the genome simultaneously with greater 
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efficiency. Such multiplexed CRISPR-Cas9 systems have been reported in the 
literature and have proven their efficacy. These all-in-one CRISPR-Cas9 vector 
systems could potentially provide an effective targeting strategy for multiplex 
epigenome editing and simultaneous activation/repression of multiple complex 
mammalian genes, activators and promoters (Gilbert et al. 2013, Sakuma et al. 2014, 
Hilton et al. 2015). In CHO cells, very recently, Grav et al. (2015) reported one-step 
generation of a CHO cell line with a triple knockout using a CRISPR-Cas9 system 
followed by FACS sorting to enrich (i.e. by linking GFP to the Cas9 nuclease via 2A 
peptide) for multiple knockout CHO clones with Bax and Bak gene disruptions, in 
addition to FUT8 knockout. The functional analysis of these triple knockout clones 
showed resistance to apoptosis and decreased fucosylated content in IgG-1 antibodies, 
in comparison to a wild-type cell line (Grav et al. 2015). 
CRISPR-Cas9 offers several advantages over traditional overexpression or insertion 
of GOI, or RNAi-mediated knockdown (Krämer, Klausing and Noll 2010, Jadhav et 
al. 2013). Transient expression of sgRNA and Cas9 nuclease can result in permanent 
gene modifications. Furthermore enrichment methods such as GFP linked via 2A 
peptide can be used for the selection of positive clones, therefore, saving labour and 
time-intensive screening for positive clones. This also provides an alternative to the 
use of selection markers, hence, reducing the transcriptional burden of expressing the 
selection marker gene. Multiplex genome engineering through the design of an all-in-
one CRISPR vector (with customizable sgRNAs targeting multiple genes) could also 
solve the problem of co-transfection of single sgRNA CRISPR-Cas9 systems, whose 
transfection may not be as high as a multi-sgRNA CRISPR plasmid. Multiplexing 
CRISPR systems has completely revolutionized genome modification in mammalian 
cells and could play a huge role in engineering CHO cells to improve recombinant 
therapeutic protein production.  
With the advent of global CHO gene expression profiling, the CRISPR-Cas9 system 
would not just be confined to knocking out undesirable genes but also for integration 
of transgenes into transcriptionally active zones of the CHO genome (Duda et al. 
2014). As discussed in Sections 1.3 and 1.4, the process of recombinant CHO cell-
line development has been seriously limited due to variable/or inconsistent expression 
of transgenes. This is particularly due to the positioning-effect(Kim and Kim 
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2014b), which results from the random integration of GOI in the CHO genome. 
Traditional methods such as Cre/loxP system, Flp/FRT system and φ C31/34 
integrases have been applied in order to mitigate the issue of uncontrollable transgene 
insertion. However, these systems are limited in that they require a prior 
establishment of a platform recombinant cell line with the insertion of recombination 
site into transcriptional hot-spot regions of the genome in order to retarget and 
generate a cell-line for the expression of GOI (Kito et al. 2003, Huang et al. 2007b, 
Lieu et al. 2009). For this reason, CRISPR-Cas9 technology can be preferred choice 
for the insertion of GOI in one-go over the traditional methods. For instance, Lee et 
al. (2015) recently reported a successful 3.7 kb gene expression cassette at a specific 
loci in CHO cells using the CRISPR-Cas9 system. The researchers successfully 
manipulated the endogenous loci of the CHO genome and precisely replaced the 
knocked out sites with homologous pieces of endogenous/exogenous donor DNA 
using the leveraged HDR-mediated targeted transgene integration systems (Lee et al. 
2015). Combining the CRISPR-Cas9 system to induce site-specific gene cleavage and 
the subsequent integration of GOI using leveraged HDR system (less frequent DNA 
repair system than NHEJ) by suppressing key molecules of NHEJ system (i.e. KU70, 
KU80 or DNA ligase by gene silencing in order to increase HDR events frequency) 
(Chu et al. 2015, Maruyama et al. 2015) could assist researchers to attain the elusive 
task of generating isogenic CHO cell lines. Moreover, successful NHEJ-mediated 
plasmid integration studies have also surfaced lately (Maresca et al. 2013, Pan et al. 
2013, Auer et al. 2014). For example, targeted recombinant plasmid integration via 
NHEJ was performed in CHO cells with insertion of donor DNA (non-homologous 
arms) with 0.45 % efficiency (Bachu, Bergareche and Chasin 2015). 
In summary, CRISPR-Cas9 genome editing tool offers great promise and flexibility 
for genome modification. In comparison to other genome modification tools such as 
ZFNs and TALENs, CRISPR-Cas9 system completely outshines them in particular, 
regarding its simple inexpensive design and highly efficient site-specific targeting in 
virtually any gene and/or even multiple gene (s).  
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1.6 microRNAs 
1.6.1 miRNAs biological relevance and potential rols in CHO cell engineering 
Efforts in the field of RNAi could provide for an alternative in order to knockdown 
the expression of target gene(s) in a sequence-dependent manner (Wu 2009). 
However, knockdown using RNAi approaches can be variable and only induce 
temporary inhibition of the target gene. A potentially investing option is the 
exploitation of endogenous miRNAs and the manipulation of their expression levels 
to increase CHO cell growth and productivity. Unlike single or multi- gene 
engineering, the use of miRNAs for gene manipulation does not put stress on cell 
translational machinery (Müller, Katinger and Grillari 2008, Barron et al. 2011c, 
Jadhav et al. 2013). 
Mature miRNAs are endogenous non-coding, 19-22 nt single-stranded RNA 
molecules that regulate gene expression globally in cells at the post-transcriptional 
level. miRNAs were first discovered in Caenorhabditis elegans. Similar to certain 
transcription factors and in contrast to siRNAs, single miRNAs post-transcriptionally 
regulate more than 10-100 of mRNAs potentially affecting cellular behavior by 
globally modifying gene expression patterns (Fire et al. 1998). This global gene 
regulation is exerted wherein mature miRNAs targets their mRNAs in the 3-
untranslated region (3-UTR) using Watson-Crick base-pairing, hence inhibiting 
translation of the targeted mRNAs and/or catalyzing mRNAs cleavage depending 
upon the complementarity between miRNA and the 3UTR of the gene. These small 
RNA molecules have been reported to regulate many biological functions and/or 
pathways in the published reports. For instance, Pasquinelli and Ruvkun  (2002) 
reported miRNAs role in the regulation of developmental timing in C.elegans 
(Pasquinelli et al. 2000), and miRNA roles in other cellular functions such as 
differentiation, cell growth and apoptosis and cell cycle (Cheng et al. 2005, Chivukula 
and Mendell 2008). Some studies have reported their effect on metabolism (Xu et al. 
2003, Gao et al. 2009, Lin et al. 2009) and deregulation in multiple diseases, 
including cancer of many types (Xi 2013). miRNAs also play a role in fine-tuning 
cellular response due to environmental insults via a well-orchestrated regulation of 
genes in a coordinated manner. They act to buffer cells against any stochastic 
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fluctuations due to any internal/external cellular perturbations and providing 
robustnessto cell. Hence, they act as rheostats to maintain cellular homeostasis (Li 
et al. 2009, Ebert and Sharp 2012, Vidigal and Ventura 2015). 
1.6.2 miRNA discovery 
The first miRNA, lin-4 was discovered in a nematode C.elegans whilst studying the 
post-embryonic developmental timing in 1993. Transcription of lin-4 negatively 
regulated LIN-14 protein levels at the L1 larval stage of development (Lee, Feinbaum 
and Ambros 1993). Following the discovery of the first miRNA, miRNAs have been 
reported in array of different organisms including worm (Lau et al. 2001) fly, rodents, 
human (Lagos-Quintana et al. 2001, Wang et al. 2008, Sanchez et al. 2014) even 
plants, green algae and viruses (Griffiths-Jones et al. 2006). 
1.6.3 miRNA biogenesis and processing 
Small non-coding RNAs ranging from 20-30 nt in length have been classified into 
three categories: siRNA, piwi-interacting RNAs (piRNAs) and miRNAs. These RNA 
molecules share common links to certain pathways, however, their biogenesis and 
mode of gene regulation is different from one-another (Bartel 2004a). Mature 
miRNAs are single stranded short 20-23 nt RNA molecules derived from long 
primary miRNA (pri-miRNA) units (several thousand kilobases transcripts 
transcribed by RNA pol II). Initially, the pri-miRNA is processed by the 
Microprocessing complex comprising DROSHA-DGCR8 (DiGeorge Syndrome 
Critical Region 8) to yield a 70 nt hairpin stem loop structure or preliminary miRNA 
(pre-miRNA) (Figure 1.6.3). This processing to yield the pre-miRNA is mediated by 
RNAse type III DROSHA enzyme and its double stranded RNA-binding adaptor 
protein DGCR8 and other nuclear components (Gregory et al. 2004, Han et al. 2004, 
Landthaler, Yalcin and Tuschl 2004). These processed pre-miRNAs are then exported 
into the cytoplasm by the nuclear protein Exportin-5 (Exp5) in a RAN-GTP 
dependent manner (Yi et al. 2003, Bohnsack, Czaplinski and Görlich 2004, Lund et 
al. 2004). The Exp5 recognition of pre-miRNA is independent of pre-miRNA 
sequence or the loop structure. Moreover, only defined lengths of ds-stem and 3 
overhangs molecules are successfully bound to Exp5 in order to ensure that only 
correctly processed pre-miRNAs are shuttled from the nucleus to the cytoplasm (Zeng 
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and Cullen 2004, Lund and Dahlberg 2006). Following this, the pre-miRNA is further 
processed by Dicer (RNAse type III enzyme), which in conjunction with ds-RNA 
binding protein (TRBP- TAR RNA binding protein) removes the loop and generates a 
~ 22 nt RNA duplex. This RNA duplex interacts with Ago family proteins to form a 
pre-RISC (pre- RNA induced silencing complex), with guide strand of the duplex 
bound to the Ago2 protein (endo-nucleolytic activity) (Peters and Meister 2007). 
 
Figure 1.6.3: The biogenesis and processing of mature miRNAs. (1) Initially, the process begins 
with the translation of a nascent transcript, pri-miRNA (2) Microprocessor complex with 
Drosha/DGCR8 cleaves the overhanging ssRNA liberating pre-miRNA processed transcript (~70 
nt in length) (3) Shuttling of the pre-miRNA transcript is carried out by Exportin-5 in a Ran-
GTP manner from the nucleus to the cytoplasm (4) The pre-miRNA transcript is further 
processed by Dicer machinery to generate a hairpin loop structured ~ 22 nt RNA duplex (5) 
Following this, a preferential strand selection occurs upon RISC loading, wherein the guide 
strand loaded onto the RISC complex targets the respective mRNA (6) Two possibilities i.e. 
either (6) translational repression occurs, or (7) mRNA degradation occurs. These two events are 
dependent on the sequence complementarity of the miRNA: mRNA interaction and the type Ago 
protein fused to RISC complex. This image was reproduced from (Barron et al. 2011c). 
The other staror passenger strand (miRNA*) is thought to be unwound from the 
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duplex and is degraded leading to the formation of mature RISC complex 
(Chendrimada et al. 2005). The preferential association of the guide miRNA strand in 
the RISC complex is based on the thermodynamic stability of its 5-end and is 
dependent on the abundance of target transcripts, which drives miRNA arm selection 
(Schwarz et al. 2003).  
1.6.4 miRNA mode of action: Translational repression and/or mRNA 
degradation. 
The mature RISC complex targets the mRNA by binding to the 3-UTR of the 
mRNA. The Ago2 protein is the main driver of the miRNA-mediated mRNA 
cleavage. There exists a number of Ago proteins in mammals, namely Ago1-4. 
miRNA-mediated RNA interference has two outcomes i.e. either translational 
repression or target mRNA degradation, with both leading to translational inhibition 
(Baek et al. 2008). Post-transcriptional regulation by miRNA is mediated through the 
base pairing of the seed region (2-8 nt at the 5-end). This region is conserved 
in most vertebrates. The translational repression efficiency is dependent on factors 
such as AU-rich composition near the seed region and miRNA binding site position 
(Grimson et al. 2007). The extent of the miRNA: mRNA 3-UTR complementarity 
also influences which of the two aforementioned outcomes. For instance, low 
complementarity (i.e. sequences with bp mismatches) of miRNA: mRNA leads to 
translational repression via deadenylation and subsequent decapping of target mRNAs 
(Bagga et al. 2005, Eulalio et al. 2009) while high-complementarity results in target 
mRNA degradation. 
1.6.5 Nomenclature of miRNAs 
With the rapid identification of the new miRNAs, it was imperative that these non-
coding small RNA molecules to have a database with an easy to understand 
nomenclature platform followed universally by researchers across the globe (Ambros 
et al. 2003). One such database is the miRBase, wherein miRNAs are catalogued 
with a classification system in order to cater for the information regarding the miRNA 
identity along with sequence information, annotation, species, affiliation, genome site 
origin, target prediction resources and quick-hyperlink to literatures.  
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1.6.6 Genomic Organization of miRNAs 
Based on their genomic locations, miRNA genes are categorized as (i) Intergenic, (ii) 
Intronic, (iii) Mirtronic, and (iv) Exonic (Rodriguez et al. 2004), Figure 1.6.6) 
 
Figure 1.6.6 Four classes of genomic organization of miRNAs. (1) Intergenic miRNAs located in 
isolation from other genes and occur either as (1a) monocistronic or (1b) polycistronic units (2) 
Intronic miRNAs within the intron of protein-coding genes, again both either as mono- or poly-
cistronic units (3) Mirtrons are intronic miRNAs that exist in short introns, however, only differ 
from intronic miRNAs in that they can by-pass Drosha processing (4) Exonic miRNAs are 
located in an exon and are independently transcribed from their own promoter. Legends list: 
Black arrow- Host gene promoter start site, Black arrow with lines- miRNA promoter start site, 
Rhombus dotted lines- Intron region, Blue rectangle- Gene, Purple big arrows- Exon. This image 
was sourced from a review on miRNA structural organization by (Barron et al. 2011c)  
1.6.7 Functional Validation of miRNAs 
Discovering the regulatory significance of the specific miRNA-target association 
involves various lose-and gain-of function approaches to confirm and verify the 
functionality of miRNAs. 
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1.6.7.1 Loss of function approaches 
Techniques that use molecules for targeted miRNA inhibition: Antagomirs are 
antisense miRNA oligonucleotides commonly employed for miRNA inhibition 
(Krützfeldt et al. 2005, Kaur, Babu and Maiti 2007, Henke et al. 2008). There are 
chemically modified versions of antagomirs i.e. 2 -O-methyl- or 2 -O-
methoxyethyl, Locked Nucleic acid (LNA) and multiple-targeting (MTg) technology 
(for miRNA cluster s functional validation) oligonucleotides. These modified 
antagomirs have been developed to antagonize miRNA in vivo (Elmén et al. 2008, Lu 
et al. 2009). These molecules are transient tools for verifying miRNA functions. The 
use of MTg-antagomirs is particularly suited for overcoming issues of miRNA 
inhibition compensation from other members of the cluster (Lu et al. 2009). However, 
these antisense oligonucleotide molecules are not suitable for long-term inhibition. 
Alternative approaches such as the use of simple expression vectors and/or the 
sponges or decoy-vectors can be particularly fruitful for long-term stable 
knockdown of miRNAs (discussed in more detail in Section 3.1 and 3.2) (Yang et al. 
2012a, Druz et al. 2013). 
1.6.7.2 Gain of function approaches 
Techniques that work by overexpression of miRNA mimics and/or vector based 
expression systems to modulate miRNA function: Overexpression of miRNAs is a 
prominent alternative for studying the miRNA function. In this regard, two commonly 
employed techniques for the ectopic expression are: miRNA mimic strategy (Wang 
2011) and/or vector based transcription of miRNA precursors, which are then further 
processed to yield mature miRNA of interest (Jadhav et al. 2013). miRNA mimics can 
be in high throughput screens for miRNA function via large synthetic libraries 
covering the entire miRNome for the specific organism. However, due to the nature of 
being transient with short-term effects, limits their application for functional 
validation of miRNAs. To overcome this, shRNA vector approaches for ectopic 
expression of mature miRNA transcripts utilizing the endogenous miRNA maturation 
pathway can be used since such constructs works well both in transient and stable 
miRNA transfection studies (Jadhav et al. 2013). 
1.6.8 Online tools and experimental prediction/validation methods for miRNA 
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targets 
The ability of a single miRNA to regulate a multitude of genes poses challenges in 
predicting target gene in the absence of experimental data due to the small seed region 
of miRNAs. However, Bioinformaticians have developed algorithms and/software 
tools that help in the prediction of targets, although they tend to suffer from large 
numbr of false positive predictions. Table 1.6.8 provides a synopsis of these online 
tools and target predicting software. These tools are mainly categorized into two: (i) 
One method searching targets on the basis of the complementarity between the 
miRNA seed region and 3-UTR of the mRNA and their thermodynamic stability of 
duplex formation, (ii) while other method provides list of predicted targets based on 
in-silico machine-learning approaches using aforementioned rules as well as 
considering extra algorithms to expand the criteria such as miRNAs multiple 
binding events, G: U wobble pairs near 6-8 nt seed region, miRNA with functional 
redundancy , target site accessibility, evolutionary conservation of binding sites and 
seed regions etc. (Li et al. 2010). Although these tools help in predicting the potential 
real biological targets, however, are not foolproof. Therefore, experimental 
approaches such as transcriptomic and proteomic profiling following the up-or down-
regulation of miRNAs needed to be performed in order to validate these predicted 
targets (Baek et al. 2008, Selbach et al. 2008, Muniyappa et al. 2009). Experimental 
approaches such as hybridization techniques: northern blotting, RNAse protection 
assays, signal-amplifying ribozyme (Lee et al. 2002, Hartig et al. 2004, Baskerville 
and Bartel 2005a) Real Time quantitative polymerase chain reaction (RT-qPCR) 
(Tang et al. 2006) microarray (Kantardjieff et al. 2009) and next generation 
sequencing (Hackl et al. 2011a) can be utilized to verify predicted direct/indirect 
miRNA targets. 
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Table 1.6.8 provides a list of prediction algorithms available and the binding criteria used for 
miRNA target prediction. The table below is sourced from review by (Barron et al. 2011c). 
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1.6.9 miRNAs as potential tools for enhancing CHO cell phenotypes 
For the overexpression of a multitude of CHO cell growth-favoring and protein-
producing genes, co-transfection could be one alternative, however, such a method 
imposes stress on the cell’s translational machinery and can also compete with the 
product. The burden on the translational machinery is doubled when other transgenes, 
such as selection marker transgenes, also needed to be expressed. An alternative route 
to the coding-gene engineering is via the use of small non-coding miRNAs 
(Pasquinelli and Ruvkun 2002). Their abilities to regulate hundreds of genes and to 
orchestrate complex cellular pathways (e.g. cell-cycle, cell metabolism, secretion and 
apoptosis) in a coordinated fashion without over-charging the cells translational 
machinery make them an attractive tool to be utilized for CHO cell engineering 
(Bratkovic et al. 2012). miRNA profiling studies of cancers of different types have 
unveiled the important role of miRNAs in cell cycle regulation. These studies have 
identified potential miRNA candidates, which when up- or down-regulated affect cell 
growth behaviour, hence, stimulating an interest in using these non-coding RNA 
molecules to positively enhance CHO cell phenotypes. Table 1.7.8 provides a list (not 
exhaustive) of potential miRNA candidates for CHO cell engineering. 
 
 Table 1.6.9 provides a selected list of potential miRNA candidates for CHO cell engineering 
Cellular process microRNA Cluster Effect Verified/Predicted 
targets 
References 
Cell cycle Let-7  miR-200/let-7a-
2  
Tumour 
suppressor 
E2F2, CCND2 (Dong et al. 2010) 
cgr-miR-7 - Tumour 
suppressor 
EGFR, AKT 
pathway, Skp2, 
Psme3 
(Kefas et al. 2008, 
Sanchez et al. 2013) 
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cgr-miR-17 miR-17~92 Oncogenic c-myc, E2F1, 
PTEN, 
CDKN1a/p21 
(O'Donnell et al. 
2005, Scherr et al. 
2007, Ivanovska et 
al. 2008) 
miR-23 
miR-24  
miR-
23a/27a~24-2 
miR-23b-24-1 
Tumour 
suppressive 
Myc, E2F2 (Cheng et al. 2005, 
Gammell et al. 
2007, Lal et al. 
2009) 
miR-31 - Oncogenic p53, LATS, 
PPP2R2A 
(Creighton et al. 
2010, Liu et al. 
2010a) 
Apoptosis 
 
miR-15a/16 miR-15a~16-1 Pro-apoptotic Bcl2, Bcl-xL (Weber and 
Fussenegger 2007, 
Calin et al. 2008, 
Yang and Paschen 
2008) 
miR-21 - Oncogenic PDCD4, Caspases 3 
and 7 
(Chan, Krichevsky 
and Kosik 2005, 
Gammell et al. 
2007) 
miR-34a miR-34b/miR-
34c 
Pro-apoptotic p53, Bcl2, SIRT1 
deacetylase  
(Raver-Shapira et 
al. 2007, 
Hermeking 2010) 
miR-133 miR-1/133 Pro-apoptotic Caspase 9, HSP (Xu et al. 2007) 
miR-
144/155 
- Pro-apoptotic Caspase 3 (Druz et al. 2011) 
miR-218 - Pro-apoptotic ECOP 
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miR-297 miR-297-669 Pro-apoptotic Bcl2L2, DAD1, 
BIRC6, STAT5a, 
SMO 
Protein 
productivity and 
Quality 
 
 
 
 
miR-34a - Post-
translation 
modification- 
core 
fucosylation 
FUT8 (Bernardi et al. 
2013) 
miR-30b/d miR-30b/d O-
glycosylation 
GALNT7 (Gaziel-Sovran and 
Hernando 2012) 
miR-148b - N-
glycosylation 
C1GALT1 (Coppo and Amore 
2004) 
miR-30c miR-30c-2* UPR XBP-1 (Byrd, Aragon and 
Brewer 2012) 
     
miR-410 miR-
323b/154/496/3
77/541/409 
miR-
412/369/656 
Protein 
secretion 
Not known yet (Hennessy et al. 
2010) 
Energy 
metabolism and 
other Cellular 
stresses 
Let-7 family Let-7 a/d/f Glucose 
metabolism 
INSR, IGF1R, 
IRS2, HMGA2 
(Zhu et al. 2011) 
miR-23 miR-23a~24-1 Glutamine 
metabolism 
GLS (Rathore et al. 
2012) 
miR-31 - Hypoxia HIF (Liu et al. 2010a) 
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miR-23 miR-
23a/27a~24-2 
Hypoxia PU1 (Dang 2010) 
miR-126 - Shear stress Bcl2, FOXO3, 
IRS1 
(Zhou et al. 2013) 
miR-375 - Lactate 
production 
LDHB (Kinoshita et al. 
2012) 
 
 
 
 
 
Abbreviations: Akt protein kinase B protein, Bcl2 B-cell lymphoma 2, Bcl2L2 Bcl 2-like 2, Bcl-xL B-cell 
lymphoma-extra large, BIRC6 Baculoviral containing repeat 6, C1GALT1 Core-1 synthase glycoprotein N-
acetylgalactosimine 3-beta-galactosyltransferase 1, CCND2 Cyclin D2 protein, CDKN1a/p21 Cyclin-
dependent kinase inhibitor 1a, DAD1 Duo and Dam 1-interacting protein 1, ECOP EGFR co-amplified and 
overexpressed protein, EGFR Epidermal growth factor receptor, E2F1 and E2F2 Transcription factors, FUT8 
Fucosyltransferase 8, FOXO3 Forkhead box O3, GALNT7 N-acetyl-galactosaminyltransferase 7, HMGA2 
High mobility group AT-hook 2 protein, HIF Hypoxia inducible factor, HSP Heat-shock protein, IGF1R 
Insulin-like growth factor 1 receptor, IRS1 and IRS2 Insulin receptor substrate 1 and 2, INSR Insulin 
Receptor, LATS Large tumour suppressor, LDHB Lactate dehydrogenase B, PDCD4   Programmed cell death 
4, PPP2R2A PPP2A regulatory subunit B alpha isoform, Psme3 Proteosome activator subunit 3, PTEN 
Phosphatase and tensin homolog, PU.1 Transcription factor for B-cell activation or differentiation, SIRT1 
Sirtuin 1, Skp2 S-phase kinase-associated protein 2, SMO Smoothened gene, STAT5a Signal transducer and 
activator of transcription 5A. 
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Right from their discovery, miRNAs were thought to be critical players in cell-cycle 
control. Deregulation of their expression was associated with both tumour-
suppressive or oncogenic phenotypes and their differential expression associated with 
cell cycle, cell-growth and cell death (Lee and Dutta 2006, Blenkiron et al. 2007, 
Porkka et al. 2007, Solomides et al. 2012). Bort et al. (2012) performed a detailed 
transcriptomic analysis in CHO cells, which identified 10 miRNAs as down regulated 
and their corresponding mRNA targets up regulated in a batch culture. These 
miRNAs played critical roles in cell cycle and apoptosis, making them targets for 
regulating cell growth and proliferation during late stage of the culture period. miR-7 
was identified as a candidate for manipulation in CHO cell culture with a view to 
enhance longevity and protein productivity (Barron et al. 2011a, Sanchez et al. 2014). 
In addition to the positive impact of depletion of miR-7 on CHO cell culture growth 
and productivity, miR-7 overexpression impact on the global protein levels in CHO 
cells was also analyzed by Meleady et al (2012a). They reported up-regulation of the 
protein folding machinery associated proteins as well as protein secretion; however, 
targets regulating translation of proteins and nucleic acid were down regulated. In 
another transcriptomic study that utilized CHO-specific microarrays, Doolan et al. 
(2013) performed an extensive screening protocol on CHO-K1-mAb secreting cell-
lines spanning a range of growth rates derived from single CHO cell line 
development.  With the use of in-silico functional analysis, they identified a 416 
transcripts associated with high growth rates (196 of which were up-regulated, while 
226 down-regulated) (Doolan et al. 2013). These above mentioned in-depth 
differential miRNA expression profiling studies were performed to get a better 
understanding of the role of miRNAs in CHO cell-cycle regulation in serum-
containing and serum-free CHO cell culture (Hackl et al. 2011a), at different culture 
time points (Bort et al. 2012) and with individual clones with different growth rates 
(Clarke et al. 2012, Doolan et al. 2013).  
Additionally, many other groups have highlighted the importance of these global gene 
expression regulating RNA molecules as potential tools to manipulate desired 
phenotypes, with improved protein titers and protein with desired attributes in CHO 
cells. With the flood of genome sequence data for CHO in the last few years and the 
advantage of using miRNAs could prove very promising in optimizing CHO cell 
growth and productivity, in comparison to single-gene CHO cell engineering 
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approaches. With this very aim, this thesis is also an attempt to screen for the two 
potential miRNAs i.e. Let-7a of the big Let-7 family, and miR-7a-5p knockout role in 
impacting CHO cell growth behaviours. 
1.6.9.1 Let-7 family 
Lethal-7 (let-7) was the first miRNA discovered in C.elegans and was reported to be 
involved cell fates at different larval transitions (Reinhart et al. 2000). Following the 
study of this miRNA in C.elegans, the discoveries of mature let-7 miRNAs in simple 
organisms such as fly, zebrafish as well as complex organisms such as mouse and 
human began. Interestingly, not only are the mature let-7 sequences and the timing of 
expression of many of let-7 family members in these organisms conserved but also it 
was observed that the genomic organization and clustering of many let-7 members is 
conserved as well (Sempere et al. 2002, Bashirullah et al. 2003, Sempere et al. 2003, 
Weber 2005). The let-7 family often present in multiple copies in a genome and the 
nomenclature of these miRNAs is a special one, in contrast to other miRNAs. For 
instance, multiple isoforms of let-7 miRNAs are indicated by a letter at the end of let-
7 to indicate slight difference in the sequence and a number after the letter usually 
denotes that the same sequence is present in multiple genomic locations. For example, 
ten mature let-7 sequences are present in humans, transcribed and processed from 13 
precursors. Three separate precursors produce mature let-7a sequence (let-7a-1, let-
7a-2, let-7a-3) and precursors from two different genomic loci produce the let-7f (let-
7f-1 and let-7f-2) sequence. Although the sequence and function of let-7 family is 
conserved across species, with few exceptions, the size of the let-7 family also differs 
between organisms. For example, D.melanogaster (fly) has only one let-7, D.rerio 
(zebrafish) has 11 mature let-7 sequences in 19 genomic locations, 9 in C.elegans, 12 
members of let-7 in 8 loci in M.musculus (Roush and Slack 2008). 
Let-7 miRNAs have been implicated in the regulation of stem-cell differentiation in 
C.elegans (Reinhart et al. 2000), neuromuscular development and adult behaviour in 
flies (Caygill and Johnston 2008, Sokol et al. 2008), limb development in chicken and 
mouse (Mansfield et al. 2004, Schulman, Esquela-Kerscher and Slack 2005) and to 
regulate cell-cycle i.e. role in cell proliferation and differentiation (Hatfield and 
Ruohola-Baker 2008). In addition to this, most let-7 family members have been 
linked to development of cancers of many types (Takamizawa et al. 2004, Johnson et 
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al. 2005, Thomson et al. 2006) and have been reviewed extensively in literature by 
(Thomson et al. 2006) and (Boyerinas et al. 2010). Most let-7 family members are 
reported to act as tumour suppressors (Esquela-Kerscher and Slack 2006, Slack and 
Weidhass 2006). For instance, let7a, let-7d and let-7f cluster is directly down 
regulated by myc overexpression (myc is an oncogenic transcription factor often 
deregulated in cancers), hence, promoting tumorigenesis. A study on the negative 
feedback loop of let-7a reports that let-7a represses myc expression in a Burkitt 
lymphoma cell line indicating the possibility of a negative-feedback loop (Rodriguez 
et al. 2004). However, it was demonstrated that the DNA methylation state, 
particularly, in the unusual oncogenic let-7a-3 miRNA is also associated with 
cancerous phenotypes. let-7 expression is reported to be regulated by DNA 
methylation.  The methylation state of CpG islands is an epigenetic mechanism for 
the regulation of gene expression. The hypomethylated let-7a-3 miRNA on 
chromosome 22q13.31 is associated with CpG islands and resulted in the up-
regulation of let-7a-3 levels, thereby inhibiting the growth of tumour cells in lung 
adenocarcinomas. In contrast to this observation, hypermethylation of let-7a-3 
resulted in down-regulation of its expression in epithelial ovarian cancer (Brueckner 
et al. 2007).  
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Figure 1.6.9.1: List of different members of Let-7 and their mature sequences in Let-7 family 
(CHO cell). Image sourced from data by Hackl et al. (2011). 
Additionally, a report by Johnson et al. (2007) assembled a list of direct targets of let-
7 involved in controlling the cell cycle, cell division and cell proliferation genes in 
humans. These targets included 8 transcription factors, consistent with C.elegans let-7 
direct targets (Großhans et al. 2005). The assessment of these targets via RT-qPCR 
when performing let-7 overexpression studies can be useful for validation purposes. 
More importantly in regard to our project, recently a study using anti-let-7a oligos to 
increase CHO cell specific productivity (by > 60 %) and improved cell viability (late 
stages of culture period) in two mAb producing CHO cell-lines surfaced. The 
researchers also reported an increased expression of let-7a targets involved in cell 
cycle related pathways and apoptosis upon endogenous let-7a inhibition by anti-let-7a 
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miRNAs (Greenlees et al. 2014). 
1.6.9.2 miR-7 
miR-7 (specifically, miR-7-1) is a mirtonic non-coding RNA molecule found in the 
intron of the hnRNP K (heterologous nuclear ribonucleoprotein K)  gene on 
chromosome 9. miR-7 is a highly conserved miRNA, in terms of both genomic 
structure and function, among diverse species (e.g. annelids to humans), suggesting its 
significance in coordinating various physiological processes. The expression profile 
of most intronic miRNAs are highly correlated with the expression profile of their 
host gene, however, miR-7 has been reported to have a differential expression to that 
of its host gene (Aboobaker et al. 2005, Baskerville and Bartel 2005b). This 
evolutionary conserved miRNA is derived from 3 miRNA precursors- miR-7-1, miR-
7-2, miR-7-3 in the human genome. The other two isoforms miR-7-2 and miR-7-3 are 
located in the intergenic region on chromosome 15 and in another host gene (non-
protein coding), respectively (NCBI Database, hsa-miR-7). The mouse miR-7 
homologs originate from mmu-mir-7a and mmu-miR-7b precursors. The mature miR-
7 processed by cytoplasmic RNAase are miR-7-5p, miR-7-1-3p and mir-7-2-3p.  
 
Figure 1.6.9.2: List of different members of miR-7 and their mature sequences (CHO cell). Image 
sourced from data by Hackl et al. (2011). 
 
1.6.9.2.1 miR-7 role in cell proliferation and apoptosis 
Lately, several studies have been conducted to disclose the regulation activities of 
miR-7 in influencing cell-cycle progression and apoptotic mechanisms. A larger 
context of these studies was mainly focused on understanding various cancer 
etiologies and therapeutic potential. Multiple studies have reported miR-7 as a 
potential player in mediating cell proliferation and apoptosis and its deregulation 
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(acting as a tumour suppressor) is associated with different types of cancers, including 
lung cancer (Rai et al. 2011, Xiong et al. 2014), breast cancer (Webster et al. 2009), 
gastric cancer (Zhao et al. 2013), glioblastoma (Karsy, Arslan and Moy 2012), 
colorectal cancer (Zhang et al. 2013), melanoma (Giles et al. 2013), cervical cancer 
(Liu et al. 2013), tongue squamous cell cancer (Jiang et al. 2010) and hepatocellular 
carcinoma (Fang et al. 2012). Many other contrasting studies have reported miR-7 
function as an oncogene. For instance, Gu et al. (2015) reported that miR-7 was up 
regulated in renal cell carcinoma where cell migration and proliferation were 
suppressed using a synthetic inhibitor that caused miR-7 down regulation (Gu, Huang 
and Tian 2015a) 
The transcriptional regulation of endogenous miR-7 expression is mediated by the 
homeodomain transcription factor homeoboxD10 (HoxD10). HoxD10 positively 
regulates the endogenous miR-7 expression by directly interacting with the putative 
miR-7 gene promoter region and the loss of HoxD10 is associated with increased 
invasiveness (Carrio et al. 2005, Reddy et al. 2008). Another transcription factor, c-
myc has been reported to control the transcription of miR-7 by binding to the miR-7 
promoter and enhancing its activity, thereby inducing lung cancer. Other targets of 
miR-7 such as EGFR, PI3K could also stimulate miR-7 expression by utilizing 
Ras/extracellular signal-regulated kinase (ERK/myc) and phosphatidylinositol-3 
kinase (PI3K/v)-Akt murine thymoma viral oncogene homolog (Akt) signaling 
pathways (Chou et al. 2010). Therefore, it can be concluded that miR-7 coordinately 
mediate several signaling pathways at multiple levels, including a number of cellular 
pathways, which are cell cycle and apoptosis relevant both in normal and tumour 
cells. 
1.6.9.2.2 Potential of miR-7 manipulation in CHO cells 
Over 28,645 miRNAs have now been registered and catalogued in miRBase database, 
with over 1800 miRNAs being identified in the human genome. The use of next-
generation sequencing techniques such as Illumina has led to the discovery of more 
than 400 conserved mature miRNA sequences, with a single study yielding 387 
miRNA identifications, from 6 biotechnologically relevant CHO cell-lines (Hackl et 
al. 2011a, Johnson et al. 2011). The potential of mir-7 as a tool to enhance CHO cell 
productivity was demonstrated when transient overexpression of miR-7 induced 
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growth arrest, thus maintaining high and sustained viability, mimicking the 
temperature shift effect of CHO cell culture to increase production of recombinant 
therapeutic proteins (Barron et al. 2011b). The importance of miR-7 as a potential cell 
cycle regulator has also been reported by Sanchez et al. (2013). Sanchez et al. 
reported miR-7 is a key regulator of the transition from G1 to S phase of the cell 
cycle, and can cause cell-cycle arrest by targeting an array of cell-cycle regulators 
components such as Skp2, myc and p27KIP1. In a follow up study, recently, Sanchez et 
al. reported over 3-fold improved CHO proliferation and ~ 30 % cell viability 
increase and 2-fold increase in protein productivity by using miR-7 sponge decoy 
vector to sequester endogenous miR-7 levels in CHO cells (Sanchez et al. 2014). 
Hence, demonstrating miR-7 as a very interesting candidate to be further explored in 
enhancing bioprocess relevant CHO cell phenotypes. With this objective in mind, the 
second half of the project is focused on completely knocking out mature miR-7a-5p 
locus sequence in industrially relevant CHO cell-line in order to enhance CHO cell 
growth and productivity. While the first half aims to manipulate endogenous Let-7 
levels using miRNA sponges approach in CHO-K1 SEAP cells to achieve the same 
objective. 
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Objectives of Thesis 
 
1. Investigation of Let-7 miRNA as a potential candidate for CHO cell 
engineering 
To: 
 
• Stable depletion of endogenous Let-7 miRNAs in CHO-K1 SEAP cells using 
Let-7 sponge ‘decoy’ vector. 
• Evaluate the impact of stable Let-7 depletion on CHO-K1 SEAP cells growth 
and productivity characteristics. 
• Validate the Let-7 sponge vector technology using: 
o Gain-of-Function approaches through the use of Let-7 specific mimics. 
o To measure endogenous Let-7a levels using RT-qPCR. 
o Quantitating the expression levels of downstream targets of Let-7 
using RT-qPCR 
 
2. Use the novel CRISPR-Cas9 system to knock out miR-7a-5p locus in an 
industrially relevant CHO cell-lines 
To: 
 
• As a Proof-of-Concept Experiment: Design CRISPR-Cas9 vectors containing 
sgRNA(s) targeting a stably integrated eGFP in CHO-eGFP cell line. 
• Evaluate and assess the indels frequencies induced by the eGFP targeting 
CRISPR-Cas9 systems using Surveyor Assay and Sanger sequencing. 
• To target the miR-7a-5p locus using CRISPR-Cas9 vector systems in an 
industrially relevant CHO cell line. 
• Evaluate and assess the indels frequencies generated by the CRISPR-Cas9 
systems employed. 
• Evaluate and assess mature miR-7a expression levels in single cell clones. 
• Isolate a clone containing homozygous deletion of miR-7a. 
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Section 2.0 
Materials and Methods 
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2.1 General Cell Culture Techniques 
 
2.1.1 Ultrapure Water 
 
All the media, solution and reagents’ dilutions were performed using Ultrapure water 
from the Elgastat Maxima Water Purification System, 12-18 MΩ/cm. This water 
purification unit combines four processes – reverse osmosis, adsorption (using 
activated carbon), deionization and photo oxidation (UV irradiation to destroy micro-
organisms of any sorts), yielding water quality of highest purity. 
 
2.1.2 Sterilisation of Glassware and other consumables 
 
All the lab glasswares and lids were initially soaked in a 2% (v/v) RBS-25 (VWR 
International) de-proteinising solution for ~ 1 hour (hr). Following this, the 
glasswares were washed and rinsed using tap water, before treating them with 
detergent. All the glasswares were then washed and rinsed with distilled water 
followed by rinse with ultrapure water. Finally, all the glasswares were sterilised by 
autoclaving at 121 °C for 20 minutes under one bar pressure.  
The spinner vessels were cleaned in the same manner as mentioned above, however, 
included an extra step of 1M NaOH treatments overnight in order to ensure the 
elimination of cell debris from the inner surface of the vessels. These vessels were 
subsequently washed twice using ultrapure water. The thermo-labile solutions (i.e. 
10% DMSO, serum) were filtered through 0.22 µm sterile filter (Millipore, millex-gv, 
SLGV-025BS).  
 
2.1.3 Cell culture cabinets  
 
Class II laminar airflow (LF) cabinets (Holten) were used during the cell culture 
work. The cleaning of LF cabinets was carried out by using 70% industrial 
methylated spirits (IMS) before and after use. Before using the LF cabinet, the 
laminar was turned on for 15 minutes to allow for the airflow to acclimatize. After 15 
minutes, the laminar was cleaned with 70% IMS solution before performing any cell 
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culture task. Items brought into the LF cabinets were sprayed with 70% IMS solution 
and regular spraying of the gloved-hands (while in and out of the cabinet) with IMS 
was performed to maintain sterile conditions. The cabinets were always used with 
single cell line type work to avoid any cross-contamination. When working with a 
different cell line subsequently, the cabinets were cleared-out with all the previous 
cell line type and waste-tips/pipettes and cleaned with 70% IMS. The empty cabinets 
were allowed to run for 15 minutes before to be used again for a different cell line. 
This standard operating procedure (SOP) was adhered in order to prevent any cross-
contamination between cell lines/clones. These LF cabinets were weekly cleaned 
using Virkon detergent solution (Virkon, Antec International; TEGO, TH. 
Goldschmidt Ltd.), followed by ultrapure water and 70% IMS. 
 
2.1.4 Incubators 
 
Kuhner (ISF1-X, Climo-Shaker) incubators with speed ranging 130-170 rpm were 
used to maintain suspension cells at 37 °C in an atmosphere of 5 % CO2 and 80 % 
humidity. Adherent cells were also maintained at the conditions mentioned above, 
however, not in shaker incubators. The incubators were cleaned weekly adhering to 
the same protocol as described for cell culture cabinets.  
 
2.2 Subculture of cell lines 
 
2.2.1 Anchorage-dependent cells (Monolayer) 
 
The spent media in the flask was removed using pipette and discarded into a sterile 
waste bottle. Following this, the flask was rinsed using 2-4 mL of PBS 
(autoclaved/sterile) to remove any residual media. Depending upon the size of the 
flask, 2-5 mL of trypsin was added to the flask forming thin film enough to cover the 
monolayer cells surface and incubated at 37 °C for ~ 2-5 minutes (Note: Did not over-
trypsinize) until all the cells have detached. A volume of serum equivalent to the 
amount of trypsin added was added in order to deactivate the trypsin once all the cells 
were detached. The cell suspension was then pipetted into a sterile 30 mL universal 
and centrifuged at 1000 rpm for 5 minutes in order to form a cell pellet. The 
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supernatant from the universal was discarded and the cell pellet was resuspended in 
fresh basal media. A small aliquot was then taken and cell count was performed. 
Finally, a required aliquot from this cell suspension was used to seed a fresh flask at a 
desired cell density. Routinely, cells were passaged once every 3-4 days at ~ 90-100 
% confluency.  
 
2.2.2 Suspension cells 
 
30-50 mL shake flasks (working volume 5 mL) were used for suspension culture cells 
at 37 °C in a shaker incubator (as described in section 2.1.4) at 170 rpm. The cells 
were passaged routinely every 3-4 days. A sample aliquot was taken from the flask 
and used for counting viable cell number using the Trypan blue exclusion method. 
Fresh flasks were then seeded at 2 x 105 cells/mL density.  
 
2.3 Cell counting and viability determination 
 
2.3.1 Trypan Blue Exclusion method 
 
The Trypan blue exclusion method allows one to distinguish between live and dead 
cells. The rational behind the technique is that the trypan dye penetrates and stains the 
dead cells blue through the damaged/compromised cell membrane. Viable healthy 
cells with an intact cell membrane appear non-blue making it easier to distinguish the 
two when observed under microscope. A cell sample was taken from the flask and 
equal amount of Trypan blue was added (Note: The sample was diluted accordingly 
as required i.e. if too concentrated) to make a final mix of 100 µl (with diluent)). 10 or 
20 µl of this mix was pipetted onto the hemocytometer coverslip-on carefully to avoid 
any air-bubbles formation or release. The number of cells was then counted by the 
cell count average of four grids (corners) in the hemocytometer. This number was 
then multiplied by 104 (volume of the grid) and by the dilution factor to get the 
number of cells/mL in the original sample. 
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2.3.2 Flow cytometry 
 
2.3.2.1 Guava Viacount®  Assay 
 
A greater number of samples and their viability can be assessed using the Guava 
ViaCount assay in comparison to the Trypan Blue Exclusion method. The assay also 
discriminates between viable and non-viable cells based on differential permeability 
of two DNA-binding dyes in the Guava ViaCount® reagent (Merck-Millipore). The 
membrane permeant-dye (LDS 751) stains all the nucleated cells producing a 
fluorescent signal detected by the photomultiplier tube 2 (PMT2). The other dye 
penetrates the damaged/compromised membrane of non-viable cells producing a 
different fluorescent signal detected by PMT1. After detection by PMT, viable cells 
are recorded as single positive events when the fluorescent signal is accompanied by a 
signal of forward-scattered light (FSC) and is of equivalent intensity to that produced 
by a cell of particular size. A low FSC event is counted as cellular debris and is 
unaccounted within the nucleated population count. The Guava Flow cytometer 
instrument allows setting a threshold prior to the analysis in order to exclude the low 
FSC events. The membrane impermeant-dye (Propidium Iodide, PI) stains only the 
damaged/compromised membrane non-viable/dead cells. This combination of the 
dyes in the Guava ViaCount® reagent differentiates between viable, non-viable and 
apoptotic cells. 
Before performing any analysis on the Guava Flow Cytometer instrument, a 
calibration run (easyCheck) was performed in order to perform assay correctly. The 
samples for anaylsis were pipetted into round bottom 96-well plate and the minimum 
sample volume was 100 µl/well. It was important that the cell count per well has no 
less than 10 cells/µl and no more than 500 cells/µl since too dilute or concentrated 
samples could lead to error-prone read-outs. The Guava ViaCount® reagent was 1:1 
ratio with sample volume, even if the sample was diluted with sterile PBS. For 
example, for 50 µl of cell sample + 50 µl of sterile PBS = 100 µl diluted cell sample 
requires 100 µl of reagent. The Guava ViaCount® was allowed to incubate at room 
temperature 30 minutes prior use. 
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2.3.2.2 EasyFit Analysis 
 
EasyFit analysis is a method in-built in the Guava software, which groups all the 
events into three individual categories i.e. viable cells, dead/compromised/apoptotic 
cells and cellular debris. This analysis using its own grouping method allows for the 
discrimination between these three populations. In order to set a threshold, manually a 
method can be executed, for example for ‘viable cells’ by changing the FSC threshold 
and hence, completely discriminating between cellular debris and viable cells.  
 
2.3.2.3 GFP expression analysis 
 
GFP positive cells were assessed for mean GFP and % GFP expression using the 
bench-top flow cytometer Guava’s Guava ExpressPlus programme. Firstly, a GFP 
negative cell line was used to gate the instrument. Forward scatter and side scatter 
were set to observe the cells on the histogram. The fluorescein isothicyanate (FITC) 
channel was manipulated depending upon the cells to be analysed for GFP expression. 
 
2.4 Cryopreservation, Thawing and Storage of cells 
 
2.4.1 Cryopreservation 
 
Cells to be preserved in liquid nitrogen dewar were supplemented with suitable 
medium with 5 % fetal calf serum (FCS) and 5 % DMSO (Sigma-Aldrich, D5879). 
Firstly, a separate solution of basal medium supplemented with 10 % DMSO/FCS 
mix was prepared. For sterility purposes this solution was filtered through 0.22 µm 
bell filter (Gelman, 121-58) and kept on ice until used. DMSO has cytotoxic effects at 
room temperature. It was imperative that cells to be cryopreserved were harvested 
during the log phase of their growth cycle and ~ 1×106 cells/mL per cryovial (Greiner, 
201151) were frozen down. After counting and centrifuging, the cells were 
resuspended in half the 1 mL volume of suitable medium making the density 2×106 
cells/mL in a cryovial. On top of this cell suspension, 500 µl of the sterile filtered 
DMSO/FCS mixture was pipetted. Finally, the cryovial was slowly frozen and was 
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kept in -20 °C for ~ 1 hour, then moved to -80 °C overnight (O/N) and the next day 
into liquid nitrogen dewar at-196 °C. 
 
2.4.2 Thawing 
 
The simple methodology of ‘slow cooling (while cryopreserving cells) and rapid 
thawing’ was followed. In order to thaw the cryopreserved cells, they were removed 
from the liquid nitrogen, immediately placed on ice and then slightly thawed at 37 °C. 
5 mL of pre-warmed fresh medium was kept in a sterile universal. Using a sterile 
Pasteur pipette, 1 mL by 1 mL of the pre-warmed medium was used to resuspend the 
cell (in the form of ice) and pipetted into a separate sterile universal until all of the 
cell-ice was resuspended. This resuspended cells solution from the cryovial was then 
centrifuged at 1000 rpm for 5 minutes in order to remove the toxic DMSO 
supernatant. The cell pellet was then resuspended in fresh pre-warmed desired 
medium in desired cell culture format. The freshly revived cells were not passaged 
with the selective media for the first passage.  
 
2.5 Other Cell-culture related techniques 
 
2.5.1 Limited Dilution Cloning (LDC) 
 
In order to attain single-cell clone, cells were diluted using a serial dilution method in 
96-well plates. Cells were harvested at ~ 90 % confluency during the log growth 
phase and were trypsinized as per section 2.1.5.1. These cells were then fed with 
fresh medium prior to the dilution process. When the cells were pelleted, the pellet 
was resuspended and mixed by pipetting up and down several times in 10 mL of 
media to ensure precise dilution. An aliquot from this 10 mL cell suspension was then 
counted 3-4 times for accuracy using the Trypan blue exclusion method (section 
2.1.6.1). Serial dilution was performed with pre-warmed medium with sterile filtered 
conditioned medium (extracted 24-48 hours after culture). At the end of dilution, the 
final concentration in 50 mL of fresh pre-warmed medium and condition medium mix 
was 5 cells/mL. Using an automatic pipette pump, aliquots of 100 µl were transferred 
to a 96-well plate already containing the desired pre-warmed medium to get one clone 
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per two wells. The cells were then incubated at 37 °C for a week and were 
intermittently observed under microscope for scoring clones in each well. The 
medium used during this procedure contained 50 µg sterile-filtered 
Penicillin/Streptomycin solution in order to avoid Gram-negative and Gram-positive 
bacterial contaminations) and appropriate Selective Agents. 
 
2.5.2 Fluorescence-Activated Cell Sorting (FACS) 
 
An automated machine such as FACS is a more advanced, timesaving alternative to 
LDC. It accurately and positively dispenses one clone per well into a 96-well plate. 
FACS is a flow-cytometer technology used for sorting out cells based on their size, 
shape and fluorescence properties. The process starts when cells are directed into a 
stream that forms droplets after which a laser is directed at the droplets to measure 
these properties. The droplets may contain fluorescent cells that, when detected are 
sorted based on the level of fluorescence i.e. low, medium and/or high by the FITC 
channel into 96-well plates containing conditioned medium along with desired basal 
medium supplemented with serum. The instrument is initially gated using GFP 
negative cells to allow the software to distinguish between GFP positive and GFP 
negative cells. 
 
2.6 Transfection 
 
2.6.1 Transfection of plasmid DNA 
 
Several reagents were utilized for transfecting DNA. Certain transfection reagents 
work with greater efficiency depending upon the cell lines used. 
 
2.6.1.1 Lipofectamine 2000 
Prior to transfection cells were seeded 5 × 105 cells/mL in adherent mode 24 hours 
before transfection in suspension culture at a density of 0.5 – 1 × 106 cells/mL. A 
separate solution containing DNA and DMEM F-12 or CHO-SFM (50 µl) media was 
prepared to dilute DNA. LipofectamineTM (Invitrogen, Cat. No. 11688-019) was 
diluted in a separate 50 µl DMEM F-12 or CHO-SFM media. Both these mixtures 
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were then gently mixed (making the volume 100 µl) and incubated at room 
temperature for 25-30 minutes, allowing for enough time to form complexes of DNA 
and Lipofectamine. The ratio of DNA to Lipofectamine used was 1:2. After 30 
minutes of incubation, the 100 µl of complex mixture was pipetted drop-wise in 
circular manner and gently mixed by shaking the plate up and down and left-right. 
Since this transfection reagent could be toxic to cells, therefore, the media after 4- 6 
hours post-transfection was changed. 
 
2.6.1.2 TransIT-2020 reagent 
 
Similarly, the complexes were formed for the Trans-IT®-2020 transfection reagent in 
CHO-SFM media in 250 µl volume. 1 µl of Trans-IT®-2020 (Mirus, Cat. No. MIR-
5400) was added to pre-warmed 250 µl CHO-SFM media containing 1 µg plasmid 
DNA to be transfected. The contents were mixed and incubated at room temperature 
for 20-30 minutes. Following the incubation period, the mixture containing 
DNA/transfection reagent complex was added drop-wise to the cells. Trans-IT®-2020 
is a non-toxic transfection reagent; therefore, it was not mandatory to change the 
media post-transfection. 
 
2.6.1.3 Electroporation 
 
Prior to the transfection, the required materials such as plasmid DNA, cells, buffer, 
cuvettes were incubated on ice for 30 minutes. In a 1.7 mL eppendorf tube, 800 µl of 
chilled filtered sterilised electroporation buffer (2 mM HEPES – 15 mM K+PO4, 1 
mM MgCl2 and 250 mM Mannitol in 50 mL final volume) 8 × 106 cells were seeded. 
The desired volume of pre-warmed media, depending upon the culture volume format 
(e.g. 5 mL spin tube or 10 mL T75 flask with 1 % serum if original culture was in 
serum-free media), was used to re-suspend cells post electroporation. The pulsing 
machine was set at standard 500 µF and 200 volts. Mammalian cells require high 
capacitance (> 50 µF). The electroporated cells were then finally revived using pre-
warmed desired media of choice by gently pipetting up and down and incubated at 37 
°C. 
 
	 72	
2.6.2 Transfection of miRNAs 
 
The following recipe for transfection of miRNA is valid for a single transfection 
reaction. The PolyPlus-transfectionTM reagent INTERFERinTM (PolyPlus-
transfectionTM, PPLU-409-01) was utilized for CHO cells transfection as per 
manufacturer’s guidelines. 1 × 105 cells/mL per well of a 6-well plate were 
transfected with a range of 100-200 nM per 2 mL volume of CHO-S-SFM II (Gibco®, 
12052-098) media in 6-well plate. The reagents such as INTERFERinTM and miRNA 
(mimics and/or inhibitors) were kept on ice until used. INTERFERinTM was brought 
to room temperature 5-10 minutes prior to use. Initially 110 µl of pre-warmed SFM 
media was aliquoted in sterile eppendorf tube and 2.2 µl of mimic/inhibitor miRNA 
was pipetted into the eppendorf with 110 µl SFM media and mixed gently by 
pipetting up and down. Finally, 1.1 µl of INTERFERinTM reagent was added to the 
aforementioned mixture of miRNA and SFM media. This final mixture was incubated 
at room temperature for 15-20 minutes. Post incubation. 100 µl of the complex mix 
was pipetted drop-wise into the well of 6-well plate and swirled briefly for uniform 
mixing. The transfected cells were then allowed to grow at 37 °C post-transfection in 
the incubator. INTERFERinTM reagent is a non-toxic transfection reagent and does 
not lead to cytotoxicity; therefore, the media change was not mandatory. 
 
2.7 Molecular Biology Techniques 
 
2.7.1 DNase Treatment and RNase-free/Sterile tips 
 
For the below mentioned techniques, only RNase-free/Sterile pipette tips were used in 
order to avoid false-positive results and/or contamination. Moreover, the DNase 
(RNase-free kit, M0303S, New England Biolabs®) treatment of RNA samples is useful 
for the removal of contaminated genomic and plasmid DNA from transfection 
performed during the early stages of experiment. The contaminated DNA sources are 
highly abundant post-transfection and during RNA isolation protocols as carry-over 
sources. 
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2.7.2 RNA extraction using Tri Reagent® 
 
RNA was isolated using the Tri Reagent®, which is a mixture of guanidine thiocyanate 
and phenol in a monophase solution. This reagent dissolves the DNA, RNA and 
protein on homogenization or lysis of the cell sample. 1 mL of Tri Reagent® was 
added to sufficiently lyse 5/6 × 106 cells/mL and then vortexed for 10-15 s. After 
vortex, 200 µl of chloroform was added and vortexed for 10 s. The sample was then 
centrifuged at 12000 rpm at 4 °C for 10-15 minutes to separate the DNA, RNA and 
protein into three different phases: a upper aqueous phase (RNA), the interphase 
(DNA) and a lower organic (proteins).  
The upper aqueous RNA phase was then decanted carefully (i.e. without disturbing 
the interphase) into a fresh eppendorf. RNA was then precipitated by adding 500 µl of 
iso-propanol and centrifuging at 12000 rpm at 4 °C for 10 minutes. The supernatant 
was discarded and the RNA pellet was then washed with 70 % ethanol and again spun 
down at 12000 rpm at 4 °C for 10 minutes. The supernatant was carefully decanted-
off and the RNA pellet was air-dried under vacuum for 10 minutes and finally 
resuspended in 200-300 µl of Nuclease-free water or appropriate elution buffer. The 
RNA sample can be stored without compromising the sample integrity at -80 °C. 
 
2.7.3 High Capacity cDNA reverse transcription 
 
RNA was reverse transcribed into cDNA using High Capacity cDNA reverse 
transcription kit (Applied Biosystems, 4368814) as per manufacturer’s protocols. 2 µg 
of RNA sample was made upto 10 µl in a 0.5 mL PCR tube using Nuclease-free 
water. A master-mix as suggested in the protocol was prepared in 1.7 mL sterile 
eppendorf (depending upon the reactions to be performed). Table below shows a 
single reverse transcription reaction master mix recipe in accordance to 
manufacturer’s guidelines: 
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Component Volume per reaction (µ l) 
 Kit with RNase 
inhibitor 
Kit without RNase 
inhibitor 
10X Reverse Transcription (RT) 
Buffer 
2 2 
25X dNTP Mix (100 mM) 0.8 0.8 
10X RT Random Primers 2 2 
MultiscribeTM Reverse Transcriptase 1 1 
RNase inhibitor 1 - 
Nuclease-free H2O 3.2 4.2 
Total per reaction 10.0 10.0 
 
 
10 µl of the RT master mix was added to 10 µl of the above prepared RNA sample 
and mixed using a pipette. The bench top thermocycler was set as per the below 
tabulated temperature profile: 
 
 Step 1 Step 2 Step 3 Step 4 
Temperature 
(°C) 
25 37 85 4 
Time ( mins) 10 120 5 ∞ 
 
The reverse transcribed cDNA is ready to use and can be stored at -20 °C for future 
use. 
 
2.7.4 Polymerase Chain Reaction (PCR) 
 
PhusionTM High-Fidelity PCR Master Mix with High-Fidelity buffer kit (Life 
Technologies, F-531S) was used to perform most of the PCR amplification reactions 
as per manufacturer’s specification. The Master Mix was thawed on ice prior to 
setting-up reaction until used. A single PCR reaction was made up to a volume of 50 
µl in 0.5 mL PCR tube. Below mentioned is the recipe for single PCR amplification 
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reaction, with the PhusionTM Master Mix added at the very last after all other 
components were added. 
 
Component Volume/Concentration 
PhusionTM PCR Master Mix 25 µl 
Forward Primer 0.1 – 1.0 µM 
Reverse Primer 0.1 – 1.0 µM 
Template DNA 1 – 100 ng 
Nuclease-free H2O To 50 µl 
Total Volume 50 µ l 
 
Once all the components were added, the PCR tube was spun and vortexed briefly. 
After this, the thermocycler was used to amplify the product of interest. The cycler 
was manipulated according to the annealing temperature (Tm) for each set of primer 
used and length of amplicon to be amplified. Below is the programme used to perform 
the polymerisation reaction cycle. 
 
Step Temperature (°C) Time No. of cycles 
Initial Denaturation 98 1 – 3 minutes 1 
Denaturation 98 30 s 25 - 30 
Annealing Tm - 5 30 s 25 - 30 
Extension 72 1 minutes/kb 25 - 30 
Final Extension 72 5 – 15 minutes 1 
HOLD 4 ∞ 1 
 
Following PCR completion, samples are ready to be used and can be stored at -20 °C 
until further use. 
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2.7.5 Fast SYBR®  Green Real-Time Quantitative PCR 
 
RT-qPCR from Applied BiosystemsTM Fast SYBR® Green RT-qPCR Master Mix 
(Applied BiosystemsTM, Cat. No. 4385612) was used to perform qPCR reactions for 
gene expression quantification, in accordance with manufacturer’s specification. The 
quantification of the gene of interest is based on the binding affinity of SYBR® 
Green for double-stranded (ds) DNA. As the PCR amplification progresses by the 
AmpliTaq® DNA polymerase, the target sequence is amplified, resulting in increased 
number of ds-amplicon to bind to SYBR® Green. As the PCR amplification 
proceeds, the fluorescent intensity is proportional to the increase in ds-amplicon. 
 
Figure 2.1 shows RT-qPCR technique for two types of assay. One based on Fast SYBR®  Green 
RT-qPCR and other based on Taqman Probe based RT-qPCR. 
 
Prior to plate set-up, master-mixes for all samples (i.e. test samples and endogenous 
controls such as beta-actin and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), in triplicate) were prepared. A single PCR reaction volume was kept to 20 
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µl as per manufacturer’s guidelines and the reaction was performed in MicroAmpTM 
Fast Optical 96-well plate. The following recipe is for a single 20 µl PCR volume: 10 
µl of Fast SYBR® Green Master Mix (2X) was added to an eppendorf with 1µl of 
primers- forward and reverse (200 mM each). 18 µl each was added to each well of 
the MicroAmpTM 96-well reaction plate from the master mix for triplicate reactions 
for both control and test samples. Using a fresh pipette tip for each time, 2 µl of 
cDNA template (~ 20 ng to achieve optimal detection of signal) was aliquoted to each 
of the wells of the MicroAmpTM 96-well reaction plate already containing 18 µl of 
Master Mix (aforementioned). Finally, the reaction plate was sealed using a 
MicroAmpTM Optical adhesive film to avoid any reaction volume loss through 
evaporation during the PCR run. The PCR run was performed on the Applied 
Biosystems RT-qPCR 7500. The data analysis was based on the Relative Quantitation 
(2-ΔΔCt) and the relative expression of the target gene was compared to the expression 
of endogenous gene as control. 
 
2.7.6 miRNA based Molecular Biology techniques 
 
2.7.6.1 Reverse Transcription for miRNA(s) 
 
Applied Biosytems Taqman microRNA Reverse Transcription kit (ABI, 4366596) 
was used to prepare separate RT master mixes for each sample according to 
manufacturer’s specification as tabulated below: 
 
Component Master Mic (15 µ l/reaction) 
100 mM dNTPs (incl. dTTP) 0.15 
MultiScribeTM Reverse Transcriptase (50 
U/µl) 
1.0 
10X Reverse Transcriptase Buffer 1.5 
5X RT Primer 3.0 
RNase Inhibitor (20 U/µl) 0.19 
Nuclease-free water 4.16 
Total 10 
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RNA samples were diluted to a working concentration of 2 ng/µl, made in nuclease-
free water. 5 µl (20 ng) of RNA sample from this working concentration was added to 
each of the above prepared 10 µl RT-master mix, which was then gently mixed and 
centrifuged. In order to validate for any genomic contamination of the primers and 
reaction components, a separate master mix reaction without the MultiScribeTM 
Reverse Transcriptase for each primer set was prepared within the assay. 
Finally, the cycler programme was used as per manufacturer’s guidelines: 
 
Step Time (minutes) Temperature (°C) 
HOLD 30 16 
HOLD 30 42 
HOLD 5 85 
HOLD ∞ 4 
 
cDNA samples were in ready-to-be-used condition for qPCR quantitification of 
miRNA using specific primers and/or could be stored at -20 °C until further needed. 
 
2.7.6.2 RT-qPCR for miRNA expression analysis 
 
The Taqman 2X Universal PCR master mix (Applied Biosystems, ABI, 4324018) was 
utilized for individual miRNA expression analysis. According to manufacturer’s 
recipe specifications (tabulated below), a single reaction was prepared: 
 
Component 20 µ l/reaction 
Taqman miRNA Assay (20X) 1.00 
Product from RT reaction (Min. dilution 1/15) 1.33 
Taqman 2X Universal PCR Master Mix, No AmpErase® UNG) 10.00 
Nuclease-free water 7.67 
Total 20 
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Figure 2.2 showing the two-step RT/PCR mechanism (i.e. reverse transcription followed by PCR 
for cDNA conversion and subsequent amplification of the cDNA) (A), wherein in Step 1 – stem 
loop RT primers anneal to miRNA targets and extended further by the reverse transcriptase 
enzyme and Step 2 – PCR reactions progress with miRNA-specific forward and reverse primer 
and detection of signal via the Taqman®  probe. Figure 2.2 (B) shows the mechanism by which 
the Probe functions. The quantification of miRNAs is based on the Ct values. MGB: minor 
groove binder; NFQ: non-fluorescent quencher; R: reporter dye (FAMTM dye). 
 
The MicroAmpTM optical reaction plate was used for the qPCR. From the above-
mentioned master-mix, 16 µl, containing the appropriate primer (or here the Taqman 
miRNA Assay), was aliquoted into the plate. The plate was then sealed with standard 
optical adhesive film and incubated on ice for 10 minutes prior to the qPCR-run. 
Finally, using the 9600 emulsion mode of thermocycler, the qPCR was performed in 
the HT7600 RT-qPCR machine with conditions tabulated below: 
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Step AmpliTaq 
Gold®  Enzyme 
Activation 
PCR 
HOLD Cycles (40) 
Denatured Anneal/Extend 
Time (minutes) 10 15 s 60 s 
Temperature (°C) 95 95 95 
 
 
 Below mentioned are the assay kits used during the course of this Master’s Degree. 
 
Applied BiosystemsTM miRNA assay kits 
miRNA Cat. No. Assay ID 
U6 snRNA (Endogenous 
control) 
4427975 001973 
hsa – Let7a – 5p 4427975 000377 
hsa – miR7a-5p 4427975 000386 
 
 
2.8 Cloning Techniques and other basic reagents preparations 
 
2.8.1 Gel and Lysogeny Broth (LB) media preparations 
 
2.8.1.1 Agarose gel preparation 
 
Agarose (Sigma-Aldrich, A9539) was aliquoted into 1X TAE (Tris base, acetic acid 
and EDTA) (Thermo, #B49) buffer as desired volume for desired gel resolution. For 
example, 2 % (w/v) being considered as high percentage for resolution for ~ 100 bp 
DNA bands. This solution of agarose and 1X TAE buffer was then heated until all of 
the agarose was completely dissolved and then cooled to hand-hot condition. 
Following this, 1 µl of ethidium bromide (0.5 µg.mL) was added and mixed as a stain 
for DNA in the gel when observed under UV trans-illuminator. Finally, the hand-hot 
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agarose, TAE and dissolved ethidium bromide was poured into a desired gel tray for 
further use. 
 
2.8.1.2 LB media preparation 
 
For 500 mL of LB media, 5 g of Tryptone (Sigma-Aldrich, #T7293), 2.5 g of Yeast 
Extract (Sigma-Aldrich, #92144) and 5 g of NaCl (Sigma-Aldrich, #S9888) was 
dissolved in 500 mL of UHP and subsequently autoclaved. 
 
2.8.1.3 LB agar plate preparation 
 
For the LB agar plate media, the recipe aforementioned was the same except addition 
of 7.5 g of Select Agar (Sigma-Aldrich, #A5306) in 500 mL of UHP and then 
autoclaved. When the LB agar was hand-hot, desired antibiotics were pipetted into it 
and then, finally, poured into 100 mm petri dishes (plastic material). 
  
2.8.2 Cloning techniques 
 
2.8.2.1 Restriction enzyme digestion 
Digestion reactions were performed in 0.5 mL PCR tube with the recipe outlined 
below: 
Component Volume (µ l) 
Plasmid DNA 2 µg 
NEB Buffer, 1-4 (10X) 2 
BSA (100X) 0.2 
Restriction enzyme 1 U (0.5 – 1 µl) 
Nuclease-free water To 20 µl reaction volume 
 
The plasmid DNA was digested at 37 °C in the hot-hole plate for the specified 
temperature according to enzymes’ manufacturers specifications. Both single and 
double digestions can be carried out with various enzymes under specified conditions. 
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2.8.2.2 Alkaline phosphatase treatment 
 
Alkaline phosphatase, New England Biolabs (NEB), enzymes such as Calf-intestinal 
phosphatase (CIP) and/or Shrimp alkaline phosphatase (SAP) catalyse the removal of 
5’-phosphate group from DNA/RNA and prevents the CIP or SAP treated DNA to 
self-re-ligate after the circularised plasmid has been linearized. 2 µg of digested 
(and/or linearized) plasmid DNA were transferred to 0.5 mL PCR tube containing 5 
µl of 10X CIP enzyme (20 U/µl) in a final volume reaction volume of 50 µl. This 
PCR tube containing the reaction mix was incubated at 37 °C for one hour. 
 
2.8.2.3 Large Klenow fragment treatment 
 
A 30 µl of reaction was set-up using 25 µl of digested plasmid DNA in 10X NEB 
buffer 2, 33 µM of dNTPs and 3X Klenow enzyme (5 U/µl). This reaction tube was 
incubated at 25 °C for 15 minutes, followed by a further incubation at 75 °C for 20 
minutes. Finally, the reaction was stopped by adding EDTA at 10 mM concentration.  
DNA polymerase I, large (Klenow) fragment is a proteolytic product of E.coli DNA 
polymerase I that retains the enzyme’s 3’ à 5’ exonuclease acitivity and 
polymerisation ability, however, has lost the 5’ à 3’ exonuclease acitivity. This 
treatment is necessary in order to trim the overhangs in order to make them 
compatible with other restriction enzymes. Moreover, Klenow treatment also inhibits 
re-ligation of linearized plasmid DNA. 
 
2.8.2.4 DNA ligation 
 
T4 DNA ligase enzyme kit (ROCHE®, Cat. No. 10 481 220 001) was used for all the 
ligation reactions that were carried out. In order to ensure efficient ligation reaction, 
the recommended ratios of 1:3 and/or 1:5 (with insert to vector saturation) were used. 
The vector backbone used per reaction was in the range of  ~ 50-150 ng, depending 
upon yields from purification processes. Each reaction was carried out with a reaction 
volume of 20 µl but also scaled up to 50 µl if required.  
The following recipe was set-up for each ligation reaction: 2 µl of 10X T4 DNA 
ligase reaction buffer was added to the reaction mix (containing the backbone and 
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insert) and made 19 µl with nuclease-free water. Finally, 1 µl of T4 DNA ligase 
enzyme (1 U) was added to the reaction mix. This final reaction mix of 20 µl was 
incubated O/N on temperature gradient in an ice bucket (with floater eppendorf-
holder). The controls such as ‘No-ligase’, ‘NO insert’ and others were also set-up 
with all the other mentioned components in order to account for DNA backbone’s 
self-ligation frequency as well as incomplete digestion of the vector backbone 
resulting in false-positive results. 
 
2.8.2.5 Kinase treatment 
 
T4 Polynucleotide Kinase (T4 PNK) is used for the phosphorylation of the DNA at 
5’-ends. 2 µl of 10X T4 kinase buffer was added to 0.5 µl (already added) of both the 
sense and anti-sense strands (annealed previously) in the 0.5 mL PCR tubes. 17 µl of 
nuclease-free water was added to make 20 µl reaction volume and at last 0.4 µl of 
Kinase enzyme (ROCHE®) was added to the 20 µl reaction mix. The reaction mix 
with kinase enzyme was incubated at 37 °C for 30 minutes. The kinase-treated DNA 
can be stored at – 20 °C for up to one year later. 
 
2.8.2.6 Bacterial Transformation for cloning 
  
Transformation experiments were done in One Shot® Max Efficiency® DH5αTM-
T1® competent cells. 50 µl of DH5α competent cells were thawed on ice prior to use 
for each transformation reaction. After thawing, 1 µl of ligation reaction/plasmid 
vector and/or DNA was added to 50 µl of competent cells. The mixture was then 
incubated on ice for about 20-25 minutes, followed by 42 °C heat-shock for ~ 30 
seconds in a hot-water bath. The heat-shocked cells were then revived on ice for 2 
minutes. Following this 300 µl of pre-warmed S.O.C rich medium was added to the 
vial and incubated at 37 °C at 225 rpm for one hour in shaker incubator. After 
incubation, the vial was centrifuged at 2000 rpm to make cell pellet and 85-90 % of 
the supernatant was discarded off. The rest of the supernatant was used to re-suspend 
the cell pellet and plated onto LB agar plate (containing the desired antibiotic) using a 
sterile spreader and incubated at 37 °C O/N. 
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2.8.2.7 TOPO-TA vector cloning 
 
The TOPO® TA Cloning® kits provide a highly efficient 5-minute, one step cloning 
strategy for the direct insertion of Taq-polymerase amplified PCR products into a 
plasmid vector for sequencing. For this kit, no ligase, post-PCR procedures, or PCR 
primers containing specific sequences are required. 
In this kit, a plasmid vector (pCRTM4-TOPO®) is supplied linearized with (i) single 
3’ thymidine (T) overhangs for TA Cloning®, and (ii) Topoisomerase covalently 
bound to the vector (referred to as “activated” vector) (Figure 2.3 and 2.4). Taq 
polymerase has a non-template-dependent terminal transferase activity that adds a 
single deoxyadenosine (A) to the 3’ ends of the PCR products. The “activated” 
linearized vector in the kit has single, overhanging 3’ deoxythymidine (T) residues 
bound to it (Shuman 1991, Shuman 1994). This allows for the PCR inserts to ligate 
efficiently with the vector. 
 
 
 
 
Figure 2.3 showing the “activated” vector 
with covalently bound Topoisomerase 
enzyme, which allows to efficiently clone 
PCR products into the linearized vector. 	
Figure 2.4 shows the complete vector 
map of the linearized pCRTM4-TOPO®   	
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After amplifying the PCR products using the Taq polymerase enzyme, they were 
cloned into the linearized pCRTM4-TOPO® TA vector as manufacturer’s 
specification. The recipe is tabulated below: 
 
Reagents Volume 
Fresh PCR product (10-100 ng) 0.5 – 4 µl 
Salt Solution 1 µl 
Nuclease-free water Add to 5 µl 
pCRTM4-TOPO® TA vector (last) 1 µl 
Final Volume 6 µ l 
 
This reaction mixture was then incubated at room temperature (preferably at 20 °C) 
for 5-10 minutes. After incubation, the reaction was ready for transformation 
(according to section 2.8.2.6) into One Shot® TOP10 and/or DH5αTM-T1R 
competent cells and plated onto LB agar plates (with either Kanamycin or Ampicillin 
antibiotic). Post-transformation, colonies were pipetted into 5 mL LB agar 
(Ampicillin or Kanamycin) containing media for DNA Miniprep purposes. Post DNA 
Miniprep (as per section 2.8.3.1), appropriate volume of DNA sample was sent for 
sequencing. 
 
2.8.2.8 SURVEYOR Assay 
 
Surveyor® Mutation Detection Kit for Standard Gel ElectrophoresisTM (Integrated 
DNA Technologies, IDT, Cat. No. 706020) was used for detecting mutations in DNA 
sequences with great sensitivity. This kit uses a mismatch-specific DNA endonuclease 
that scans mutations and polymorphisms in heteroduplex DNA. The Surveyor 
Nuclease is an endonuclease that cleaves DNA with high specificity at sites where 
insertions, deletions (indels) or any frame-shift mutations are present in the DNA 
sequence. The Surveyor DNA endonuclease cut both strands of a DNA heteroduplex 
on the 3’-side of the mismatch site. Indels and other base-substitution mismatches are 
recognized, however, the efficiency of cleavage varies with the sequence of mismatch 
(Qiu et al. 2004). Surveyor assay has been reported to be robust and reproducible tool 
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for the detection of mutations accurately in human, other mammalian, bacterial and 
plant genomes (Qiu et al. 2004, Tsuji and Niida 2008).  
Surveyor Mutation detection kit allows easy detection of mutational DNA sequences 
after nuclease cleavage and its subsequent visual analysis by agarose gel 
electrophoresis or PAGE. DNA size range between 200-4000 bp can be easily 
analysed using agarose gel and/or PAGE. A detailed step-by-step protocol is 
explained below: 
 
Step 1 Preparing PCR amplicons from mutant (test) and wild-type (reference) DNA. 
The most critical requirements for the successful nuclease digestion in this step are: 
PCR yield is sufficiently high (i.e. > 25 ng/µl), has low background (i.e. specific 
single PCR bands of correct sizes, with no non-specific bands) and the amplicons are 
free from any PCR primer-dimer artefacts. Other important requirements are outlined 
in the protocol of the Surveyor Nuclease Assay kit and were strictly adhered to while 
performing the experiments. 
The amount of purified PCR amplicons (using PCR purification kit as per section 
2.8.3.3) used in the reaction mix was 400 ng in total, which is optimal substrate 
required for the range of Surveyor Nuclease S enzyme used (i.e. 0.5-2 µl). 
 
Step 2 Formation of homo/hetero-DNA duplexes 
The appropriate volumes for 200 ng and 400 ng DNA for both the test and reference 
DNA were worked out. In order to detect homogeneous mutation in a test sample, the 
PCR product must be hybridized with a wild-type reference PCR product to generate 
mismatches for Nuclease S cleavage. Both the test sample and wild-type reference 
DNA were amplified separately with same PCR primers and then mixed in 1:1 ratio 
(i.e. 200 ng: 200 ng, 400 ng in total) to maximize the heteroduplexes formation during 
hybrization protocol (tabulated below). 
Similarly, the heterogeneous DNA (containing pools of fragments derived from 
genetically different homozygous or heterozygous sources) was also PCR amplified 
according to Step 1. Such heterogeneous PCR amplicon samples were also hybridized 
without mixing them with a wild-type reference DNA. The proportion of mutant to 
reference DNA in the DNA populations should be more than 5-10 % for efficient gel 
electrophoresis analysis. 
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Equal amounts of test sample and reference PCR products in a 0.2 mL tube were 
mixed. A separate 0.2 mL tube was used for reference DNA as control. For efficient 
annealing the reaction volume was kept at least 10 µl. (Note: Each tube should 
contain total DNA ~ 400 ng. 
Table below shows a summarised view of homo and hetero mixes of DNA or PCR 
amplicons for one reaction, including the respective Controls. It also shows the 
possible results if experiments performed adhering to all aspect of sample 
preparations according to manufacturer’s specifications. 
 
Experiment DNA 
amount 
Purpose and Expected result 
Control 1: Wild-
type reference 
DNA (Nuclease 
positive) 
400 ng Nuclease +ve control: Nuclease cleaves no part of 
the Homo-duplexes, which in theory have no 
mutations. Therefore, Single Band on agarose gel. 
Control 2: Wild-
type reference 
DNA (Nuclease 
negative) 
400 ng Nuclease -ve control: No Nuclease S à no 
digestion of the homo and hetero duplexes. 
Therefore, Single Band on agarose gel 
Test Control 1: 
Test + Reference 
wild-type DNA 
(Nuclease 
negative) 
200 ng + 
200 ng = 
400 ng 
No Nuclease test control: No Nuclease Sà no 
digestion of the homo and hetero duplexes. 
Therefore, Single Band on agarose gel. 
Test: Test + 
Reference wild-
type DNA 
(Nuclease 
positive) 
200 ng + 
200 ng = 
400 ng 
Test: Nuclease positive test sample à Nuclease S 
digests the hetero duplexes of reference DNA and 
test DNA. Therefore, resulting in Two Bands on 
agarose gel 
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The thermocycler set-up for hybridization for the formation of homo/heteroduplexes 
is tabulated below: 
Temperature (°C) Time (minutes) Temperature ramp 
(°C/s) 
95 10  
95 to 85  -2.0 
85 1  
85 to 75  -0.3 
75 1  
75 to 65  -0.3 
65 1  
65 to 55  -0.3 
55 1  
55 to 45  -0.3 
45 1  
45 to 35  -0.3 
35 1  
35 to 25  -0.3 
25 1  
4 ∞  
 
Following the cycler hybridization programme, the heteroduplex samples (as 
mentioned in the table were treated with Nuclease S enzyme on ice in Step 3. 
 
Step 3 Treatment with Surveyor Nuclease S 
In this step, the heteroduplex test sample DNA from Step 2 was cleaved with 
appropriate amount Nuclease S enzyme and Enhancer S (amount depending on PCR-
type used, as per manufacturer’s specifications), along with necessary reference DNA 
and controls 
The hetero/homoduplex DNA experimental samples and any reference DNA samples 
were kept in separate tubes. The internal G and C controls supplied with the kit were 
also set-up in separate tubes according to manufacturer’s specifications. 
	 89	
All the reactions were carried out using Phusion High-Fidelity PCR Master Mix with 
HF buffer (ThermoFisher Scientific, F531S). Therefore, 2 µl of Nuclease S and 1 µl 
of Enhancer S was used each time, without the need for the STOP solution (supplied 
in the kit) after Nuclease S digestion. The nuclease digestion was performed at 42 °C 
for exactly 60 minutes. 
 
Figure 2.5 Overview of the Surveyor Experiment. CRISPR-Cas9 induces double stranded breaks 
in the target DNA, which are repaired by cells natural machinery via the error prone NHEJ 
mechanism. NHEJ is an imperfect DSBs repair method of the cell and often yield mutations in 
the sequence. These mutations are detected with the highly mutation-sensitive Surveyor Assay. 
The Surveyor Assay begins with PCR amplification of the targeted locus and formation of the 
homo-/hetero-duplexes of the equimolar amounts of wild-type (reference DNA) and the test PCR 
amplicons. The cross-annealing of the mutated (test) amplicons with the reference or wild-type 
amplicons, converts mutations into mismatched duplexes. Following this, the re-annealed 
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amplicons are digested with Surveyor Nuclease S enzyme, which is mis-match specific and 
cleaves the distorted duplexes at the site of mismatch, generating digested products. Finally, these 
digested products can then be visualized on agarose or poly-acrylamide gels at appropriate 
resolutions. Legends: Horizontal half arrows à  PCR primers; Straight double-lines à  wild-type 
PCR amplicons  and Jagged lines à  Mutated amplicons. 
 
Step 4 Analysis of DNA fragments 
DNA fragments in 1000-4000 bp range were resolved on 1.2 % Agarose Gel using 1X 
TAE buffer. The heteroduplex test sample digested with Nuclease S will yield two 
products of different/same sizes. 
 
2.8.3 DNA purification 
 
2.8.3.1 Plasmid DNA purification MiniPrep 
 
Post-transformation reaction, 20 µg of plasmid DNA was purified using the QIAprep 
Spin Miniprep kit (QIAGEN Cat. No. 27104). After overnight (O/N) incubation of the 
LB agar plate, a positive transformant colony was picked to inoculate a 5 mL LB 
medium culture supplemented with appropriate antibiotic concentration. This culture 
was then inoculated at 37 °C O/N at 225 rpm in a shaker incubator. The following 
day, the bacterial culture was centrifuged at 4000 rpm for 10 minutes at 4 °C. The 
supernatant discarded-off and the pellet was resuspended using 250 µl of 
resuspension P1 buffer (supplied in the kit). The resuspended cell pellet mixture was 
then transferred to a 1.7 mL eppendorf into which equal amount of cell-lysis buffer P2 
was aliquoted. Cells were lysed using the lysis buffer and then mixed vigorously by 
inverting the eppendorf up down several times, immediately after the addition of lysis 
buffer (Note: The lysis was not allowed to go more than 5 minutes). Following the 
lysis of cells, 350 µl of neutralization buffer was added to enhance precipitation of 
DNA and the tube was inverted several times immediately after the addition of 
neutralization buffer and spun at 13000 rpm for 10 minutes. The supernatant was then 
applied to QIAprep spin column and spun at 13000 rpm to bind the DNA to the 
column for 3 minutes. Following this, the column was washed with 500 µl of PB 
buffer to remove any traces of nuclease activity. This was followed by addition of 750 
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µl PE buffer wash, then spinning at 13000 rpm for 1 minute. The column after first 
spin was spun again at 13000 rpm in order to remove any traces of PE buffer. 
DNA was then eluted from the column by applying 50 µl of luke-warm EB buffer 
(pH 8) in the center of column filter. The column was incubated at room temperature 
after the EB buffer addition for 2-3 minutes, and then centrifuged for 1 minute at 
13000 rpm to elute DNA into a fresh eppendorf. 
 
2.8.3.2 Plasmid DNA purification: Maxiprep 
 
Post-transformation reaction, 500 µg of plasmid DNA was purified using the QIAprep 
Spin Miniprep kit (QIAGEN Cat. No. 27104). After O/N incubation of the LB agar 
plate, a positive transformant colony was picked to inoculate a 25 mL LB medium 
culture supplemented with appropriate antibiotic concentration. This culture was then 
inoculated at 37 °C O/N at 225 rpm in a shaker incubator. The following day, the 
bacterial culture was centrifuged at 6800xg for 15 minutes at 4 °C. The supernatant 
was discarded-off and the pellet was resuspended using 10 mL of pre-chilled 
resuspension P1 buffer (supplied in the kit). After cell-pellet resuspension, 10 mL of 
lysis buffer P2 was added to lyse the cells and the tube was mixed vigorously by 
inverting up and down and incubated at room temperature for not more than 5 
minutes. Subsequently, 10 mL of neutralization buffer N3 was added to neutralize the 
lysis buffer and the tube was mixed vigorously, immediately. The cell lysate was 
transferred to a QIAfilter cartridge and incubated at room temperature for 10 minutes. 
The lysate was then filtered through cartridge in a separate centrifuging tube by 
inserting a plunger to the cartridge. During the incubation time when the lysate was 
applied to the QIAfilter cartridge, a QIAgen-tip 500 was equilibrated with 10 mL of 
QBT equilibration buffer in order to reduce the surface tension to allow easy entry of 
fluid through the filter. The filtrate (containing the DNA) was applied to the 
equilibrated QIAgen-tip 500, which was then washed with QC buffer twice to remove 
any possible contaminants. Finally the DNA was eluted using 15 mL of QN buffer. 
The eluted DNA was then precipitated with 10.5 mL of room temperature isopropanol 
in pyrogen-free centrifuge glass tube. The glass-tube was spun at 15000 rpm for 30 
minutes at 4 °C. After centrifuging, the supernatant was decanted-off and the DNA 
pellet was washed with 5 mL of 70 % ethanol to remove precipitated salts. This 5 mL 
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volume containing the washed DNA pellet was then again centrifuged at 15000 rpm 
for 10 minutes at 4 °C. Finally, the DNA pellet was air-dried for 5-10 minutes and the 
purified DNA redissolved in lukewarm EB buffer. 
 
2.8.3.3 PCR Purification 
 
Amplified PCR products were purified using QIAGEN® QIAquick PCR purification 
kit (QIAGEN®, 28104) in accordance with manufacturer’s specifications. Other 
purifications of single/double-stranded DNA from PCR and enzymatic reactions such 
as Kinase/CIP/Klenow were also carried out using this kit. 
Firstly, 5 volumes of PB buffer (with pH indicator) were added to the 1 volume of 
PCR reaction mix. The mixture will turn yellow, however, if the mixture appears 
orange or violet then 10 µl of 3M sodium acetate was added and mixed for 15 s using 
vortex. This reaction mix was then applied to the QIAquick spin column and 
incubated at room temperature for 2-3 minutes. After incubation, the spin column was 
spun at 13000 rpm for 1 minute to bind the DNA to the column. A wash step with 750 
µl of buffer PE was performed after the DNA binding step, and the column was spun 
at 13000 rpm for 1 minute. The flow-through after this spin was discarded and 
QIAquick column was placed into the collection tube and spun again at 13000 rpm 
for 1 minute in order to get rid-off any residual wash buffer PE. Following this, 30-40 
µl of lukewarm nuclease-free water or EB buffer was pipetted into the center of the 
column filter and incubated at room temperature for 2-3 minutes. After incubation, 
the column was spun down with a fresh eppendorf as the collection tube at 13000 rpm 
for 1 minute. The purified DNA can be stored at – 20 °C until further used. 
 
2.8.3.4 NanoDrop®  Spectrophotometer 
 
The purified DNA/RNA samples were quantified using the NanoDrop® ND-1000 
Spectrophotometer (NanoDrop Technologies). The pedestal of the NanoDrop was 
wiped using a lint-free tissue with wet UHP, before analysing any DNA/RNA sample. 
2 µl of UHP was loaded to ‘Initialize’ the system and wiped after initializing the 
system, then another 2 µl UHP was then used to ‘Blank’ the instrument. The 
programmes stored to measure the DNA/RNA samples were DNA-50 and RNA-50, 
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respectively at 260 nm. The concentration of RNA/DNA was calculated by software 
using the following formula: 
OD260nm x Dilution factor x 40 = ng/µl RNA 
Abs260/Abs280 and Abs260/Abs230 ratio for each sample was recorded. Ratios ~ 2 of 
Abs260/Abs280 and ~ 1.8-2.2 of Abs260/Abs230 are indicative of pure DNA/RNA 
samples. Samples with absorbance values outside these ratio ranges were indicative of 
potential contaminants due to protein or phenol or ethanol and of bad quality 
DNA/RNA. 
 
2.9 Proteomic-based techniques and assays 
 
2.9.1 Bradford assay 
 
A Bovine serum albumin (BSA) standard (Bio-Rad, Cat. No. 500-0206) starting with 
1 mg/mL from the stock concentration of 2 mg/mL was serially diluted using UHP at 
0.5, 0.25, 0.125 and 0 mg/mL. The Standards and samples were measured in 
triplicates and ~ 5 µl of each sample were pipetted into the corner of the base of a 
well in a 96-well plate. 250 µl Quick startTM Bradford 1X Dye Reagent (Bio-Rad, 
Cat. No. 500-0205) was added to each well and incubated in the dark for 10-15 
minutes. The absorbance readings were measured on a spectrophotometer at a 
wavelength of 595 nm. 
 
2.9.2 Western Blot 
 
Sodium dodecyl sulphate - Polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to resolve proteins analysed from Western Blotting. The cell pellet was lysed on ice 
for 20 minutes using the lysis buffer containing urea and vortexed. After 20 minutes, 
the lysate was centrifuged at high speed for 15 minutes at 4 °C to remove any 
insoluble debris. The 2X Laemlli buffer (Loading dye from Sigma-Aldrich, S#3401) 
and appropriate volumes of lysis buffer were used to dilute protein samples. The 
protein samples were quantified according to aforementioned, Bradford protocol.  
The samples were boiled for 5 minutes and cooled on ice, before loading onto the gel. 
4-
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was used for loading 5-20 µg of protein and the molecular weight marker (NEB).  
Electrophoretic transfer, blocking and development of western blots was carried out. 
The membranes were probed with the appropriate antibody of choice diluted in Tris-
buffer saline containing 0.1 % - 20 % Tween (TBS-T). An anti-mouse GAPDH mAb 
(Abcam, #ab8245) was used as an internal control. 
 
2.9.3 SEAP assay 
 
Lipscomb et al., (2005) reported an enzymatic assay method for the quantification of 
SEAP (secreted alkaline phosphatase). According to the assay, 50 µl of supernatant 
was transferred to a flat-bottom well of a 96-well plate. On top of this 50 µl of 2X 
SEAP reaction buffer (10.5 diethanolamine (100 %), 50 µl of 1M MgCl2 and 226 mg 
of L-homoarginine in a total of 50 mL volume) was pipetted. Following the 96-well 
plate was incubated at 37 °C in order to increase enzymatic activity. A phosphate 
substrate (158 mg of p-nitro-phenol-phosphate) in 5 mL of 1X SEAP reaction buffer 
was made fresh for each use (adjusted to volume to suit the number of samples to be 
tested). 10 µl of this substrate was added to each well (Note: Avoid direct contact 
with light). A kinetic absorbance assay was performed in the Micro-titer plate reader 
in the KC4 instrument using the Gen5TM programme (Biotek® Instruments, Inc.). 
This measures absorbance readings and the changes in the readings per minute, which 
are indicative of the amount of SEAP present in the sample as the reaction progresses 
(i.e. the substrate depletion by SEAP per minute). Mean V values were taken as the 
change in the average of the kinetic slope.  
 
2.9.4 Enzyme-linked immunosorbent assay (ELISA) 
 
Bethyl Laboratories Human IgG ELISA Quantitation set (Bethyl Laboratories Inc., 
E80-104) was used to quantify CHO-secreted IgG antibody as per manufacturer’s 
specifications. CHO cells were centrifuged at 1000 rpm for 5 minutes and the 
supernatant was harvested in a microcentrifuge tube. In order to remove any trace 
amount of residual cells, the supernatant was further spun again at 13000 rpm for 5 
minutes before the assay. 
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The coating antibody (goat anti-human IgG-affinity purified) was first diluted (1 µl in 
100 µl Coating Buffer) and used at 100 µl/well to coat the immunoassay plate 
(Sigma) wells. Following this, in order to avoid any non-specific binding, the plate 
was blocked with 200 µl/well of 1 % BSA blocking solution for at least one hour at 
room temperature. The test sample supernatant was then applied to each well of the 
plate in order to allow interaction with the coating antibody.  CHO-IgG antibodies 
were detected by addition of 100 µl/well of the secondary antibody (goat anti-human 
IgG-linked to horse radish peroxidase (HRP)). 3-5 washes were performed using a 
wash solution between each step of the assay. 100 µl of 3,3’,5,5’- 
tetramethylbenzidine (TMB) solution was used to prepare the enzyme substrate 
reaction, which develops a deep blue product after 15 minutes upon interaction with 
HRP conjugates in ELISA. The reaction is stopped by a H3PO4 solution at 2M (100 
µl/well), which gives a yellow colour as a signal. A standard curve with purified 
recombinant human IgG1 antibody (rHIgG1) was used to quantify the amount of 
rHIgG1 present in the samples. The absorbance readings of the reader plate were 
measured at 450 nm. 
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Section 3.1 & 3.2 
Stable Depletion of endogenous Let-7 
microRNA levels in CHO-K1 SEAP 
cells using “sponge” decoy vectors 
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3.1.1 miRNA “sponge” decoy vectors  
 
For loss-of-function studies, miRNA sponge decoy vectors were employed for stable 
long-term gene knockdown in vivo. These decoy vectors were constructed by cloning 
miRNA anti-sense sequences into an appropriate backbone vector. The key advantage 
of using miRNA sponges is that they potentially inhibit a whole miRNA family 
(sharing the common seed region sequence) by using the complementary heptameric 
seed sequence. miRNA sponge technology was first explored by Ebert and colleagues 
(Ebert, Neilson and Sharp 2007). 
 
3.1.2 Let-7 sponge design and description 
 
 As mentioned in Section 1.6.9.1, Let-7a manipulation resulted in enhanced cellular 
viability and specific productivity in two different CHO cell lines. Moreover, 
previously our lab reported 4-fold improvement in CHO cell normalised productivity 
following Let-7e manipulation (unpublished data). Previously our laboratory also 
reported Let-7 family members being differentially expressed in CHO-K1 cells 
cultivated at two different temperatures, suggesting their importance in regulating 
growth (Gammell et al. 2007). These positive observations stimulated our interest to 
observe the impact of stable depletion of endogenous Let-7 in CHO-K1 SEAP cells 
using a Let-7 miRNA sponge decoy vector (henceforth referred to as Let-7 sponge). 
In particular, we were interested in improving CHO cell growth rate and as a result, 
the overall protein yield.  
Briefly, the endogenous mature Let-7 miRNA recognizes its mRNA targets by 
sequence complementarity between the seed region of miRNA (2-8 nt of 5’-end) and 
binding sites in the 3’-UTR of the mRNA targets and inducing post-transcriptional 
repression. Let-7 sponge was designed to cause efficient endogenous Let-7 inhibition 
(by ‘soaking-up’ the endogenous Let-7 levels in the cells like a ‘sponge’) by 
competing with mRNA targets for Let-7 binding and diverting the endogenous Let-7 
function of post-transcriptional gene regulation. As outlined in Figure 3.1.1, four Let-
7 binding sites were inserted in tandem in the 3’-UTR of a destabilized enhanced 
green fluorescent protein (deGFP) i.e. at XhoI and EcoRI sites (Table 3.1 for 
Sequence details) (Fig. 3.1.2). The deGFP reporter has a short half-life of 2 hours 
and any change in the deGFP fluorescence induced by the binding of the miRNA 
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(Let-7 in this case) to the sponge is correlated to the change in miRNA expression. In 
simple terms, post binding of endogenous Let-7 to the sponge, the miRNAs prevent 
deGFP from being expressed (or translated), hence, the deGFP acts as a reporter of 
miRNA depletion. The Let-7 sponge sequences incorporated in the sponge vector 
were designed to be almost fully complementary to Let-7. However, a few base 
mismatches  (wobble/bulge) at nucleotides 9-11 were introduced in order to prevent 
RNAi type cleavage. Moreover, the miRNA binding sites were kept to four since 
including more than ten miRNA binding sites have been reported to promote sponge 
degradation (Ebert, Neilson and Sharp 2007). The modification to introduce a 
“wobble” increases the functional half-life of the sponge construct (Ebert, Neilson 
and Sharp 2007, Ebert and Sharp 2010, Kluiver et al. 2012). A negative control 
sponge vector (henceforth referred to as NC sponge) was also designed in a similar 
manner, however, instead of Let-7 binding sites, the NC sponge contained non-
specific sequence that should not bind any known miRNAs. 
 
Table 3.1: miRNA sponge sequence details for Let-7 sponge design 
5’ to 3’ Let-7 miRNA sponge sequence 
Sponge XbaI site XhoI site Let-7 sponge sequence EcoRI site XbaI site 
Let-7 
sponge 
TCTGA CTCGAG acgcgAACTATACAATGATCTA
CCTCAacgcgAACTATACAATG
ATCTACCTCAacgagAACTATAC
AATGATCTACCTCAtgacgtAAC
TATACAATGATCTACCTCAtcat
c 
GAATTC TCTAGA 
NC-
sponge 
TCTGA TCTGA tcgagCCGGAAGTTTTCAGAAA
GCTAACAccggAAGTTTTCA 
GAAAGCTAACAccggAAGTTTT
CAGAAAGCTAACAccggAAGTT
TTCAGAAAGCTAA CAccgg 
 
GAATTC TCTAGA 
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Figure 3.1.1: Let-7 sponge cassette. CMV à Cytomegalovirus promoter; deGFP à destabilized 
enhanced green fluorescent protein; polyA à polyadenylation signal for transcription termination; 
PGK à human phosphoglycerate kinase promoter; Hygromycin à Selective Marker gene. 
XhoI/EcoRI à restriction enzyme sites used for cloning. Yellow vertical rectangular boxes represent 
miRNA response elements in tandem. 
 
 
 
Figure 3.1.2: Plasmid constructs’ maps for pEX-A (with miRNA sponge sequences) and miRNA 
sponge backbone vector. (A) The miRNA sponge concatamers were cloned into pEX-A bacterial 
expression vector with Ampicillin as Selective Marker gene (sourced from MWG Eurofins) and 
various other transgene elements, as well as restriction enzyme’s recognition sites marked. (B) The 
final cloned vector with miRNA backbone containing multiple cloning site (MCS), marked with 
restriction enzymes sites, deGFP reporter sequence and Hygromycin B as Selective Marker gene and 
other transgene elements included along with restriction enzyme’s recognition sites marked. 
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3.1.3 Stable transfection of NC and Let-7 sponge in CHO-K1 SEAP cells 
 
CHO-K1 SEAP cells (henceforth referred to as SEAP cells) were transfected with NC 
and Let-7 sponge vectors separately in two wells of a 6-well plate (refer to Section 
2.6.1.2). 24 hours post-transfection, cells were selected using hygB antibiotic for the 
next 2-3 passages. At this point we had mixed pools for both NC and Let-7 sponge 
CHO-K1 SEAP cells. 
The NC and Let-7 sponge mixed pools exhibited varying degrees of GFP intensities 
as assessed by Guava. In addition to copy number, this variation in GFP expression 
was due to the random integration of the sponge cassette constructs within the 
genome and not a reflection on the transfection efficiency. The control vector 
transfected into SEAP cells during the same experiment demonstrated 65 % 
transfection efficiency (data not shown). Let-7 sponge mixed cells exhibited ~ 4-fold 
lower GFP expression due to the interaction of endogenous Let-7 with the Let-7 
sponge repressing deGFP translation, whilst in the control sponge mixed cells, the NC 
sponge did not bind to any miRNA and showed higher mean GFP expression 
(Fig.3.1.3). This observation was further validated in Section 3.3.1 in the transient 
transfection study. 
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Figure 3.1.3: Stable transfection of SEAP cells with NC and Let-7 sponge vector. Mean GFP 
expression analysis of NC and Let-7 sponge mixed SEAP pools. Experiments were performed in 
biological triplicate and GFP expression was analysed using Guava. A standard student t-test was 
performed to calculate the statistical significance of the GFP data in both the mixed pools of SEAP 
cells (p-value < 0.0001, n = 3). 
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3.1.4 Impact of Let-7 depeltion on bioprocess relevant phenotypes in CHO-K1 
SEAP mixed sponge pools in 5 mL culture spin tubes 
 
3.1.4.1 Impact of Let-7 sponge on growth characteristics 
 
Following the transfection and selection of mixed SEAP cells with hygromycin, the 
mixed pools of NC and Let-7 sponge cells were assessed for growth in a 5 mL batch 
suspension culture. Cell growth and viability were monitored over a time-period of 
six days. It was observed that the Let-7 sponge expressing mixed SEAP pool showed 
significantly increased viable cell density (VCD) (p-value = 0.01) of 5.26 × 106 
cells/mL on Day 4 i.e. 1.23-fold higher in comparison to NC sponge control mixed 
SEAP pool of 4.27 × 106 cells/mL. The VCD of Let-7 sponge mixed pool seemed to 
peak at 5.25 × 106 cells/mL on Day 3 and Day 4 (Fig. 3.1.4A), however, in the NC 
sponge mixed SEAP pool the VCD dropped from 5.18 × 106 cells/mL on Day 3 to 
3.66 × 106 cells/mL on Day 5 (Fig. 3.1.4A). On Day 6, Let-7 sponge mixed pool also 
exhibited higher VCD than the NC sponge mixed SEAP pool. In addition to the VCD 
data, we also observed a significant increase in the % cell viability (p-value = 0.01) 
between the Let-7 sponge mixed pool i.e. ~ 56 % and 38 % on Day 5 and Day 6, 
respectively, as opposed to NC sponge mix pool of cells, which displayed 46 % and 
21 % cell viability on Day 5 and Day 6, respectively (Fig. 3.1.4B). Based on these 
observations, we inferred that the Let-7 sponge expressing mixed SEAP cells seemed 
to have advantageous features of increased VCD and enhanced % cell viability in 
comparison to NC sponge mixed SEAP expressing cells. In a follow-up experiment, 
we also performed SEAP productivity analysis in the two mixed SEAP cell pools. 
 
 
 
 
	 103	
 
 
 
Figure 3.1.4: Viable Cell density (A) and % cell viability (B) comparison between NC and Let-7 
sponge mixed pools. Cells were seeded at 2 × 105 cells/mL in a 5 mL working volume in a 50 mL spin 
tube in biological triplicate in serum-free medium. Samples were harvested from Day 2 onwards. Cell 
counts were performed using Guava Viacount reagent and Guava. A standard student t-test was 
performed to analyse statistically significant data (p-value ≤ 0.05, n = 3). 
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3.1.4.2 Impact of Let-7 sponge on productivity characteristics 
 
The volumetric productivity or titer each day of the culture period in the Let-7 sponge 
cells was significantly higher than the NC sponge mixed SEAP cells (p-value = 0.01). 
The volumetric productivity of Let-7 sponge cells was ~ 1.5-fold higher than the NC 
sponge cells on Day 4, Day 5 and Day 6 of the culture period (Fig. 3.1.5). We 
inferred that this higher volumetric SEAP productivity in Let-7 sponge cells was due 
to enhanced specific SEAP productivity (data not shown) on Day 3 and Day 4, which 
reflected upon the improvement in volumetric SEAP productivity (Fig. 3.1.5). These 
findings of improved VCD, % cell viability and improved volumetric stimulated our 
interest in replicating the observed improved phenotypes in stable Let-7 sponge 
clones.  
 
 
Figure 3.1.5: Volumetric SEAP productivity comparison between NC and Let-7 sponge mixed 
pools. Cells were seeded at 2 × 105 cells/mL in a 5 mL working volume in a 50 mL spin tube in 
biological triplicate in serum-free medium. Samples were harvested from Day 2 onwards. A standard 
student t-test was performed to analyse statistically significant data (p-value < 0.05, n = 3). 
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3.1.5 Generation of clones from stable mixed pools of CHO-K1 SEAP cells 
 
3.1.5.1 FACS sorting NC and Let-7 sponge mixed pools 
 
Our preliminary experiments suggested a possible positive impact of Let-7 sponge in 
SEAP expressing cells, however, these experiments only represented an average 
across a heterologous population. Therefore, the phenotypic effect of Let-7 sponge 
expression in stable single cell clones from each NC and Let-7 sponge pool was 
investigated. Firstly, a panel of stable clones from NC and Let-7 mixed populations 
were sorted using FACS. The approach was based on sorting medium to high GFP 
expressing clones from both the NC and Let-7 mixed populations in order to ensure 
that they all are expressing excess sponge transcript above the level of saturation by 
endogenous Let-7 (3.1.6b and 3.1.6c). A GFP negative parental CHO-K1 SEAP cell 
line was used to set a strict cut-off gate for GFP negative versus GFP positive cells 
(3.1.6a). Following FACS clone isolation, 24 single cell clones (SCC) (12 high GFP 
& 12 medium GFP) from each NC and Let-7 stable clonal pool were generated. These 
were expanded and routinely passaged in serum-containing media containing G418 
and HygB. However, the adaptation of these stable clones to suspension serum-free 
media resulted in the loss of few candidates i.e. reduced the number of candidates to 
20 stable clones from each NC and Let-7 group. 
	 106	
 
Figure 3.1.6: FACS sort of NC and Let-7 sponge mixed CHO-K1 SEAP pools. (a) A GFP negative 
cell line (i.e. CHO-K1 SEAP, Grey) was used for gating the FACs instrument. (b) NC and (c) Let-7 
sponge mixed pools of cells were sorted based on medium-high range of GFP intensity. The GFP 
expression was analysed using the FITC channel (Emission 525 nm; Exicitation at 488 nm) using the 
flow-cytometer (FACS, BD Biosciences). 
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3.1.5.2 GFP expression in stable clonal panels in 24-well plate format 
 
As mentioned above, the original 24 stable clones for each NC and Let-7 panel was 
now reduced to 20 stable clones for each. Once all the clones were fully adapted to 
suspension culture and serum-free medium, they were routinely passaged with 
selective and non-selective media separately to ensure both the SEAP and sponge 
transgene expression was maintained. Following this, GFP expression across the 40 
stable clones was analysed using the Guava. A range of GFP expression from high to 
low was observed in both the NC and Let-7 clonal panels (Fig 3.1.7A and 3.1.7B). 
This range could be due to random sponge construct integration within the genome as 
indicated by our data, in addition to copy number influence. Furthermore, it was 
observed that mean GFP expression in Let-7 sponge clones (Fig. 3.1.7B) was lower 
than in the NC sponge individual clones (Fig. 3.1.7A). The average GFP expression 
for the Let-7 sponge clonal panel was 88.2 FU in comparison to 281.7 FU for the NC 
sponge panel. This reduced GFP expression in Let-7 sponge clonal panel was 
potentially due to endogenous Let-7 binding to the four binding sites in the Let-7 
sponge vector leading to deGFP translational repression. The NC sponge clones 
exhibited higher GFP expression due to the absence of miRNA binding sites, hence, 
more deGFP expression resulting in greater magnitude of GFP expression and 
intensity. 
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Figure 3.1.7: Mean GFP expression of 20 stable clones isolated from both the (A) NC and (B) 
Let-7 sponge mixed pools using FACS. Cells were seeded at 2 × 105 cells/mL in 24-well plate 
suspension format in 1 mL/well working volume. Cells were harvested on Day 3 for GFP expression 
analysis using Guava. A gate for GFP negative cells (using CHO-K1 parental cell line) versus the GFP 
positive cells was performed prior to mean GFP expression analysis. The dashed line in Green shows 
the average mean GFP expression across each clonal panel. 
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3.1.6 Impact of Let-7 depletion on bioprocess relevant phenotypes in a panel of 
CHO-K1 SEAP stable clones 
 
3.1.6.1 Growth characteristics of stable clonal panels in 24-well plate format 
 
The main objective of this experiment was to discover whether we could identify 
exceptionally good performing stable clones from the Let-7 sponge clonal panel with 
enhanced cell culture longevity and viability compared to the control panel. 
Therefore, the test and control clones were subjected to 24-well plate suspension 
batch culture for their phenotypic characterisation. The NC and Let-7 stable clones 
were cultured in 24-well plate format with serum-free media. The cell samples were 
harvested on alternate days for a 7-day period batch culture. It was observed that in 
contrast to the positive impact of the Let-7 sponge in mixed SEAP cells, the same 
phenotype was not reflected in the behaviour of the individual clones. The growth 
profile for almost all of the Let-7 sponge clones (Fig. 3.1.8B) was similar to the NC 
throughout the batch culture period (Fig. 3.1.8A). The viable cell densities of all 20 
stable Let-7 sponge clones were not significantly different than their control 
counterparts (p-value > 0.05). Moreover, not even a single clone performed better (or 
worse either) than any of the NC clone as the average cell densities across both panels 
were very similar on Day 3 (~ 1.7 × 106 cells/mL) and Day 5 (~ 1.27 × 106 cells/mL). 
However, similar to the results with mixed pools an increase in cell viability was 
observed in Let-7 sponge clone 2, 6 and 7. All had at least 50 % cell viability on Day 
6, while the highest in the control panel was less than 30 % on Day 6. Furthermore, in 
the Let-7 sponge panel, clone 6 and 7 both showed ~ 80 % cell viability (Fig. 3.1.8C). 
Overall statistically significant difference in the cell viability was observed between 
Let-7 and NC clones (p-value ≤ 0.05). The reason for the enhanced % cell viability in 
the Let-7 sponge clone 6 and clone 7 could be the fact that clone no. 6 maintained 
VCD of 1.2 × 106 cells/mL on Day 3, which only rose to 1.6 × 106 cells/mL on Day 5 
resulting in improved cellular viability on Day 6. 
 
 
 
	 110	
  (A)                                                              (B) 
 
 
Figure 3.1.8: Batch Growth analysis of NC (A) and Let-7 sponge (B) clonal panels in 24-well 
plate (sorted from highest to lowest VCD). Each well of two 24-well plates was seeded at a cell 
density of 2 × 105 cells/mL in 1 mL suspension culture volume (biological duplicate, n = 2). VCD on 
Day 6 was measured, however, not presented as the culture was in decline. Cell counts were performed 
using Guava Viacount reagent and Guava. Yellow bars highlighted in each clonal panel set represents 
selected clones chosen for further Scale-up growth and productivity analysis later. The dashed Black 
line represents average cell density across the clonal panels. A standard student t-test was performed to 
analyse statistically significant data (p-value > 0.05). 
   
0.0 
5.0 
10.0 
15.0 
20.0 
25.0 
30.0 
clo
ne
 7 
clo
ne
 5 
clo
ne
 1 
clo
ne
 4 
clo
ne
 6 
clo
ne
 2 
clo
ne
 3 
clo
ne
 13
 
clo
ne
 14
 
clo
ne
 10
 
clo
ne
 16
 
clo
ne
 12
 
clo
ne
 11
 
clo
ne
 9 
clo
ne
 8 
clo
ne
 15
 
V
C
D
  
(x
1
0
5
 c
e
ll
s/
m
L
) 
Average = 8.1x 105 
Day 1 
Day 3 
Day 1 
Day 5 
Day 3 
Day 5 
0.0 
5.0 
10.0 
15.0 
20.0 
25.0 
30.0 
clo
ne
 8 
clo
ne
 4 
clo
ne
 3 
clo
ne
 14
 
clo
ne
 6 
clo
ne
 13
 
clo
ne
 7 
clo
ne
 16
 
clo
ne
 9 
clo
ne
 1 
clo
ne
 10
 
clo
ne
 5 
clo
ne
 2 
clo
ne
 11
 
clo
ne
 12
 
clo
ne
 15
 
V
C
D
  
(x
1
0
5
 c
e
ll
s/
m
L
) 
 
Average = 1.69x 106 
0.0 
5.0 
10.0 
15.0 
20.0 
25.0 
30.0 
clo
ne
 13
 
clo
ne
 1 
clo
ne
 15
 
clo
ne
 14
 
clo
ne
 7 
clo
ne
 9 
clo
ne
 6 
clo
ne
 8 
clo
ne
 10
 
clo
ne
 12
 
clo
ne
 11
 
clo
ne
 16
 
clo
ne
 3 
clo
ne
 4 
clo
ne
 5 
clo
ne
 2 
V
C
D
  
(x
1
0
5
 c
e
ll
s/
m
L
) 
Average = 1.27x 106 
0.0 
5.0 
10.0 
15.0 
20.0 
25.0 
30.0 
clo
ne
 16
 
clo
ne
 13
 
clo
ne
 14
 
clo
ne
 1 
clo
ne
 15
 
clo
ne
 9 
clo
ne
 11
 
clo
ne
 12
 
clo
ne
 5 
clo
ne
 10
 
clo
ne
 4 
clo
ne
 2 
clo
ne
 3 
clo
ne
 6 
clo
ne
 8 
clo
ne
 7 
Average = 1.65 x 106 
0.0 
5.0 
10.0 
15.0 
20.0 
25.0 
30.0 
clo
ne
 13
 
clo
ne
 10
 
clo
ne
 11
 
clo
ne
 7 
clo
ne
 6 
clo
ne
 8 
clo
ne
 14
 
clo
ne
 5 
clo
ne
 15
 
clo
ne
 16
 
clo
ne
 2 
clo
ne
 12
 
clo
ne
 9 
clo
ne
 4 
clo
ne
 3 
clo
ne
 1 
Average = 1.26 x 106 
NC sponge Let-7 sponge 
0.0 
5.0 
10.0 
15.0 
20.0 
25.0 
30.0 
clo
ne
 14
 
clo
ne
 16
 
clo
ne
 12
 
clo
ne
 11
 
clo
ne
 5 
clo
ne
 2 
clo
ne
 1 
clo
ne
 15
 
clo
ne
 9 
clo
ne
 3 
clo
ne
 6 
clo
ne
 13
 
clo
ne
 7 
clo
ne
 8 
clo
ne
 4 
clo
ne
 10
 
Average = 6.85 x 105 
	 111	
 
     (C) 
 
Figure 3.1.8C: Batch Growth analysis- % cell viability comparison between NC (Blue bars) and 
Let-7 sponge (Red bars) clonal panels in 24-well plate on Day 6 (sorted from highest to lowest % 
cell viability. Each well of two 24-well plates was seeded at a cell density of 2 × 105 cells/mL in 1 mL 
suspension culture volume (biological duplicate, n = 2). Cell counts were performed using Guava 
Viacount reagent and the Guava flow-cytometer. Yellow bars highlighted in each clonal panel set 
represents selected clones chosen for further Scale-up growth and productivity analysis later. The 
dashed Black line represents average cell density across the clonal panels. A standard student t-test was 
performed to analyse statistically significant data (p-value ≤ 0.05). 
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3.1.6.2 Productivity characteristics of stable clonal panels in 24-well plate format 
 
The amount of SEAP protein produced by the NC and Let-7 sponge clones was 
measured using a kinetic absorbance based SEAP assay (refer to Section 2.9.3). 
However, it was observed that none of the NC and Let-7 sponge clones produced 
SEAP protein in measurable amounts (Fig. 3.1.9A and Fig. 3.1.9B). Typical 
volumetric SEAP production lies in the range of 100-450 units/mL for CHO-K1 
SEAP cell densities in the range of 2-50 × 105 cells/mL, however, none of the NC or 
Let-7 clones surpassed 10 SEAP units/mL. 
 
Figure 3.1.9: Volumetric SEAP productivity of NC (A) and Let-7 (B) sponge clonal panels. Cells 
were seeded at 2 × 105 cells/mL in a 1 mL working volume in a 24-well plate well in biological 
duplicate in serum-free medium. Samples were harvested from Day 2 onwards. A standard student t-
test was performed to analyse statistically significant data (p-value > 0.05). 
 
 
We suspected a potential loss of the SEAP transgene in both the NC and Let-7 sponge 
clonal panels. In order to confirm, we performed RT-qPCR to assess the expression of 
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SEAP transcript in a subset of clones picked from each NC and Let-7 panel (Fig. 
3.1.9C). We observed a 25-fold down regulation in SEAP gene expression in both NC 
and Let-7 sponge clones in contrast to NC and Let-7 mixed pools. This observation 
was rather surprising since the clones were maintained by routinely passaging and 
selecting with hygromycin and geneticin containing media to ensure that they were 
maintaining the expression of both the sponge cassette, as well as the SEAP encoding 
transgene. Given the tendency for CHO cell lines to be genetically instable and 
susceptible to gene silencing, we suspected that this loss of SEAP expression could be 
a case of transcriptional gene silencing by methylation (Chusainow et al. 2009, Yang 
et al. 2010). This is further discussed in the Section 4.2. To investigate the root cause 
for the loss of SEAP expression in both the NC and Let-7 sponge panels was beyond 
the scope of this project, therefore, no further investigative study was conducted. 
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(C) 
 
Figure 3.1.9C: Relative expression levels of SEAP transcript in NC and Let 7 sponge clones 
calculated using RT-qPCR. A parental CHO-K1 cell line was used as negative control for SEAP 
expression, while mixed pools of NC and Let-7 SEAP cells were chosen as the positive controls for 
SEAP expression. A standard student t-test was performed to calculate the statistical significant data 
(p-value < 0.0001). The levels of SEAP encoding gene were normalised to endogenous beta-actin 
control. 
 
The absence of SEAP productivity data for NC and Let-7 clones stymied the process 
of identifying better-performing clones for further scale-up analysis. Therefore, we 
based our choice of clones on the basis of improved VCD on Day 3 and % cell 
viability on Day 6. We selected four clones from each NC and Let-7 sponge panel 
(Highlighted in Yellow bars in Fig 3.1.8A, Fig. 3.1.8B and Fig. 3.1.8C). From the 
NC sponge panel, we selected clone number 4, 10 (based on the VCD on Day 3 Fig. 
3.1.8A and Fig. 3.1.8B), 13 and 16 (based on the highest % cell viability in 
comparison to other clones within the panel on Day 6 Fig. 3.1.8C). From the Let-7 
sponge panel, clone number 2, 6 (based on the highest % cell viability in comparison 
to other clones within the panel on Day 6 Fig. 3.1.8C), 11 and 16 (based on the VCD 
on Day 3 Fig. 3.1.8B) were chosen for further scale-up growth and productivity 
analysis. 
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3.2 Impact of Let-7 depletion on bioprocess relevant phenotypes in a panel of 
selected CHO-K1 SEAP clones in 5 mL culture spin tubes 
 
As described in the previous section, in total 8 stable clones were chosen for analysis 
in 5 mL. The clones from both the panels i.e. NC and Let-7 sponge were seeded at 2 × 
105 cells/mL in a 5 mL working volume in 50 mL vented spin tubes. The experiment 
was monitored over a week and samples were harvested on Day 2, Day 3, Day 4 and 
Day 5. It was observed that the Let-7 clones 6 and 11 failed to demonstrate the same 
enhanced growth phenotypes in 5 mL batch conditions as observed in the 24-well 
plate format. The VCD of clone 6 and 11 only rose to 1.24 × 106 cells/mL (Day 3) 
and 1.43 × 106 cells/mL (Day 3), respectively followed by declining numbers (Fig. 
3.1.10B) versus any of the NC clones, which were > 2 × 106 cells/mL on Day 3 and 
Day 4 (Fig. 3.1.10A). Let-7 clones 2 and 16 were observed to have higher VCDs i.e. 
2.55 × 106 cells/mL and 2.79 × 105 cells/mL, respectively on Day 3 (Fig. 3.1.10B). 
However, Let-7 clone 2 did not show any sign of improved % cell viability as 
observed in the 24-well plate format and declined to < 70 % cell viability on Day 4. 
Let-7 clone 16 was found to have cell viability of 75 % on Day 5 of the culture, which 
was higher than the rest of the Let-7 sponge clones (Fig. 3.1.11B). However, this 
increased cell viability was not significantly higher than three of the NC sponge 
clones on Day 5 (p-value > 0.05) (Fig. 3.1.11A). Therefore, it can be concluded that 
Let-7 sponge overexpression had no positive impact on growth of these clones in 5 
mL batch culture. Moreover, all the NC clones were observed to have a better growth 
and viability profiles (Fig. 3.1.10A and Fig. 3.1.11A) than the Let-7 clones (Fig. 
3.1.10B and Fig. 3.1.11B).  
Hence, Let-7 depletion using the Let-7 sponge did seem not to confer any positive 
impact on CHO-K1 SEAP cell growth as inferred in this particular experiment.  
 
 
 
	 116	
 
 
 
Figure 3.1.10: Batch culture growth analysis of (A) NC and (B) Let-7 selected sponge clones in 5 
mL spin tubes. Cells were seeded at 2 × 105 cells/mL in a 5 mL working volume in a 50 mL spin tube 
in biological triplicate for each NC and Let-7 selected clones in serum-free medium. Cell counts were 
performed using Guava Viacount reagent and Guava. A standard student t-test was performed to 
analyse statistically significant data (p-value > 0.05). 
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Figure 3.1.11: Batch culture % cell viability analysis of (A) NC and (B) Let-7 selected sponge 
clones in 5 mL spin tubes. Cells were seeded at 2 × 105 cells/mL in a 5 mL working volume in a 50 
mL spin tube in biological triplicate for each NC and Let-7 selected clones in serum-free medium. Cell 
viability was analysed using Guava viacount reagent and Guava. A standard student t-test was 
performed to analyse statistically significant data (p-value > 0.05, n = 3) 
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3.3 Validation of Let-7 sponge technology 
 
3.3.1 Let-7 sponge efficiency and specificity 
 
Before performing any other large-scale batch and/or fed-batch based phenotypic 
analysis, it was imperative to validate and assess the Let-7 sponge’s efficiency and 
specificity in binding endogenous Let-7 family members. Therefore, for this purpose 
we transiently transfected Let-7 mimics molecules into two i.e. one high and one low 
GFP expressing NC (clone number 10 & 17) and Let-7 (clone number 11 & 19) 
sponge clones. 
As mentioned in Section 3.1.3 Let-7 sponge clones expressing the sponge constructs 
exhibited lower GFP expression than the NC sponge clones. To verify that this was 
indeed due to Let-7 binding to the sponge, all four clones picked for this study were 
transiently transfected with non-specific miRNA mimics (pm-neg) and Let-7 specific 
mimics (pm-7), separately. Three days post-transfection, this up-regulation of Let-7 
induced further significant reduction in GFP fluorescence intensity in the Let-7 
sponge clone 11 as the GFP units reduced from 128 FU in pm-neg to 64 FU in pm-7. 
Clone 19 showed the same effect in the reduction of GFP fluorescence intensity as the 
GFP units reduced from 84 FU in pm-neg to 50 FU in pm-7. However, the GFP 
expression in NC sponge clone 10 and 17 remained unchanged, largely (Fig. 3.2.1). 
This further reduction in the mean GFP expression upon pm-7 transient transfection 
confirmed that the Let-7 sponge was efficient in its job to specifically bind to Let-7 
family members and hence, reduce the levels available to bind to its endogenous 
target mRNA cohort. Based on this observation, wherein both the Let-7 clones 
displayed significantly reduced GFP levels upon exogenous Let-7 transfection, it was 
safe to say that theoretically all the stable clones contained enough Let-7 sponge 
transcript copies to fully soak-up the endogenous Let-7 levels and the lack of 
phenotypic outcome was not due to ineffective Let-7 depletion in the cells. 
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Figure 3.2.1: Mean GFP expression analysis post-transfection of two NC and two Let-7 sponge 
clones with non-specific miRNA mimics (pm-neg) and Let-7 specific mimics (pm-7). Cells were 
seeded at 1 × 105 cells/mL per well of three 6-well plates in biological triplicate and transfected with 30 
nM of mimic molecules. GFP expression was analysed using Guava post 72 hours transfection. A 
standard student t-test was performed to analyse the statistically significant data (p-values 0.025 and ≤ 
0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
50 
100 
150 
200 
250 
300 
350 
NC10 NC17 Let7 11 Let7 19 
M
ea
n 
G
FP
 e
xp
re
ss
io
n 
(F
U
) 
Clones 
pm-neg pm-7 
***	 **	
	 120	
3.3.2 Expression levels of downstream targets of Let-7 upon Let-7 depletion 
 
For further validation, another experiment was conducted in order to confirm that Let-
7 was deflected from its downstream targets by quantifying the expression levels of 
known Let-7 targets in NC and Let-7 sponge clones. We chose Bcl2 based on 
miRTARbase & miRwalk predicted list of targets (Garzon et al. 2007) and cyclin-
dependent kinase-6 (CDK6), which has been shown to be a direct target of Let-7 in 
humans (Johnson et al. 2007). We quantitated their expression levels in NC (Clone 
10, 13 and 16) and Let-7 sponge clones  (Clone 2, 11, and 16) using RT-qPCR. We 
observed that the Bcl2 expression levels in all 3 Let-7 sponge clones were not 
significantly different than in the NC clones and the parent cell line (p-value > 0.05) 
(Fig 3.2.2A). Moreover, no difference in the expression levels of CDK6 in Let-7 
sponge clones in comparison with NC clones (p-value > 0.05) was observed (Fig 
3.2.2B). This experiment and from the findings in Section 3.3.1, we suspected that 
cells were somehow compensating for the lack of Let-7 via certain feedback loop 
mechanism (Ebert and Sharp 2012). Finally, we were interested in quantitating the 
endogenous Let-7 expression levels in the Let-7 stable sponge clones by qPCR. We 
surmised upon Let-7 depletion we could observe increased expression levels of Bcl2 
and CDK6 in Let-7 sponge clones but there was no impact on mRNA transcripts of 
these two genes. However, we could not rule the possibility on any impact at protein 
level. 
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Figure 3.2.2A: Relative expression levels of Bcl2 measured using real-time qPCR in NC and Let-
7 sponge clones. . A standard student t-test was performed to analyse statistically significant data (p-
value > 0.05). The levels of Bcl2 were normalised to endogenous beta-actin control. 
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Figure 3.2.2B: Relative expression levels of CDK6 measured using real-time qPCR in NC and 
Let-7 sponge clones. A standard student t-test was performed to analyse statistically significant data 
(p-value > 0.05). The levels of expression of CDK6 were normalised to endogenous beta-actin control. 
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3.3.3 Endogenous Let-7 expression levels in stable sponge clones 
 
This study was important in order to address the hypothesis that post Let-7 depletion 
in the Let-7 clones, there was a compensation mechanism occurring in the Let-7 
sponge clones to maintain the normal levels of endogenous Let-7, hence resulting in 
no apparent phenotypic outcome. We measured endogenous Let-7a levels across a 
subset of the stable Let-7 and NC sponge clones using RT-qPCR. We observed that 
the mature Let-7a levels in all three of the Let-7 sponge clones (Clone 2, 6 and 11) 
were very similar to the expression levels in NC sponge clones (p-value > 0.05) (Fig. 
3.2.3). This observation could explain why we observed no phenotypic outcome, 
however, was not in agreement with the data in Section 3.3.1. These observations 
point towards the possibility of target-mediated miRNA protection (TMMP), whereby 
increased mRNA target availability could potentially lead to accumulation of 
miRNAs due to protection from exoribonuclease turnover through target association 
(Chatterjee et al. 2011) (discussed in more detail in Section 4.3). 
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Figure 3.2.3: Relative Expression levels of the mature Let-7 levels in NC and Let-7 sponge clones 
assessed using real-time qPCR. A standard student t-test was performed to analyse statistically 
significant data (p-value > 0.05). The levels of expression of Let-7 were normalised to endogenous 
snRNA U6 control. 
 
In summary, we demonstrated that the sponge technology was an efficient means to 
effectively and specifically sequester endogenous Let-7 levels with our mimics 
experiment (refer to Section 3.3.1). However, our findings showed no sign of 
improved growth characteristics in CHO-K1 SEAP cells after using Let-7 sponge 
technology. In the absence of productivity data, we could not establish if Let-7 stable 
depletion impacted the cellular productivity positively or negatively. The real-time 
qPCR results to validate the sponge efficacy were consistent with the growth results 
showing no apparent phenotypic change in the Let-7 sponge clones, in comparison to 
control clones. In theory, Let-7 sponge should bind all Let-7 family members, 
however, with RT-qPCR we measured very slightly increased or similar Let-7a 
expression levels in the Let-7 sponge clones as in the control sponge clones. We 
believe that the similar Let-7a expression levels in control and Let-7 sponge clones 
could be due to some unknown feedback mechanism to compensate for the loss of 
Let-7a in the cells. This observation is discussed in more detail in Section 4.3. This 
0 
0.5 
1 
1.5 
2 
CHO-K1 
SEAP 
NC-10 NC-13 NC-16 Let7-2 Let7-6 Let7-11 
R
el
at
iv
e 
m
at
ur
e 
L
et
-7
a 
ex
pr
es
si
on
 le
ve
ls
 
	 125	
study was a first report for the stable depletion of Let-7 levels in CHO cells, therefore, 
it could be interesting to observe if we employ a different technique to knockout the 
Let-7 family members, as opposed to stable depleting Let-7 levels in CHO cells with 
sponges. In doing so, it would be interesting to see if we could evade the mechanism 
of compensation of miRNA loss by the cells. Furthermore, it would be interesting to 
see if Let-7 knockout in CHO cells genome yields any interesting phenotypes. 
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Section 3.4, 3.5 & 3.6 
Applying CRISPR-Cas9 genome editing 
technology to knockout miR-7 in 
industrially relevant CHO cell-lines 
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As the second objective of this thesis, a genome editing technology (CRISPR-Cas9) 
was employed to knock out the miR-7 locus sequence in the CHO genome. Stable 
knock down of miR-7 in CHO cells using sponges has been reported as an attractive 
approach to increase CHO cell growth and protein productivity. We were interested in 
completely knocking out the miR-7a-5p locus in CHO cells with a view to improve 
CHO cell bioprocessing phenotypes. The introduction and application of CRISPR-
Cas9 technology in CHO cells was fairly new to our laboratory, therefore, firstly we 
implemented it in a CHO-eGFP cell line (henceforth referred to as eGFP cell line) for 
an easy read-out of the CRISPR-Cas9 activity. Moreover, this study also allowed us 
to optimize the CRISPR-Cas9 technology for the later part in this project. Hence, 
initially as proof-of-concept experiment, CRISPR-Cas9 system was employed in 
eGFP expressing CHO cell line to induce a functional eGFP gene knock out in the 
CHO genome. 
 
3.4 Proof of Concept Study: Implementing CRISPR-Cas9 technology to induce 
functional gene knockout in eGFP cell line. 
 
3.4.1 Designing eGFP sgRNA and cloning into the CRISPR vector (pCas9) 
 
A CRISPR-Cas9 vector (pCas9), sourced from OriGene (9620 Medical Center Drive, 
Rockville MD, USA) was used as a backbone vector for cloning a 20 nucleotide (nt) 
guide-RNA sequence that targets the eGFP gene in eGFP cell line. The cloning 
strategy is outlined in Figure 3.4.1. Firstly, the pCas9 vector was doubly digested 
with BamHI and BsmBI restriction enzymes to linearize it (refer to Section 2.8.2.1). 
The single guide-RNA (sgRNA) sequences were then designed (refer to Fig. 3.4.1 for 
eGFP sgRNA sequence details) (as per OriGene and www.blueheronio.com 
specifications) to target the eGFP gene at the 5’ and 3’-end of the eGFP sequence. 
Following pCas9 backbone vector linearization, the sgRNA oligo sequence were 
annealed and then ligated into the linear pCas9 vector (refer to Section 2.8.2.4). The 
sgRNAs were designed to contain an extra ‘G’ nucleotide (nt) at the 5’-end of the 
guide sequence since it’s a preferred start nucleotide by U6 RNA pol III promoter for 
efficient transcription (Hwang et al. 2013, Ran et al. 2013). Another extra ‘G’ nt was 
appended at the 3’-end of the guide sequence as well as per manufacturer’s 
specifications. 
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Figure 3.4.1: Schematic of design and cloning strategy for eGFP sgRNAs into pCas9 vector 
backbone for targeting eGFP gene. The single stranded oligonucleotides (i.e. eGFP 1s and eGFP 2s) 
were annealed with their respective anti-sense sequences and ligated into two separate linearized pCas9 
vectors digested using BamHI and BsmBI, thereby, resulting in eGFP 1 (5’-eGFP end targeting) and 
eGFP 2 (3’-eGFP end targeting) CRISPR plasmids. A BsmBI (gatc) recognition site was also placed at 
the 5’-end of the guide sequences of both eGFP 1 and eGFP 2 CRISPRs for diagnostic gel purposes. 
Highlighted letter g at the 5’-and 3’-end is an extra Guanine, as per manufacturer’s gRNA design 
protocol. The pCas9 vector consists of mammalian U6 RNA pol III promoter to transcribe the ligated 
target sequence and the gRNA scaffold (crRNA and tracrRNA complex). The pCas9-Guide vector also 
contains a CMV (cytomegalo viral promoter) driven human-codon optimized Cas9 nuclease (spCas9).  
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3.4.2 Proof-of-Concept experiment 
 
As a preliminary task i.e. before applying CRISPR-Cas9 technology in the 
industrially relevant CHO cell line, it was imperative that we optimized and tested the 
efficiency of CRISPR-Cas9 systems in a model CHO cell line. For this purpose, we 
used a CHO-K1 cell line with a stable eGFP gene integrated in the genome, hence, 
referred as CHO-eGFP cell line.  
 
3.4.2.1 CHO-eGFP cell line 
 
CHO-eGFP cell line used in this project contains limited copies of eGFP gene in a 
transcriptionally active region of the CHO genome and exhibits strong, stable eGFP 
expression. This cell line was established using adeno-associated virus for the stable 
integration of the eGFP transgene into the genome without selective pressure. We 
performed a GFP expression study over 5 days using Guava in order to ascertain the 
consistency of eGFP. An eGFP negative (i.e. CHO-K1 parental) cell line was used to 
gate the instrument prior to GFP expression analysis and the same settings were used 
for each culture time point. For this experiment, CHO-eGFP cells were cultured in a 
6-well plate and each culture time point was measured in biological triplicate. During 
the early stages of the culture period, we observed increasing VCD (Fig. 3.4.2A). The 
mean GFP expression for most of the time of the culture period stayed consistently 
around 2100 FU. However, on Day 4 and Day 5 the GFP expression dropped ~ 250 
FU i.e. from 2146.48 FU to 1900 FU (Fig. 3.4.2A and Fig. 3.4.2B) This drop could 
potentially be attributed to the fact that the culture on Day 5 was already in decline. 
The VCD and % cell viability on Day 5 were 2.14 × 106 cells/mL (Fig. 3.4.2A) and 
45 % (data not shown), respectively (Fig. 3.4.2A). From this study it can be 
concluded that the eGFP expression of the CHO-eGFP cell line is quite consistent. It 
can also be seen that there are two different clusters of eGFP positive cells in Fig. 
3.4.2B, which suggest that eGFP cell line contains a mix of two eGFP positive 
populations. These two different populations exhibit varying degrees of GFP 
fluorescence i.e. one being brighter (higher red cluster) than the other (lower red 
cluster). Therefore, we believe that eGFP cell line maybe a mixed population of bright 
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and less bright eGFP cells. Other members of our research group working with eGFP 
cell line, as well as from our study, we could not completely discern the reason for 
observing varying degrees of GFP fluorescence.  
 
 
(A) 
 
Figure 3.4.2A: VCD and Mean GFP expression analysis. CHO-eGFP VCD (cells/mL) in Light 
Green Curve and mean GFP expression curve in Dark Green Curve. Cells in the 6-well plate were 
seeded at 2 × 105 cells/mL in biological triplicate. Cell counts and mean GFP expression analysis 
performed using Guava Viacount and Guava ExpressPlus programme, respectively using the Guava. 
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   (B) 
 
Figure 3.4.2B: Mean GFP expression imaged in the form of dot-plots. Screenshots for ExpressPlus 
programme representing clusters of GFP positive (Red) and negative cells (Green) from Guava 
software. The top extreme left screenshot shows the cluster of GFP negative CHO-K1 cells used to 
Gate the instrument prior GFP expression analysis.  
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3.4.2.2 Two different eGFP sgRNAs designed to target eGFP gene 
 
The length of each of the two eGFP sgRNA used in this study was 20 nt long. These 
two eGFP CRISPRs were designed to target two different sites in the eGFP gene i.e. 
sgGFP 1 targets the 5’-end, while sgGFP 2 targets the 3’-end (Fig 3.4.3). Upon 
successful transfection of eGFP CRISPRs, we expected to observe bright green cells 
transitioning to dark cells (non-green cells) due to eGFP gene knockout by the Cas9 
nuclease component in each of the eGFP CRISPR. We expected Cas9 would induce 
DSBs in the eGFP gene, which are then repaired by the cells’ error prone NHEJ repair 
mechanism leading to frame shift mutations or indels (causing pre-mature STOP 
codon formation in a percentage of cells), thereby disrupting the ORF of the eGFP 
gene. The efficiency of eGFP targeting will depend on a number of factors including 
the transfection efficiency, sgGFP 1 and sgGFP 2 designs and the degree of error 
introduced during DSB repair process. 
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Figure 3.4.3: Outline of the Proof-of-Concept experiment rationale. 20 nt long eGFP 1 and eGFP 2 
CRISPRs induce DSBs in the eGFP gene via Cas9 nuclease. The resulting DSBs are then repaired by 
the cells’ error prone NHEJ repair mechanism leading to frame shift mutations or indels, thereby 
disrupting the ORF of eGFP gene, hence rendering it non-functional. Hence, green cells transitioning 
to dark cells. DNA cartoon image reproduced from www.neb.com 
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- Optimization of Transfection conditions 
 
eGFP cells seeded at 5 × 105 cells/mL the day before were transfected with 5 µg of 
sgGFP 1 and sgGFP 2 in two separate wells of a 6-well plate. 5 µg and 10 µg of 
negative control vector 1 and 2 (i.e. pCas9 NC 1 and pCas9 NC 2), respectively, were 
also transfected into eGFP cells in two separate wells of the 6-well plate (refer to 
Section 2.6.1.2). 10 days post transfection, the results were visually analysed using 
the confocal microscope (Fig. 3.4.4A). We observed some CRISPR activity in each of 
the eGFP CRISPR treated samples. Mean GFP expression was reduced from 3418 FU 
(99 % GFP positive) in pCas9 NC 1 control to 2700 FU (82 % GFP positive) in 
sgGFP 1 and 2671 FU (85 % GFP positive) in sgGFP 2. Mean GFP expression of 
combination sgGFP (1+2) was also low i.e. 2700 FU (80 % GFP positive) in 
comparison to pCas9 NC 2 control i.e 3386 FU (99 % GFP positive) (Fig. 3.4.4B). It 
can also be seen in Fig. 3.4.4C cells with reduced GFP intensities drifting down 
towards the GFP negative area, however, a few cells with reduced GFP intensities 
were also observed very close to the GFP negative area in the pCas9 NC 1 and pCas9 
NC 2 controls. Therefore, it was hard to infer that these cells in the GFP negative area 
are due to CRISPR activity or a sub population of less green cells.  
We also hypothesised that expanding the cells from 6-well plate wells to T75 flasks 
could allow for more area for dark cells (targeted cells) to outgrow the eGFP 
expressing cells. We reasoned that maybe after one or two passages in T75 flasks, 
dark cells (i.e with eGFP knocked out gene) would outgrow the eGFP positive cells 
since dark cells won’t be expressing the eGFP gene anymore and suffer less 
translational burden as opposed to eGFP positive cells. However, we did not observe 
any dramatic impact in the test populations, in terms of mean GFP expression 
reduction (data not shown). These findings led to speculations about the pCas9 eGFP 
CRISPR’s efficiency in inducing knock out of the eGFP gene. In order to address if 
there was an issue with pCas9 accessing the eGFP sequence within the genome, we 
performed co-transfection experiment described in Section 3.4.2.3.  
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(A) 
 
Figure 3.4.4A: Confocal Microscopy Images for the visual inspection of the eGFP 1 and eGFP 2 
CRISPR activities. The black and white images with each set are the phase-contrast images. Cells 
were seeded at 2 × 105 cells/mL per well of a 6-well plate, then expanded to T75 flasks and images 
were taken using a confocal microscope post transfection in T75 flasks. 
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(B) 
 
 Figure 3.4.4B: Mean GFP expression analysis post eGFP 1 and eGFP 2 CRISPR transfection in 
eGFP cells. Mean GFP expression data analysed post transfection in control and eGFP CRISPR 
treated samples. Cells were seeded at 2 × 105 cells/mL per well of a 6-well plate and then expanded to 
T75 flasks. Mean GFP expression analysed using the Guava. A standard student t-test was performed 
to calculate statistically significant data (p-value ≤ 0.05).  
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 (C) 
 
Figure 3.4.4C: Mean GFP expression imaged in the form of dot-plots. Screenshots for ExpressPlus 
programme representing clusters of GFP positive (Red) and negative (Green) cells in control and test 
eGFP CRISPR treated samples. The bottom extreme right screenshot shows the cluster of GFP 
negative CHO-K1 cells used to gate the instrument prior to GFP expression analysis. Cells were seeded 
at 2 × 105 cells/mL per well of a 6-well plate and then expanded to T75 flasks.  
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3.4.2.3 pCas9 eGFP CRISPR and eGFP plasmid (peGFP) transient co-
transfection 
 
In order to test the efficiency of the sgGFP 1 and sgGFP 2 CRISPRs at targeting a 
non-genome integrated eGFP sequence, eGFP CRISPRs were transiently co-
transfected with peGFP plasmid in CHO-K1 SEAP cells separately i.e. sgGFP 1 + 
peGFP (5 µg) and sgGFP 2 + peGFP (5 µg) (refer to Section 2.6.1.2). This 
experiment was performed to check if the eGFP CRISPRs were specific in binding to 
eGFP sequence, and consequently disrupting the eGFP sequence in peGFP plasmid 
co-transfected in CHO-K1 SEAP cells. Following co-transfection of sgGFP 1 and 
sgGFP 2, we achieved ~ 50 % transfection efficiency as evidenced from peGFP + 
pCas9 control vector (no guide sequence) image. The test sgGFP 1 + peGFP sample 
was observed to have reduced numbers of eGFP positive cells (~ 25 %, data not 
shown) suggesting that sgGFP 1 CRISPR is specifically binding and disrupting the 
peGFP. Similar numbers of eGFP positive cells (~ 25 %, data not shown) were 
observed with sgGFP 2 + peGFP treated sample. The fluorescent microscope imaging 
demonstrated that the eGFP CRISPRs effectively reduced the eGFP signal in the 
transiently co-transfected cells (Fig. 3.4.5). We also observed that mean GFP 
expression in test samples was low (i.e. 60-67 FU range) in comparison to the control 
sample (109 FU) (Fig. 3.4.5) i.e. ~ 50 % reduction in GFP fluorescence, which was 
significant (p-value = 0.025). This study confirmed that eGFP CRISPRs are efficient 
in targeting the eGFP sequence of peGFP in CHO-K1 SEAP cells. 
In summary, although the Section 3.4.2.2 study showed a reduction in mean GFP 
expression in the CRISPRs treated cells, which was also significant (p-value ≤ 0.05) 
(Fig 3.4.4B). However, for the amount of CRISPR DNA used, we were unsatisfied 
with the efficiency eGFP CRISPRs in eGFP cells. Therefore, at this stage we wanted 
to improve the efficiency and decided to try an alternative expression vector system. 
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Figure 3.4.5: Fluorescent Microscopy images (Top) and Mean GFP expression (Bottom) analysis 
in CHO-K1 SEAP cells post co-transfection. Cells were seeded at at 2 × 105 cells/mL in biological 
triplicate. Three days post co-transfection each well of the 6-well plate was imaged using fluorescent 
microscope. Cells from each well were then analysed for mean GFP expression using the Guava. An 
eGFP negative (i.e. CHO-K1 parental) cell line was used to gate the instrument prior to GFP 
expression analysis. A standard student t-test was performed to analyse statistically significant data (p-
value = 0.025). 
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3.4.3 A fresh start: Designing and cloning strategy for new eGFP targeting 
sgRNA in a different CRISPR vector 
  
As mentioned above the pCas9 eGFP targeting CRISPR-Cas9 system did not induce 
site-specific eGFP gene disruptions as efficiently as we would have expected. In order 
to address this issue, we employed a completely new plasmid, px459 (pSpCas9(BB)-
2A-Puro, Plasmid #48139) that has proven track record of efficient CRISPR activity 
as reported in numerous publications. Moreover, we designed two sgRNAs (i.e. 19 nt 
and 20 nt long) for each of two eGFP sites to be targeted. Therefore, in total four 
eGFP CRISPR-Cas9 vector constructs were designed (Table 3.4.3 for sgRNA 
sequence details).  
Table 3.4.1 List of sgRNA sequences used for targeting eGFP gene. sgRNA sequences (A à19 nt 
or B à20 nt Highlighted in Yellow). Only sense strands are shown. The BbsI site (cacc) is also 
included at the 5’-end of the sequence for ligation into px459 vector. Red highlighted G appended 
at 5’-end (as preferred base) is the first base of the guide sequence. NGG is PAM sequence in the 
CHO genome. 
CRISPR-Cas9 
constructs 
sgRNA sense-strand sequences (or guide sequences) PAM (5’-
end 
upstream 
of guide 
sequence) 
sgGFP 1A 5’ – CACCGGGGCGAGGAGCTGTTCACC – 3’ TGG 
sgGFP 1B 5’ – CACCGAGGGCGAGGAGCTGTTCACC – 3’ TGG 
sgGFP 2A 5’ – CACCGCGCGATCACATGGTCCTGC – 3’ TGG 
sgGFP 2B 5’ – CACCGGCGCGATCACATGGTCCTGC – 3’ TGG 
 
The px459 vector was used as backbone vector for cloning sgGFP 1 and sgGFP 2 as 
guide sequences (sgRNAs), after linearizing using BbsI (refer to Section 2.8.2.1). The 
Cas9 expression cassette construct consists of a CBh (hybrid form of chicken-β actin 
promoter, a Cas9 ORF human codon-optimized (not shown), SV40 nuclear 
localization sequence (NLS) and bovine growth hormone (BGH) polyadenylation 
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signal and transcription termination sequence. The sgRNA expression cassette 
consisted of a U6 polymerase III promoter, a target sequence, a gRNA scaffold 
sequence and a poly (T) termination sequence. An additional advantage of using the 
px459 vector over the pCas9 vector was the presence of a puromycin resistance gene 
in the selection of transfected cells (Fig. 3.4.6).  
 
 
Figure 3.4.6: Schematic of Cas9 and sgRNA expression cassettes in px459 vector backbone. A 19 
nt or 20 nt guide sequence containing BbsI cut compatible sticky-ends was cloned into a 
linearized px459 vector backbone (linearized using BbsI). The final sgRNA expression cassette 
and Cas9 construct consisted of a U6 polymerase III promoter, a target sequence, an sgRNA 
scaffold sequence (Orange structure) and a poly (T) termination sequence. Further downstream 
are other transgene elements such as CBh promoter, 3X FLAG peptide, SV40, NLS, spCas9 
cassette linked with 2A peptide. 2A is also linked to puromycin (Selection Marker Gene), NLS 
and BGH, polyadenylation signal and transcription termination sequence. 
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The sgRNA sequences for sgGFP 1A, sgGFP 1B and sgGFP 2A, sgGFP 2B were 
designed using the CRISPR Design Tool (http://tools.genome-engineering.org) 
(Table 3.4.1). The sgGFP 1 and sgGFP 2 CRISPR systems differ in that sgGFP 1 
targets the 5’-end, while sgGFP 2 targets the 3’-end of the eGFP gene. A and B refers 
to the length of the guide sequence, wherein A is 19 nt long sgRNA and B is 20 nt 
long sgRNA oligo annealed and ligated into the BbsI linearized px459 vector (refer to 
Section 2.8.2.4). The resulting constructs will be referred as sgGFP 1A, sgGFP 1B, 
sgGFP 2A and sgGFP 2B CRISPRs. We also investigated CRISPR-Cas9 efficiency 
when different sgRNAs were used for different sites in the eGFP gene.  
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3.4.3.1 Knocking out eGFP gene in CHO-eGFP cells  
As a preliminary task, it was imperative that we test the efficiency of the designed 
eGFP CRISPR-Cas9 systems in CHO cells. For this purpose, we performed the 
CRISPR-Cas9 eGFP gene knockouts in the eGFP cell-line with the newly designed 
eGFP CRISPR constructs. The experimental rationale was the same as outlined in 
Figure 3.4.3, except that on this occasion we tested four sgGFP CRISPRs i.e. sgGFP 
1A, sgGFP 1B, sgGFP 2A and sgGFP 2B. 
We transfected 5 wells of a 6-well plate containing eGFP cells seeded at 5 × 105 
cells/mL one day before transfection with 1 µg of control px459 (empty vector only 
i.e. no guide sequence) DNA, sgGFP 1A, sgGFP 1B, sgGFP 2A and sgGFP 2B 
CRISPR DNA (s). We included a control for ‘eGFP cells only’ to monitor the 
transfection efficiency when selecting the non-transfected eGFP cells and control 
px459 only transfected cells using puromycin containing media and comparing the 
number of viable green cells visually using the fluorescent microscope. Ten days post 
transfection, we observed ~ 70 % viable eGFP cells in the control px459 vector only 
treated sample (Fig. 3.4.7A), however, the ‘cells only’ control had all non-green 
floating dead cells. We also observed that in all eGFP CRISPRs treated cells 65-70 % 
of eGFP positive cells transitioned to dark, viable cells. The fluorescent microscopy 
results confirmed significant number of eGFP cells with eGFP gene knocked out (Fig. 
3.4.7A). 
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  (A) 
 
Figure 3.4.7A: Fluorescent Microscopy images post transfection in eGFP cells treated with 
control px459 vector and eGFP CRISPRs. The top left image is the CHO-eGFP cells only control 
visualised post transfection showing dead non-transfected cells in the presence of puromycin. The 
px459 empty vector only control (negative (-ve) control) shows only a few CHO-eGFP green cells due 
to random area chosen for imaging. The (-ve) control showed 70 % eGFP positive cells. Cells were 
seeded at 2 × 105 cells/mL per well of a 6-well plate and images were taken post transfection using the 
fluorescent microscope. 
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In order to further confirm the visual evidence, we quantified mean GFP expression in 
each of eGFP CRISPR treated samples. We observed a dramatic drop in mean GFP 
expression and % GFP positive cells in the eGFP CRISPR treated samples in 
comparison to the control px459 vector only sample. The mean GFP drop in all the 
eGFP CRISPR treated samples was 25-fold (average mean GFP across four eGFP test 
samples was 82 FU) lower than the control px459 vector only treated sample (2282 
FU) (Fig. 3.4.7B). Moreover, there was a huge drop in the % GFP positive cells in the 
control px459 vector only sample i.e. 68 % to 4.5 % (an average across all four eGFP 
CRISPR test samples) in eGFP CRISPR treated samples (Fig. 3.4.7B).  
 
(B) 
 
Figure 3.4.7B: Mean GFP expression (Bar Graphs) and GFP expression (%) (Δ  Plots) analysed 
using Guava for control, non-GFP cell-line  (CHO-K1) and test CRISPR samples. Cells were 
seeded at 2 × 105 cells/mL per well of a 6-well plate and were analysed for GFP expression using the 
Guava. An eGFP negative (i.e. CHO-K1 parental) cell line was used to gate the instrument prior to 
GFP expression analysis. 
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In Fig. 3.4.7C, it can be seen that the px459 vector only control has a cluster of cells 
in the GFP positive rectangular region, however, there were also cells in the GFP 
negative quadrant as well. These events could possibly be dead non-transfected eGFP 
cells. In contrast to control px459 only, all the eGFP CRISPR treated samples show 
the bulk of the cells clustered in the eGFP negative quadrant. However, eGFP positive 
events were also acquired representing a puromycin resistant population, which was 
also evident from the fluorescent microscopy results. The aim of this study was to 
establish the proof-of-concept that CRISPR-Cas9 system can efficiently and 
specifically knock out a stably integrated eGFP gene in CHO genome. All the above 
findings also demonstrated that using either a 19 nt or 20 nt eGFP sgRNA did not 
impact upon the efficiency of CRISPR induced eGFP knockouts since mean GFP 
expression and % GFP drop was observed to be similar in all eGFP CRISPR treated 
samples. 
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 (C) 
 
Figure 3.4.7C: Mean GFP expression imaged in the form of dot-plots. Screenshots for ExpressPlus 
programme representing clusters of GFP positive (Red) and negative (Green) cells in control and test 
eGFP CRISPR treated samples. Top left screenshot shows the cluster of GFP negative (Green) CHO-
K1 cells used to gate the instrument prior to GFP expression analysis. Cells were seeded at 2 × 105 
cells/mL per well of a 6-well plate and then expanded to T75 flasks.  
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3.4.3.2 High indel frequency obtained by all four eGFP targeting sgRNAs 
In order to assess the % efficiency of indels induced in the eGFP gene, we performed 
a Surveyor Assay. This assay is an easy, straightforward and highly sensitive assay to 
assess for any mutations, including point mutations, in the sequence of interest. This 
assay uses a highly mismatch specific endonuclease enzyme that scans through the 
sequence of interest and cleaves the sequence upon mutation detection with respect to 
a reference DNA sequence (or the wild-type DNA). The cleaved fragments can be 
visualized on higher resolution agarose or polyacrylamide gels. The methodology of 
the assay is explained in detail in Section 2.8.2.8.  
We analysed the genomic DNA from the four eGFP CRISPR transfected populations 
in order to assess the % indels efficiency attained. For this purpose, we extracted the 
genomic DNA from the four eGFP CRISPR transfected populations, as well as the 
genomic DNA from the control px459 vector only cells, according to protocol 
described in Section 2.8.3.1. We then PCR amplified the eGFP (~ 800 bp) DNA 
fragment-of-interest using flanking primers (refer to Table 5.1 in Appendix Section) 
from the genomic DNA (as template) extracted from all the four CRISPR and px459 
only transfected eGFP cells, according to Section 2.7.4. The PCR fragments were 
then purified (refer to Section 2.8.3.3) before performing the Surveyor Assay. 
Homo/Hetero-duplexes of the reference DNA (i.e. eGFP PCR amplicon from px459 
vector only eGFP cells) and test DNA (i.e. eGFP PCR amplicons from CRISPR 
transfected cells) were formed using equal amounts of DNA, separately (refer to 
Section 2.8.2.8). Finally, the Surveyor assay, whereby the homo/hetero-duplex eGFP 
fragments from control and test DNA(s) were cleaved by the Nuclease S enzyme and 
the cleaved fragments were visualized on a 1.2 % high-resolution agarose gel (Fig. 
3.4.8). 
The cleavage intensity of the bands was estimated using Ran et al. (2013b) 
methodology, wherein the integrated intensity of the PCR amplicon and cleaved 
bands was measured using GelAnalyzer software. For instance, for each lane, the 
fraction of the PCR product cleaved (fcut) by the nuclease was calculated using the 
formula: fcut = (b+c)/(a+b+c), where a is the integrated intensity of the undigested 
PCR product and b and c are the integrated intensities of each cleavage product. 
Finally, a formula based on the binomial probability distribution of duplex formation 
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was used to calculate the indel occurrence/ indel (%). 
Indel (%) = 100 × (1 - √(1- fcut))  
We observed that the sgGFP 1A and sgGFP 1B gave rise to the highest (50 %) indel 
frequency, while sgGFP 2A and sgGFP 2B demonstrated (40 %) indel frequency 
(Fig. 3.4.8). 
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Figure 3.4.8: Agarose gel image post Surveyor Assay. The +ve and -ve stands for samples with 
Nuclease S and samples without Nuclease S enzyme, respectively. px à Reference DNA Control, (px 
+ 1A) à Homo/Heteroduplex mix formed using PCR amplicons from reference px459 and sgGFP 1A, 
(px + 1B) à Homo/Heteroduplex mix formed using PCR amplicons from reference px459 and sgGFP 
1B, (px + 2A) à Homo/Heteroduplex mix formed using PCR amplicons from reference px459 and 
sgGFP 2A and (px + 2B) à Homo/Heteroduplex mix formed using PCR amplicons from reference 
px459 and sgGFP 2B. All Control samples are highlighted with White font, while Green labeled 
samples are Test eGFP CRISPR samples. Red Arrow Heads represent the bands for the cleaved 
mutated fragments. The Surveyor kit internal controls were also ran on the gel. 
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3.4.3.3 Analysis of the nature of indels induced in the eGFP gene 
To further assess the nature and frequency of the indels attained with eGFP sgRNAs, 
TOPOTM-TA cloning (refer to Section 2.8.2.7) and sequencing of the gel-purified 
amplicons from the eGFP genomic site was performed (Fig. 3.4.9). The PCR 
amplicons covering the sgRNA-target site i.e. the eGFP gene fragment (~ 800 bp) 
were TOPOTM TA-cloned and transformed into DH5α cells (refer to Section 2.8.2.6). 
Ten single colonies for each of the eGFP CRISPRs transformant containing plates 
were sent for Sanger sequencing to check the frequency and types of genomic (micro) 
deletion or inversion, indel mutations created by the NHEJ repair mechanism (Fig. 
3.4.9). We observed almost all the eGFP CRISPRs induced different types of indel 
mutations, some of them were large deletions in the eGFP sequence and a few were 1 
bp or 2 bp insertions at the eGFP target site. We observed that the ten TOPO-cloned 
samples for the sgGFP 1A CRISPR mostly contained deletions at the target site in the 
eGFP gene, some were 1-3 bp long, other were 12 bp, 15 bp and 27 bp. In addition to 
deletions, two samples contained indels, with 73 bp (69 random bp insertion, 4 bp 
deletion) and large 219 bp (204 random bp insertion, 15 bp deletion) downstream of 
the PAM sequence (Fig. 3.4.9). The majority of indels in sgGFP 1B CRISPR TOPO-
cloned samples were > 10 bp. sgGFP 1B CRISPR resulted in eight positives for 
mutations induced at the eGFP target site, while two sequencing results were reported 
negative i.e. no indels observed. Similar to sgGFP 1A, 8 sgGFP 1B CRISPR TOPO-
cloned samples mostly contained big deletions ranging from 13 bp to 27 bp long, with 
one TOPO-cloned sgGFP 1B sample resulting a 2 bp insertion at the target eGFP site. 
Only the sgGFP 1B CRISPR TOPO-cloned samples showed consistent large deletions 
in all the positive samples (Fig. 3.4.9). 
All four eGFP CRISPRs resulted > 40 % indel efficiencies, however, as previously 
observed in the Surveyor assay the eGFP CRISPR (i.e. sgGFP 2A and sgGFP 2B 
CRISPRs targeting the 3’-end of the eGFP gene sequence resulted in ≤ 40 % indel 
frequencies (Fig. 3.4.8). Therefore, it was interesting to observe the types and 
frequencies of mutations induced by these eGFP CRISPRs. We observed that both the 
sgGFP 2A and sgGFP 2B CRISPR TOPO-cloned samples resulted in 1 or 2 bp 
insertion and/or deletions at the eGFP 3’-end target site. Two TOPO-cloned samples 
from each sgGFP 2A and sgGFP 2B CRISPR were negative i.e. no indels observed, 
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while eight samples for each were positive for indels. Of the eight positive indel 
samples, two samples sgGFP 2A CRISPR resulted 26 bp long sequence deleted at the 
target site and most of the bases downstream of the PAM sequence were deleted. 
Moreover, one sample showed 133 bp deleted in the GFP sequence with indels (118 
bp deletions and 15 bp random sequence insertion) (Fig. 3.4.9). Similar sequencing 
results for sgGFP 2B CRISPR TOPO-cloned samples were observed, however, with 
sgGFP 2B CRISPR 1 or 2 bp insertion were reported more often than 1 or 2 bp 
deletion (Fig. 3.4.9). In addition to small indels, one sgGFP 2A CRISPR TOPO-
cloned sample resulted in 31 bp indels, while another had 102 bp deletion 
downstream of the PAM sequence (Fig. 3.4.9). 
 
	
1.	sgGFP	1A	CRISPR	or	eGFP	5’-end	targe8ng	19	bp	eGFP	in	CHO-eGFP	genome	(red	underlined	19	bp	target	sequence	&	NGG	blue->	PAM).	
								
							5’-	ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT…..-3’	GFP1A	
	
							5’-	ATGGTGAGCAAGGGCGAGGAGCTG	-	TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT….-3’	(1bp	del)	
							5’-	ATGGTGAGCAAGGGCGAGGAGCTG-	-	-ACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT	….-3’	(3bp	del)	
							5’-	ATGGTGAGCAAGGGCGAGG	-	-	-	-	-	-	-	-	-	-	-	-		-		-		-TGGTGCCCATCCTGGTCGAGCTGGGAGCAAGGGCGAGGAGCGCGATAGCGG…-3’(15+204bp	indel)	
							5’-	ATGGTGAGCAAGGGCGAGGAGCTGTTC	-	-	-	-	GGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT….-3’	(4bp	del)	
							5’-	ATGGTGAGCAAGGGCGAGGAGCT	-	-	-	-	ACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT…..-3’(4bp	del)	
							5’-		-	-	-		-		-		-	-	-	-	-		-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-			ACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT….-3’	(27bp	del)	
							5’-	ATGGTGAGCAAGGGCGAGGAGCT		-	-	-	-	ACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT....-3’	(4	bp	del)	
							5’-	ATGGTGAGCAAGGGCGAGGAGCTGTT	-	-	-	-	GGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAG..-3’	(4	+	69bp	indel)	
							5’-	ATGGTGAGCAAGGGCGAGGAGC	-	-	-	TCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT…-3’	(3	bp	del)	
							5’-	ATGGTGAGCAAGGGCGAGGAGC	-	-	-	-	-	-		-	-	-	-	-	-	TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT…-3’	(12	bp	del)		
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2.sgGFP	1B	CRISPR	or	eGFP	5’-end	targe9ng	20	bp	eGFP	in	CHO-eGFP	genome	(red	underlined	20	bp	target	sequence	&	NGG	blue->	PAM).	
								
				5’-	ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT…..-3’	GFP1B	
						
				5’-	ATGGTGAGCAAGGGCGA	-	-	-	-		-	-	-	-	-		-	-	-	-	-	-	-	-	-	GGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT…..-3’	(18bp	del)	
				5’-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-	-	-	-	-	-	ACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT..-3’(27bp	del)	
				5’-	ATGGTGAGCAAGGGCGAGGAG	-	-	-		-	-	-		-	-	-	-	-	-	-	-	-	-	-	-	-	CCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT	….-3’	(19bp	del)	
				5’-	ATGGTGAGCAAGGGCGAGGAGCTGT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	TCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT	…-3’	(18bp	del)	
				5’-	ATGGTGAGCAAGGGCGA	-	-	-	-		-		-	-		-	-	-		-	-	GGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT…-3’	(13	bp	del)	
				5’-	ATGGTGAGCAAGGGCGAGGAGCTGTTCTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAA..-3’(2	bp	inser7on)	
				5’-		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		-	-	-	-	-	-	-	-	-	ACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT..-3’	(27bp	del)	
				5’-	ATGGTGAGCAAGGG	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	CGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT…3’	(15	bp	del)	
				5’-	ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT	…-3’	(NO	indels)	
				5’-	ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTT	…-3’	(NO	indels)	
	
	
	
	
3.	sgGFP	2A	CRISPR	or	eGFP	3’-end	targe8ng	19	bp	eGFP	in	CHO-eGFP	genome	(red	underlined	19	bp	target	sequence	&	NGG	blue->	PAM).	
								
				5’-.…….............GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG	-3’							GFP	2A	
					
				5’-	………………..GAAGCGCGATCACATGGTC	–	TGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG-3’	(1	bp	del)	
				5’-	………………..GAAGCGCGATCACATGGTC	–	TGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG-3’	(1	bp	del)	
				5’-	………………..GAAGCGCGATCACATGGTCC	–	GCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG-3’	(1	bp	del)	
				5’-	…----------------------------------------------------------------------------------------------------TTTGGCATGGACGAGCTGTACAAGTAG-3’	(118	+	15	bp	indels)	
				5’-	…………………GAAGCGCGATCA		-	-	-	-	-	-	-		CTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG-3’	(7	bp	del)	
				5’-	…………………GAAGCGCGATCACA	–	G	-	-	CC	–	G	-	-	GGA	-	T	–	C-	-	-ACC	--	---	----	--	TC	-	-T	–T	–	GGCATGGACGAGCTGTACAAGTAG-3’	(26	bp	del)	
				5’-	...………GAAGCGCGATCACATGGTCCTGCTGGAGTTCGAAGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG-3’	(1	bp	inser7on)	
				5’-		………..GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTTTGGCATGGACGAGCTGTACAAGTAG-3’		(1	bp	inser7on)	
				5’-	…………………GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTTGGCATGGACGAGCTGTACAAGTAG-3’	(NO	indels)	
				5’-	…………………GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTTGGCATGGACGAGCTGTACAAGTAG-3’	(NO	indels)	
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Figure 3.4.9: Analysis of indels in eGFP gene of the CHO-eGFP cells. TOPOTM TA – based 
sequence analysis of eGFP was performed and compared with the reference (or wild-type) eGFP 
sequence (Top sequence in every panel), with the CRISPR target site Underlined and the PAM site 
highlighted in Blue. 1 shows the indels generated using sgGFP 1A CRISPR, 2 shows indels generated 
using sgGFP 1B CRISPR, 3 shows indels generated using sgGFP 2A CRISPR, while 4 shows indels 
generated using sgGFP 2B CRISPR. Dashed Red line shows the bases deleted from the eGFP sequence 
(numbers of bases deleted in Red), while Green bases and/or Dashed Green line shows the bases 
inserted (numbers of bases inserted in Green).  
In summary, all four eGFP CRISPR demonstrated significant indel frequencies, with 
sgGFP 1A (19 nt guide) and sgGFP 1B (20 nt guide) CRISPRs targeting the 5’-end of 
the eGFP gene, demonstrating highest ~ 50 % indel efficiencies in both. Moreover, 
majority (more than 60 %) of indels were > 10 bp i.e. 11 out of 18 positive TOPO-
cloned sgGFP 1A and sgGFP 1B samples collectively. On the other hand, sgGFP 2A 
and sgGFP 2B CRISPRs targeting the eGFP 3’-end of the eGFP gene generated ≤ 40 
% indels only. Moreover, it was observed that sgGFP 2A and sgGFP 2B CRISPRs 
induced 1 or 2 bp indels more often (~ 57 %) than big indels (i.e. 9 out of 16 positive 
TOPO-cloned sgGFP 2A and sgGFP 2B samples collectively, yielded 1 or 2 bp only 
indels). Only (25 %) 4 out of 16 positive TOPO-cloned eGFP 2A and eGFP 2B 
4.	sgGFP2B	CRISPR	or	eGFP	3’-end	targe9ng	20	bp	eGFP	in	CHO-eGFP	genome	(red	underlined	20	bp	target	sequence	&	NGG	blue->	PAM).	
								
				5’-.…….............GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG	-3’							GFP	2B	
					
				5’-	…………..	GAAGCGCGATCACATGGTCCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG-3’	(1	bp	inser+on)	
				5’-	…………..	GAAGCGCGATCACATGGTCCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG-3’	(1	bp	inser+on)	
				5’-	……………GAAGCGCGATCACATGGTCCTGCTGGAGT	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	------downstream------3’	(	102	bp	del)	
				5’-	……………GAAGCGCGATCACATGGTCCCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG-3’	(2	bp	inser+on)	
				5’-…………….GAAGCGCGATCACATGGTC	-	-	GCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG	-3’	(2	bp	del)	
				5’-……………..….-	ATTCTT-G	-	-	GC	–	C	-	-	-C	-	-	-TGGCCCCACAACATG	-	A	-	T		-	CAAAAAAGTTTTTTC	–	C	–	G	-	-	GGGCC	–	CACTCTT.-3’	(19	+	12	bp	indel)	
				5’-	………………GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAG-3’	(1	bp	dele+on)	
				5’-		……………..GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTTTGGCATGGACGAGCTGTACAAGTAG-3’		(1	bp	inser+on)	
				5’-	………………GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTTGGCATGGACGAGCTGTACAAGTAG-3’	(NO	indels)	
				5’-	………………GAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTTGGCATGGACGAGCTGTACAAGTAG-3’	(NO	indels)	
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samples collectively, yielded > 20 bp indels (Fig. 3.4.9). 
3.5 Applying the CRISPR-Cas9 system to target the miR-7 locus in an 
industrially relevant CHO cell line 
There have been several studies published in the literature, wherein the potential of 
manipulating miR-7 levels is associated with enhancing growth and productivity 
phenotypes. For instance, lately Sanchez et al. (2014) reported 3-fold improved CHO 
cell proliferation, ~ 30 % cell viability increase and 2-fold protein productivity 
increase by using a loss-of-function approach to deplete endogenous miR-7 levels. 
Therefore, with this in mind, we wished to explore this CRISPR-Cas9 genome 
modification approach to knockout the miR-7a-5p sequence from the CHO-K1 1.14 
cell line. CHO-K1 1.14 cell-line is a monoclonal antibody producing cell line 
(henceforth referred as 1.14).  
3.5.1 Designing and cloning of miR-7 sgRNA into the px459 CRISPR vector 
The sgRNA sequences for a miR-7 targeting CRISPR-Cas9 system were designed 
using the CRISPR Design Tool (http://tools.genome-engineering.org) (Table 3.5.1). 
The miR7 1 and miR7 2 CRISPRs differ in that miR7 1 targets the miR-7a-5p 
sequence upstream of the mature miR-7 sequence, while miR7 2 targets the miR-7a-
5p sequence downstream of the mature miR-7, loop and star-strand sequence. A and 
B refer to the length of the guide sequence, wherein A is 19 nt long sgRNA and B is 
20 nt long sgRNA oligo sequences annealed and ligated into the BbsI linearized 
px459 vector (refer to Section 2.8.2.1 and Section 2.8.2.4). We designed four 
sgRNAs targeting two different sites of the miR-7a-5p sequence in 1.14 cells (Fig. 
3.5). The resulting constructs will be referred as sgmiR7 1A, sgmiR7 1B, sgmiR7 2A 
and sgmiR7 2B CRISPRs. This allowed us to investigate the CRISPR-Cas9 efficiency 
of using different sgRNAs targeting different sites in the gene. 
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Table 3.5.1 List of miR7 sgRNAs used for targeting cgr-miR-7a-5p sequence. sgRNA sequences 
(A à19nt or B à20 nt Highlighted in Yellow). Only sense strands are shown.  The BbsI site 
(cacc) is also included at the 5’-end of the sequence for ligation into px459 vector. Red 
highlighted G appended at 5’-end (as preferred base) is the first base of the guide sequence. NGG 
is PAM sequence in the CHO genome. 
CRISPR-Cas9 
constructs 
sgRNA sense-strand sequences (or guide sequences) PAM (5’-
end 
upstream 
of guide 
sequence) 
sgmiR7 1A 5’ – CACCGTGGACAGGCCAGCCCCGCC – 3’ TGG 
sgmiR7 1B 5’ – CACCGATGGACAGGCCAGCCCCGCC– 3’ TGG 
sgmiR7 2A 5’ – CACCGGCGGGTCCTCTGAGCATCA – 3’ GGG 
sgmiR7 2B 5’ – CACCGGCGGGTCCTCTGAGCATCA – 3’ GGG 
 
The sgRNAs for miR7 1 and miR7 2 were cloned into the px459 vector as described 
previously in Section 3.4.3. 
 
Figure 3.5: Sense cgr-miR-7a-5p locus sequence highlighting in Blue the two miR7 1 and miR7 2 
CRISPR target sites upstream and downstream of the mature miR-7a sequence. Sequence 
highlighted in Cyan represents the miR-7 loop sequence and the Underlined sequence represents 
the Star strand sequence. TGG and GGG represent the PAM at the 3’-end of miR7 CRISPR sites 
1 and 2, respectively. Strike through three bases upstream and downstream of mature miR-7 
sequence represents Cas9 Cleavage sites. 
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3.5.2 Transfection of px459 miR7 CRISPR constructs in 1.14 cells 
 
The results in Section 3.4.3.2 and 3.4.3.3 did not assist in the choosing of preferred 
type of sgRNA to be used for targeting any other gene sequence. For this reason, we 
employed all four miR7 CRISPRs to disrupt the miR-7a-5p sequence. The sgRNA 
designed to target the 5’-end of the eGFP gene performed marginally better than 
sgRNA targeting the 3’-end of the eGFP gene in inducing indels. However, the fact 
that targeting an ORF of gene encoding protein is easier since only one bp knock out 
is enough to disrupt the reading frame of eGFP gene, could not be excluded. For non-
coding gene like in the case of miR-7 (with two alleles located on two different 
chromosomal loci), where there are possibly four copies of the gene with functional 
redundancy due to paralogs, we assumed that it would be a harder task to knock out 
all the four copies. Moreover, in order to render miRNAs functionless, we required 
significant deletions in the sequence as opposed to single base indels.  
We transfected 5 wells of a 6-well plate containing 1.14 cells seeded at 5 × 105 
cells/mL cell density one day before transfection with 1 µg of control px459 vector 
only (i.e. no guide sequence), sgmiR7 1A, sgmiR7 1B, sgmiR7 2A and sgmiR7 2B 
CRISPR DNA (s) (refer to Section 2.6.1.2). Three days post transfection, we 
observed ~ 65-70 % viable cells in the px459 only control well of the 6-well plate, on 
the other hand, 1.14 cells-only control contained only dead cells (data not shown). 
Similar percentages of viable cells were observed in our test CRISPR wells of the 6-
well plate. We then expanded each well of the 6-well plate to T25 flasks and selected 
cells for another week in order to extract sufficient amount of genomic DNA for 
further analysis. During this time-period, cells were monitored every day and had 
their media replenished routinely and were not under any stress.  
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3.5.3 High indel frequency attained by all miR-7a-5p locus targeting miR7 
CRISPRs 
 
A similar workflow as used for analysing eGFP indels was followed to analyse indels 
induced by miR7 CRISPRs in 1.14 cells. To assess the % efficiency of targeting the 
miR-7a-5p locus, we performed a Surveyor Assay. The methodology of the assay is 
explained in detail in Section 2.8.2.8.  
We analysed the genomic DNA from the four miR7 CRISPR transfected populations 
in order to assess the % indels efficiency attained. For this purpose, we extracted the 
genomic DNA from the four miR7 CRISPR transfected populations, as well as the 
genomic DNA from the control px459 vector only cells. Following this, we PCR 
amplified the miR7 (~ 855 bp) DNA fragment-of-interest using flanking primers 
(designed ~ 400 bp upstream and 230 bp downstream of the 224 bp miR-7a-5p 
sequence) (refer to Table 5.2 in Appendix Section) from genomic DNA (as 
template). The PCR fragments were then purified before performing the Surveyor 
assay. Homo/Hetero-duplexes of the reference DNA (i.e. miR7 PCR amplicon from 
control px459 vector only treated sample) and test DNA (i.e. miR7 PCR amplicons 
from CRISPR treated samples) were formed using equal amounts of DNA in a 
thermocycler. Finally, the Surveyor assay, whereby the homo/hetero-duplex miR7 
fragments from control and test DNA(s) were cleaved by the Nuclease S enzyme and 
the cleaved fragments were visualized on a 1.2 % agarose gel (Fig. 3.5.1). The 
cleavage intensity of the bands was estimated as described previously in Section 
3.4.3.2. 
We observed that the sgmiR7 1A and sgmiR7 1B gave rise to (35 %) indel frequency, 
while sgmiR7 2A and sgmiR7 2B demonstrated (40 %) indel frequency. In summary, 
we estimated ~ 35-40 % indel frequencies with each of miR7 CRISPR in the miR-7a-
5p sequence of CHO-K1 1.14 cells (Fig. 3.5.1).  
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Figure 3.5.1: Agarose gel image post Surveyor Assay. The +ve and -ve stands for samples with 
Nuclease S and samples without Nuclease S enzyme, respectively. px à Reference DNA Control, (px 
+ m1A) à Homo/Heteroduplex mix formed using PCR amplicons from reference px459 and sgmiR7 
1A, (px + m1B) à Homo/Heteroduplex mix formed using PCR amplicons from reference px459 and 
sgmiR7 1B, (px + m2A) à Homo/Heteroduplex mix formed using PCR amplicons from reference 
px459 and sgmiR7 2A and (px + m2B) à Homo/Heteroduplex mix formed using PCR amplicons from 
reference px459 and sgmiR7 2B. All Control samples are highlighted with White font, while Green 
labeled samples are Test eGFP CRISPR samples. Red Arrow Heads represent the bands for the cleaved 
mutated fragments. 
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3.5.4 Analysis of the nature of indels induced at the miR-7 locus 
To further assess the indel type and frequency attained with miR7 sgRNAs, TOPOTM-
TA cloning and sequencing of the gel-purified amplicons from the miR7 genomic site 
was performed (Fig. 3.5.2). The PCR amplicons covering the sgRNA-target site i.e. 
the miR-7a-5p flanking gene fragment (~ 855 bp long) were TOPOTM TA-cloned and 
transformed into DH5α cells. Ten single colonies for each of the miR7 CRISPR 
transformant containing plates were sent for Sanger sequencing to check the 
frequency and types of genomic (micro) deletion or inversion, indel mutations created 
by the NHEJ repair mechanism (Fig. 3.5.2). We observed that most of the miR7 
CRISPRs generated 1 bp or 2 bp insertion. 80 % of the sgmiR7 2A CRISPR TOPO-
cloned samples generated 1 or 2 bp indels (Fig. 3.5.2). Similar to sgmiR7 2A, 60 % of 
the sgmiR7 1A CRISPR TOPO-cloned samples generated 1 or 2 bp indels, however, 
two sgmiR7 1A CRISPR TOPO-cloned samples showed big deletions of 18 bp and 96 
bp (32 bp in miR-7a-5p sequence and 64 bp upstream of miR-7a-5p sequence deleted) 
each. Therefore, 20 % of the 10 sgmiR7 1A CRISPR TOPO-cloned samples sent for 
sequencing showed big deletion (Fig 3.5.2). The similarity in sgmiR7 1A and sgmiR7 
2A guides was the length of the sgRNA, which was 19 nt. Therefore, we could infer 
that the guide-length here made the difference in miR7 CRISPR activities in 
generating the magnitude of indels observed. Based on our previous observation in 
Section 3.4.3.2, we hypothesized that the sgRNA with guide length 20 nt long should 
be more efficient than sgRNA 19 nt long based on results from our 10 TOPO samples 
for each type of eGFP CRISPR. We observed that sgmiR7 1B CRISPR also generated 
mostly of 1 or 2 bp deletion, however, less frequently. 80 % of TOPO-cloned sgmiR7 
1B samples contained indel sizes in the range of 3 -10 bp. In addition to small indels, 
two of the TOPO-cloned sgmiR7 1B samples contained big deletions of 25 bp and 
175 bp (knocking out the mature miR-7a-5p sequence, loop an star strand sequence 
downstream of the miR7 1 CRISPR target site) (Fig. 3.5.2). The sgmiR7 2B CRISPR 
demonstrated the highest CRISPR efficiency in terms of generating big deletions in 
30 % of the 10 TOPO-cloned 2B samples sent for sequencing. The size of the 
deletions observed were 127 bp (mature miR-7a-5p sequence along with the loop 
sequence deleted), 249 bp (89 bp deleted from the miR-7a-5p sequence downstream 
of the miR7 2 CRISPR target site and another 160 bp deleted downstream of the miR-
7a-5p sequence) and 240 bp (169 bp knocked out of the miR-7a-5p sequence and 
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another 71 bp upstream of the miR-7a-5p sequence). Moreover, the frequency of 1 or 
2 bp indels was the lowest i.e. 20 % of 10 TOPO-cloned sgmiR7 2B samples resulting 
in single base bp indels (Fig. 3.5.2). With these observations, we inferred that the 
location of the sequence against where the guide is designed to bind in relation to 
miR-7a-5p sequence is also critical, in addition to the sgRNA length, for efficient 
CRISPR-Cas9 activity.  
 
 
	
	
1.	miR-7a	sequencing	results	for	sgmiR7	1A	CRISPR:	
	
5’GGTAGTATCCAAGGATGATAGACAGGTGGTGGCCAAGGCCCAGAGCCAGGCCTGGTCAGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’	(18	bp	mm	+	1	bp	in	+	6	bp	
del	&	and	1	bp	inser3on,	9	bp	dele3on	and	16	bp		few	bp	mismatch	muta3ons	upstream	of	miR-7a-5p	sequence).	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(1	bp	inser3on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’					(5	bp	dele3on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(1	bp	inser3on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(1	bp	inser3on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(1	bp	inser3on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCCGCCTGGAAGACTAGTGATTTCGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(1	bp	inser3on	+	1	bp	mm)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’	(32	bp	dele3on	+	64	bp	
deleted	upstream	of	miR-7a-5p	sequence)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(2	bp	inser3on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’					(18	bp	dele3on)	
	 162	
 
 
	
	
2.	miR-7a	sequencing	results	for	sgmiR7	1B	CRISPR:	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC..-3’			(175	bp	dele+on	+	2	bp	
downstream	of	miR-7a-5p	sequence)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(2	bp	inser+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’	(1	bp	dele+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(1	bp	inser+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’	(1	bp	inser+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’					(5	bp	dele+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’					(1	bp	inser+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATGTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’				(4	bp	del	+	1	bp	inser+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’							(5	bp	dele+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’						(	25	bp	dele+on)	
	
	
	
	
	
3.	miR-7a	sequencing	results	for	sgmiR7	2A	CRISPR:	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(3	bp	dele)on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAGAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCA
CACGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(1	bp	dele)on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCAATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(1	bp	inser)on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCAATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(1	bp	inser)on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCAATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(1	bp	inser)on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(6	bp	dele)on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGAAAGGCTCTGGACAGGTCAGCCCTGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACA
CGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(1	bp	dele)on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCGGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(1	bp	mm)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCAATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’	(1	bp	del	+1	bp	in)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCAC
ACGGTGCGGGTCCTCTGAGCAATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’	(1	bp	inser)on)	
	 163	
 
Fig. 3.5.2: Analysis of indels in the miR-7a-5p sequence. TOPOTM TA – based sequence analysis of 
miR-7a-5p sequence was performed and compared with the reference (or wild-type) miR-7a-5p 
sequence. 1 shows the indels generated using sgmiR7 1A CRISPR, 2 shows the indels generated using 
sgmiR7 1B CRISPR, 3 shows the indels generated using sgmiR7 2A CRISPR, while 4 shows the 
indels generated using sgmiR7 2B CRISPR. Red letters in the sequence denote the bases deleted from 
the miR-7a-5p sequence and the numbers of deleted bases mentioned in the closed brackets in Red, 
Green letters represent the inserted bases in the miR-7a-5p sequence and the number of bases inserted 
mentioned in the closed brackets in Green, while Orange letters denote the bases substituted (mismatch 
mutations) in the miR-7a-5p sequence and the number of mismatches introduced mentioned in the 
closed brackets in Orange. The mutations in the upstream and downstream of the miR-7a-5p sequence 
are also mentioned in the closed brackets in Black. Underlined sequence represents the mature miR-7a 
sequence. 
 
 
 
 
 
 
 
 
	
	
4.miR-7a	sequencing	results	for	sgmiR7	2B	CRISPR:	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(127	bp	dele+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(8	bp	dele+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCAATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(1	bp	inser+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(16	bp	dele+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCACATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(	2	bp	inser+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGCTCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’						(2	bp	mm)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCAATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’		(1	bp	inser+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTATGTATACTCAACAACAAGTTCCATTTTACCTCAA
CAACAAGTTCCTGTGTGCCACCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’			(17	bp	mm	+	1	bp	inser+on)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’	(89	bp	del	+	160	bp	deleted	
downstream	of	miR-7a-5p	sequence)	
	
5’GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGCCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAACAACAAGTCCCAGTCTACCACAC
GGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTAGCAAACTACCAAAATATTCCTC3’	(169	bp		+	71	bp	deleted	
downstream	of	miR-7a-5p	sequence)	
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3.5.5 Isolating single cell clones with big indels in the miR-7a-5p sequence  
 
miR-7 has been reported as one of the critical players in inducing cell cycle arrest in 
CHO cells, consequently leading to improvement in cellular longevity and 
productivity in CHO cell (Sanchez et al. 2013, Sanchez et al. 2014). From a 
bioprocessing context, we hypothesized that picking a CHO clone with mature miR-
7a-5p sequence knocked out or altered would yield interesting phenotypes. For this 
reason, we chose sgmiR7 2B CRISPR 1.14 mixed cells for single cell cloning due to 
higher probability of finding a potential CHO clone that has a part of or the whole 
mature miR-7a-5p sequence knocked out. Since with sgmiR7 2B CRISPR we attained 
~ 40 % indel frequencies and 30 % of the TOPO-TA cloning sequencing results 
demonstrated big indels. Once isolated each clone was subjected to real-time qPCR 
analysis for the quantitation of endogenous mature miR-7a levels. 
 
3.5.6 Endogenous mature miR-7a expression analysis in single cell clones 
 
We hypothesized that deleting one copy of miR-7a might not result in any phenotypic 
outcome due to compensation by the other copy of the gene or, sometimes, paralogs 
such as miR-7b in this case. However, it has been reported that miR-7a is more 
strongly expressed than miR-7b in many CHO cell lines (Hackl et al. 2011b). 
Therefore, before performing any phenotypic analysis across the 36 clones, we 
screened the clones on for mature miR-7a expression levels. We performed a real-
time qPCR for each of the 36 clones hoping to isolate a clone that had both the miR-
7a allele knocked out i.e. both miR-7a copies. We observed that out of 36 clones, 22 
clones demonstrated less than 5-fold down regulation in the endogenous mature miR-
7a expression levels when compared to the parental 1.14 cell line. However, 11 
individual clones reported more than 5-fold down regulation, with Clone 6 and Clone 
29 demonstrating ~ 10-fold down-regulation. Clone 14 showed nearly ~ 160-fold 
down regulation in mature miR-7a expression levels, which seemed to us as the 
potential clone with both miR-7a copies knocked out in the 1.14 cells genome. In 
order to confirm the mature mir-7a expression displayed by these clones, we re-
analysed a few of these clones again for mature miR-7a expression levels as a 
validation step. Fresh total RNA samples were harvested again from Clone 6 & 14 
(low mature miR-7a expression), Clone 25 & 30 (medium mature miR-7a expression) 
	 165	
and Clone 34 & 36 (high mature miR-7a expression). To our surprise, we observed 
that the levels of mature miR-7a expression levels were less down regulated for Clone 
6 (from 0.107 units to 0.47 units), 14 (from 0.006 units to 0.39 units) and 30 (from 
0.328 units to 0.75 units). However, the levels of mature miR-7a expression in Clone 
25 did not change significantly (from 0.53 units to 0.62 units), for Clone 34 and Clone 
36 stayed the same (i.e. ~ 0.9 units). At this stage, we did not have a single clone that 
showed more than 10-fold mature miR-7a down regulated since all the clones were 
still expressing mature miR-7a transcripts (Fig. 3.5.3a). We hypothesized that 
following one miR-7a copy knock out in these clones, the cells are somehow 
compensating for the lack of miR-7a by up regulating the other mir-7a copy through 
increased pre-mir-7a transcription. In addition to pre-mir-7a, although from Hackl et 
al. (2011) data we understood the miR-7a-5p is very strongly expressed as opposed to 
miR-7b-5p in CHO cell lines, we also hypothesized that up-regulation of miR-7 
paralogs could also account for the loss of miR-7a as a compensation mechanism by 
the cells (explained later in Section 4.5.5).  Therefore, we performed RT-qPCR for 
pre-mir-7a and pre-mir-7b expression levels, separately for each Clone 6, 14, 25, 30, 
34 and 36. We observed that the pre-mir-7a or pre-mir-7b expression levels were 
unchanged in all of the clones relative to the control (CHO-K1 1.14 parental cell line) 
(p-value > 0.05), although insignificant but clone 34 showed slightly increased levels 
of pre-mir-7b in comparison to the control (Fig. 3.5.3b). Therefore, the speculation of 
possible compensation of miR-7a and/or miR-7b through increased pre-mir-7a and/or 
pre-mir-7b transcriptional rates through some feedback mechanism was unfounded. 
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Figure 3.5.3a: Relative Expression levels of the mature miR-7a expression levels across single cell 
clones assessed using Real-Time qPCR. Cyan bars represent the first qPCR run across 38 clones, 
while Blue bars represent second qPCR run for few selected clones from a different total RNA sample 
for each. A standard student t-test was performed to analyse statistically significant data (p-value > 
0.05). The levels of expression of mature miR-7a were normalised to endogenous snRNA U6 control. 
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Figure 3.5.3b: Relative Expression levels of the premir-7a and premir-7b expression levels across 
selected single cell clones assessed using Real-Time qPCR. A standard student t-test was performed 
to analyse statistically significant data (p-value > 0.05). The levels of premir-7a and premir-7b were 
normalised to endogenous beta-actin control. 
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3.5.7 Sanger sequencing to analyse indels in individual isolated clones 
 
The qPCR data above did not clearly report any of the clones contained miR-7a 
knockout. For this purpose, we chose Clone 6, 14, 25, 30, 34 and 36 to analyse the 
types of indels induced using Sanger sequencing. From each clone, we sent a 855 bp 
amplicon, flanking the 224 bp miR-7a-5p sequence, amplified using the primers 
mentioned in Table 3.5.2. We found that Clone 6, 14, 30 and 36 did not show any 
indels at the target site  (i.e. miR-7a-5p sequence) (Fig. 3.5.4). Clone 25 showed 8 
random bases inserted without disrupting the mature miR-7a sequence. Clone 34 
showed 148 bp deletion i.e. 137 bp deleted in the miR-7a-5p sequence (with mature 
miR-7a, loop and star strand sequence knocked out) and 11 bp upstream of the miR-
7a-5p sequence also deleted (Fig. 3.5.4). We hypothesized that the up regulation of 
mature miR-7a expression levels could be due to heterozygous deletion of only one 
miR-7a copy, whilst the other copy being up regulated as a result of cell’s 
compensation mechanism for the perceived lack of the deleted miR-7a copy. To 
further check that Clone 34 contained homozygous or heterozygous deletion of 
mature miR-7a sequence, we PCR amplified the deleted 148 bp in the miR-7a-5p 
sequence in the wild-type 1.14 cells (wt 1.14), Clone 14 and Clone 34 using 
combinations of different flanking primers mentioned in the schematic diagram (Fig. 
3.5.5). The primers flanking deleted 148 bases in the miR-7a-5p sequence should 
result in strong single 169 bp band with the genomic DNA from 1.14 wt and Clone 14 
(since the miR-7a-5p sequence in both of these was intact). For Clone 14 and Clone 
34 the expected bands were observed at their respective sizes. We found that Clone 34 
had a faint band at the 169 bp mark (Fig. 3.5.6, Table 3.5.2). The faint band at 169 bp 
raised the speculation that the sgmiR7 2B CRISPR induced a heterozygous deletion 
of one miR-7a copy in Clone 34, while the other copy still either undisrupted or 
contained insignificant indels. We sequenced the faint 169 bp band gel excision and 
found that mature miR-7a sequence of the second copy undisrupted, however, there 
were 2-3 bases inconsequential random mismatch mutations as well 2-3 bases 
deletion upstream of it (Fig. 3.5.7). This observation also explained the unchanged 
mature miR-7a expression levels in Clone 34 in Fig. 3.5.3. For Clone 14, the presence 
of intact miR-7a-5p sequence was rather surprising since we observed ~ 5-fold down 
regulation in the mature miR-7a expression in Section 3.5.6. In order to address this 
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anomaly between these two experiments for Clone 14, we performed another 
validation study as described in the upcoming section. 
 
 
 
 
 
Figure 3.5.4: Multiple sequence alignment results for individual clones 855 bp amplicon 
sequences versus wt-1.14 854 bp amplicon sequence. Only the sequence wherein indels were 
observed is shown. Highlighted in Green represent the insertion in Clone 25, Dashed Black Lines 
represent deleted bases and Asterisks (*) represent strong similarity in bases with the wt1.14. 
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Figure 3.5.5: Schematic diagram of miR-7a-5p sequence amplified using different flanking 
primers. Green solid boxes represent the 224 bp miR-7a-5p sequence showing the mature, loop, star 
and sgmiR7 2B CRISPR target site. F1 and R1 are Forward 1 and Reverse 1 flanking primers, 
respectively. F2 and R2 are Forward 2 and Reverse 2 flanking primers, respectively. 
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Table 3.5.2: List of PCR products obtained from wt 1.14, Clone 14 and Clone 34 templates using 
different combinations of flanking primers 
Primers Expected PCR product size 
for wt 1.14 template 
Observed PCR product size 
for wt 1.14 template 
F1 + R1 854 bp 854 bp 
F2 + R2 169 bp 169 bp 
F1 + R2 575 bp 575 bp  
F2 + R1 449 bp 449 bp 
Primers Expected PCR product size 
for Clone 14 template 
Observed PCR product size 
for Clone 14 template 
F1 + R1 854 bp 854 bp 
F2 + R2 169 bp 169 bp 
F1 + R2 575 bp 575 bp  
F2 + R1 449 bp 449 bp 
Primers Expected PCR product size 
for Clone 34 template 
Observed PCR product size 
for Clone 34 template 
F1 + R1 706 bp 706 bp & very faint band at 850 
bp 
F2 + R2 No band 169 bp faint band 
F1 + R2 404 bp 404 bp & 575 bp faint band 
F2 + R1 301 bp 449 bp band 
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Figure 3.5.6: Agarose gel image showing PCR amplicons from wt 1.14, Clone 14 and Clone 34 as 
DNA template with different combinations of flanking primers (refer to Fig. 3.5.5, Table 3.5.1 for 
primers details). 
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Figure 3.5.7: Sequence alignment of the 169 bp gel excision of Clone 34. Highlighted sequence in 
Cyan represents the mature miR-7a sequence. 
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3.5.8 Impact of miR-7a-5p knockout on miR-7 downstream targets 
 
We performed real time qPCR on two previously validated miR-7 downstream targets 
from our laboratory in order to observe if deleting one copy of miR-7 would result in 
changes in the expression levels of DNA-repair and recombination protein 54-like 
(Rad54L) and Proteosome (prosome, macropain) activator subunit 3 (Psme3) in wt 
1.14 cells, Clone 14 and Clone 34. Moreover, this study was also important to address 
the anomaly observed in Section 3.5.7 for Clone 14. miR-7 has been reported to play 
a key role in the regulation of Rad 54L and Psme3 (Sanchez et al. 2013). Upon miR-7 
mimics transfection Rad 54L and Psme3 were ~ 21-fold and 19-fold down regulated 
(data not shown) as previously validated in our laboratory. Therefore, from the 
observations in Section 3.5.6 and 3.5.7, we expected that Clone 14 would result in 
increased levels of expression of Rad54L and Psme3 than Clone 34. Since Clone 14 
had 5-fold less mature miR-7a expression than Clone 34, in which the mature miR-7a 
expression level was insignificantly down regulated. To our surprise, we observed 
that Clone 14 showed lowered expression levels (i.e. 10-fold and 2.5-fold down 
regulated) of Rad54L and Psme3, respectively. Clone 34 showed similar expression 
levels of Psme3 as observed in the wt 1.14 cells. Moreover, Clone 34 showed Rad54L 
gene slightly overexpressed, although insignificant (p-value > 0.05) (Fig. 3.5.8 and 
Fig. 3.5.9). From this study, we inferred that mature miR-7a expression in Clone 14 
was a false positive result when compared with the sequencing and validation data. 
For Clone 34, we observed that we were successful in achieving a heterozygous miR-
7a deletion as demonstrated by Sanger sequencing and PCR studies. 
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Figure 3.5.8: Relative expression levels of Psme3 measured in wt 1.14 cells, CHO-K1 parental 
cells, Clone 14 and Clone 34 using real time qPCR. A standard student t-test was performed to 
analyse statistically significant data (p-value > 0.05). The levels of Psme3 were normalised to 
endogenous beta-actin control. 
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Figure 3.5.9: Relative expression levels of Rad54L measured in wt 1.14 cells, CHO-K1 parental 
cells, Clone 14 and Clone 34 using real time qPCR. A standard student t-test was performed to 
analyse statistically significant data (p-value > 0.05). The levels of Rad54L were normalised to 
endogenous beta-actin control. 
 
In summary, we were able to induce ~ 50 % indels in the stable eGFP gene integrated 
in CHO-K1 cells’ genome using CRISPR-Cas9 system. Following this, we also 
attained 35-40 % indels frequencies in the miR-7a-5p locus in industrially relevant 
CHO cell line using four different CRISPR-Cas9 systems. However, due to less 
number of single clones screened we were not able to find clone that contained 
homozygous miR-7a allele knockout. We were only able to find a clone containing 
heterozygous miR-7a knockout, which was evident from both the sequencing as well 
as the mature miR-7a expression levels RT-qPCR data. We inferred from this study 
that despite similar targeting efficiencies of the CRISPR as was the case for protein-
coding gene, for non-protein coding gene i.e. miRNA, an effective knockout requires 
more than single base indel to cause a frameshift mutation. This illustrates the 
additional challenge in effectively knocking out a miRNA compared to a protein-
coding gene. Therefore, in such a case we believe a multiplex CRISPR strategy could 
prove instrumental in enabling an effective miRNA sequence knockout. 
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We also strongly believe that we could have found interesting candidates from the rest 
of the 32 clones, which were not analysed further using Sanger sequencing due to 
time constraint for the project. 
 
3.6 Multiplex CRISPR-Cas9 systems 
 
3.6.1 Duplex px459 CRISPR-Cas9 constructs designing and cloning strategy 
 
Following successful gene knockouts of the eGFP gene in CHO-eGFP cells, as well 
as of the miR-7a-5p sequence in the 1.14 cells via single sgRNA CRISPR, we 
hypothesized that a duplex CRISPR system (i.e. containing two sgRNAs) would be an 
attractive approach to effect a complete gene sequence knockout. Initially as 
prototype to check the % efficiency induced by a Duplex system, we designed a 
duplex CRISPR system using sgGFP 1B px459 as the backbone vector (described 
above in Section 3.4.3) and linearized it using XbaI and KpnI (refer to Section 
2.8.2.1). Following sgGFP 1B px459 linearization, we cloned and ligated the sgmiR7 
2B sgRNA sequence (along with U6 promoter sequence upstream of it) sequence into 
the linearized sgGFP 1B px459 vector. This resulted in a Duplex sgGFP 1B + miR7 
2B CRISPR-Cas9 system (henceforth referred to as GFP Duplex) (Fig. 3.6.1) with 
two sgRNAs in one plasmid DNA. 
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Figure 3.6.1: Schematic of Cas9 and sgRNA expression cassettes in eGFP 1B px459 vector 
backbone. A 19 nt or 20 nt guide sequence containing BbsI cut compatible sticky-ends was cloned 
into a linearized sgGFP 1B px459 vector backbone (linearized using the same BbsI). The final 
sgRNA expression cassette and Cas9 construct consisted of a U6 polymerase III promoter, two 
guide RNAs (sgGFP 1B backbone as well as sgmiR7 2B), a sgRNA scaffold sequence (Orange 
shaped structure) and a poly (T) termination sequence. Further downstream are other transgene 
elements such as hybrid form of chicken beta-actin (CBh) promoter, 3X FLAG peptide, SV40, 
NLS, spCas9 cassette linked with 2A peptide, which is also linked to Puromycin (Selection 
Marker Gene), NLS and BGH, polyadenylation signal and transcription termination sequence. 
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3.6.2 Testing the efficiency of the GFP Duplex CRISPR system 
 
We tested the efficiency of the GFP Duplex CRISPR-Cas9 system in the eGFP cell 
line (used earlier in Section 3.4.3). We transfected eGFP cells with 1 µg of px459 
GFP Duplex CRISPR, as well as the px459 empty vector separately to monitor the 
transfection efficiency. Post transfection (~ 10 days), we observed ~ 60 % of viable 
green cells in the control px459 vector only treated sample (data not shown). 
Similarly in the duplex CRISPR treateded cells, we observed ~ 60 % of non-green 
viable cells, suggesting that the sgGFP 1B guide in the duplex CRISPR worked 
successfully in knocking out eGFP gene in the cells (Fig. 3.6.2). 
 
Figure 3.6.2: Fluorescent Microcopy images of the eGFP cells transfected with GFP Duplex 
CRISPR system. Image on the left is imaged on fluorescent lamp, while image on the right is the 
phase contrast image of the image in left. Cells were seeded at 2 × 105 cells/mL per well of a 6-well 
plate and images were taken post transfection using the fluorescent microscope. 
 
Following the visual confirmation of sgGFP 1B guide working efficiently, we tested 
the % indels frequencies induced by both the eGFP 1B and miR7 2B encoding 
sgRNAs in the GFP Duplex CRISPR system using the Surveyor Assay. Using the 
same methodology of calculating % indels as described in Section 3.4.3.2 and 
Section 3.5.3. We observed that the sgeGFP 1B resulted in (~ 35-40 %) indels 
efficiency, however, the second guide i.e. sgmiR7 2B generated low % indels in the 
range of (15-20 %) (Fig. 3.6.3). 
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Figure 3.6.3: Agarose gel image post Surveyor Assay. The +ve and -ve stands for samples with 
Nuclease S and samples without Nuclease S enzyme, respectively. px à Reference DNA Control, (px 
+ G1A) à Homo/Heteroduplex mix formed using PCR amplicons from reference px459 and sgGFP 
1B and (px + m2B) à Homo/Heteroduplex mix formed using PCR amplicons from reference px459 
and sgmiR7 2B. All Control samples are highlighted with White font, while Green labeled samples are 
Test eGFP CRISPR samples. Red Arrow Heads represent the bands for the cleaved mutated fragments. 
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As mentioned above in Section 3.5.2, we hypothesized that it is necessary to target 
miR-7a-5p sequence to introduce significant indels with greater frequency since 1 or 
2 bp indel might not be enough to impact miRNA expression. Based on the same 
protocol, we also designed a miR-7 Duplex CRISPR system that contained two guides 
i.e. sgmiR7 1B (as the backbone vector) with sgmiR7 2B alongwith U6 promoter 
sequence upstream of the sgmiR7 2B guide. However, due to time constraints we did 
not reach to a stage to implement and check the efficiency of this miR7 Duplex 
CRISPR-Cas9 system. We anticipate that multiplex CRISPR-Cas9 system would 
generate greater magnitude of indels in miRNA sequence that could provide us with 
interesting CHO phenotypes, when the CHO cells with big knockouts are evaluated 
for bioprocess-related phenotypes. 
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Section 4.0 
Discussion 
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4. Discussion 
 
In the past two decades, significant progress has been witnessed in the field of 
production of biopharmaceuticals in order to meet the increasing market needs. 
Biotechnologists have been able to keep-up with demand by improving the product 
titres by a commendable 100-fold. This significant improvement in product titres is 
mainly attributed due to the development of serum-free media compositions and 
feeding strategies. The remaining 20-fold biologics production improvement is due to 
improved vector expression and genetic engineering approaches commonly employed 
during the development of recombinant CHO cell line (Hacker, De Jesus and Wurm 
2009). However, certain recombinant proteins that have to be administered at a higher 
dose e.g. mAbs and with the current product yield of 5 g/L, would mean that there 
still at large an issue that is required to be addressed in the field of biopharmaceuticals 
production process. Therefore, for this purpose single gene engineering approaches 
are employed in CHO cells with a view to enhance bioprocess-related CHO cell 
phenotypes and to fast track the production process of biologics (Hacker, De Jesus 
and Wurm 2009).  However, single and/or multi-gene engineering approaches are 
limited in their ability to modify entire cellular pathways or processes and could 
potentially result in undesirable side effects (Borth et al. 2005). An alternative and 
more attractive solution to single and/or multi-gene engineering approaches is through 
the exploration and manipulation of endogenous microRNA(s). miRNAs offer two 
main advantages over conventional gene engineering approaches; (i) miRNA are 
capable of targeting hundreds of genes as they are involved in regulation of many 
cellular pathways, (ii) their manipulation does not impose any burden on the cell’s 
translational machinery as they are not processed by the translational machinery of 
the cell (Bartel 2004b). All these positive points have encouraged many research 
groups across the globe in the CHO area to explore these beneficial tools to positively 
influence CHO cell phenotypes such as cellular growth and productivity by searching 
for potential engineering targets.  
With a similar objective, this project was mainly focused on improving CHO cell 
phenotypes (in bioprocess context) by manipulating two different miRNAs using two 
different gene-engineering approaches.  
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4.1 Sponge technology: GFP an effective mean to gauge sponge activity in CHO-
K1 SEAP cells 
 
The ‘miRNA sponge’ technology was previously demonstrated to result in efficient 
inhibition of endogenous miRNA by competing with the endogenous mRNA targets 
for miRNA binding (Ebert, Neilson and Sharp 2007). The application of both 
transient and stable knockdown of miRNA using miRNA sponges has been 
extensively described (Ebert and Sharp 2010). The stable knockdown of endogenous 
miRNAs using miRNA sponge vectors in CHO cells has been reported to enhance 
CHO VCD and/or protein productivity in various reports from our research group 
(Sanchez et al. 2013, Kelly et al. 2015b, Kelly et al. 2015a). These reports also led our 
interest to use the Let-7 sponge approach with a view to increase CHO cell growth 
and productivity characteristics in this project. 
In our study, the Let-7 sponge was designed in order to soak-up endogenous Let-7 by 
competing with mRNA targets for Let-7 binding. To ensure efficient endogenous Let-
7 sequestration by the Let-7 sponge, four Let-7 binding sites were placed in tandem in 
the 3’-UTR of the destabilized GFP (deGFP). Ebert et al. (2007) reported that there is 
a threshold for the number of binding sites that can be incorporated in a single 
miRNA sponge system and suggested a range of 4-10 binding sites separated by a few 
nucleotides each. Ebert et al. (2007) also reported that increasing the number of 
binding sites increases the susceptibility of the miRNA sponge system to RNAi-
mediated degradation.  Moreover, it was also reported that a bulge or “wobble” in at 
nt position 9-11 could increase the stability of miRNA sponge by evading RNAi-
mediated cleavage since perfect complementarity at nt position 9-11 is recognised by 
the Ago 2 protein (Ebert, Neilson and Sharp 2007). Let-7 is a big family of miRNAs, 
hence we anticipated the combined impact of using Let-7 sponge to deplete all 
endogenous Let-7 members in CHO cells and would generate interesting phenotypes. 
The Let-7 sponge also contained a deGFP upstream of the four Let-7 binding sites as 
a reporter gene. This unstable deGFP has a short half-life of 2 hours and provides a 
perfect read-out of the miRNA sponge effective binding since there is a change in 
fluorescence upon binding of the endogenous Let-7. When the Let-7 and NC sponge 
systems were stably transfected into CHO-K1 SEAP cells separately, we observed a 
range of different mean GFP expression in the both NC and Let-7 mixed SEAP 
populations. The mean GFP expression in the Let-7 SEAP mix population was lower 
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than the NC SEAP mix population potentially due to the endogenous Let-7 binding to 
the four binding sites in the Let-7 sponge vector, leading to deGFP translational 
repression. For our phenotypic analysis, only medium to high GFP expressing clones 
were picked in order to ensure that they were all expressing the excess sponge 
transcript above the level of saturation by endogenous Let-7.  
To ensure that the Let-7 sponge was efficient and specific in binding the endogenous 
Let-7 family members, we conducted a validation experiment by transiently 
transfecting Let-7 mimics in the Let-7 stable sponge clones. Post Let-7 mimic 
transfection, a further reduction in GFP expression in these clones verified that the 
Let-7 sponge was efficiently binding the endogenous Let-7, hence reducing the Let-7 
levels available to bind to its endogenous mRNA targets. 
 
4.2 Stable Let-7 depletion using sponge technology did not enhance growth in 
CHO-K1 SEAP cells 
 
As mentioned above in Section 1.6.9.1 that Let-7 miRNAs have been implicated in 
regulating an array of genes involved in various cellular pathways. Let-7 plays an 
important role in the development of C.elegans and various other organisms. Let-7 
miRNAs have also been reported to act as tumour suppressors in many cancer types 
(Roush and Slack 2008). Let-7 is reported to be involved in regulating the expression 
of a multitude of genes involved in the process of cell division and cell proliferation 
(Johnson et al. 2007) (Fig. 4.4). Recently, a research group reported a more than 60 % 
increase in CHO cell specific productivity in two mAb producing cell lines by using 
anti-let-7a miRNA inhibitor molecules (Greenlees et al. 2014). Moreover, previously 
our laboratory research group reported an anti-proliferative role of Let-7e in CHO 
cells through gain-of-function (use of Let-7 mimics) studies i.e. transient up-
regulation of Let-7e decreased the VCD by 3 to 4-fold. Additionally, the cells were 
observed to be growth arrested for 5 days of the culture period and this resulted in 
increased > 4-fold improvement in the normalised productivity in two CHO cell lines 
(unpublished data).  
Initially, we observed that the Let-7 sponge expressing cells showed enhanced VCD 
and improved cell viability compared to the NC sponge mixed pool of cells during the 
later stages of the culture. Following this we FACs sorted lones, but did not observe 
any significant improvement in VCD in the Let-7 sponge stable clones with all clones 
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displaying similar growth profiles to the NC sponge stable clones. However, we also 
observed that the stable knock down of endogenous Let-7 improved the % cell 
viability during the later stages of the culture in 24-well plate format for some clones, 
in contrast to the NC sponge clones. Greenlees et al. (2014) observed a similar 
improvement in cell viability during the later stages of culture. They employed anti-
let-7a inhibitor molecules that led to the improvement in cell viability as well as the 
specific protein productivity in two CHO cell-lines, in comparison to the controls 
(Greenlees et al. 2014). Moreover, increased cell survival in two carcinoma cell lines, 
MT-1 and HeLa, was also reported with the use of Let-7 sponge vector (Yang et al. 
2012a). In addition to the growth data, we also observed increased volumetric SEAP 
productivity in the Let-7 sponge in comparison to NC sponge mixed pool of cells, 
which was due to enhanced specific productivity. 
Furthermore, we were interested in confirming this enhanced viability data in scale-up 
studies as well. We could not choose our best performing clones on the basis of both 
the growth and productivity data due to loss of the SEAP transcript in both sets of NC 
and Let-7 sponge clones. From our speculation, we believe this could have occurred 
due to changes in the methylation state of the SEAP transgene resulting in silencing, 
which was further confirmed by qPCR of SEAP mRNA expression levels. We 
observed the levels of SEAP transgene were 25-fold lower in both the stable NC and 
Let-7 sponge clones compared to the reference control population. The loss of SEAP 
transgene in both the NC and Let-7 sponge clones is inexplicable since all the clones 
from both NC and Let-7 panels were routinely pulsed separately with hygromycin and 
geneticin containing media. However, production instability due to loss of transgene 
expression is not a novel phenomenon since CHO cells are genetically instable. The 
loss of cell-specific productivity during sub-culture is completely unpredictable in 
that it may occur, it may not occur or it may occur after several passages. For 
instance, Heller-Harrison et al. (2009) reported that 8-63 % of all recombinant CHO 
cell lines suffered from production instability. Moreover, the cell lines established 
using GS and DHFR based gene expression systems are more susceptible, whether in 
the presence or absence of selection agent, to loss of transgene expression (Fann C.H. 
et al. 2000, Jun S.C. et al. 2006). The molecular mechanisms underlying mosaicism or 
variegation as well as the complete cessation of transgene expression have not been 
completely deciphered. However, methylation of CpG islands, thereby inhibiting 
transcription factors recruitment or promoting transcription repressor binding could 
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result in epigenetic gene silencing. Promoter methylation and other histone 
modifications such as deacetylation, hypoacetylation of DNA proteins are among the 
reported mechanisms responsible for transgene silencing in CHO and other 
mammalian cells as well (Yang et al. 2010). For instance, recently, CHO cell line 
expressing a recombinant protein, established independently of any of the traditional 
gene amplification processes, was reported to have its recombinant protein-encoding 
gene silenced due to hypoacetylation of H3 histone protein (Paredes et al. 2013).  To 
further investigate the reason for SEAP transgene loss, was beyond the scope of this 
project, therefore, no such studies were conducted. 
In the absence of productivity data, we chose a set of four clones from each NC and 
Let-7 sponge stable clonal panels. This choice was based on improved VCD on Day 3 
of the culture period and cell viability on Day 6. We observed all the clones failed to 
demonstrate improved cell viability and VCD. In summary, none of the Let-7 clones 
exhibited statistically significantly improved growth characteristics in comparison to 
the NC sponge stable clones. The improved cell viability for two clones in 24-well 
plate format could have been a result of either clonal variation or 24-well plate versus 
5 mL tube growth format difference. It has been reported that commercially available 
adhesive plate seals could result in two outcomes, in terms of volume and oxygen 
transfer rate i.e. (i) plate seals wherein volume can reduce due to evaporation (edge 
effects in shallow plates, mostly), but oxygen transfer is comparable to that of 
unsealed plates, and (ii) plate seals wherein volume preservation is higher (no loss 
due to evaporation), but oxygen transfer is slower (Zimmermann et al. 2003, Patel, 
Tuckerman and Dong 2005). We surmised that in 24-well plate format due to edge 
effect (since both the clones that showed improved cellular viability were around the 
edge of the plate) resulted in evaporation of media and accounted for the improved 
cellular viability, as a calculation error. Chaturvedi et al. (2014) recently reported that 
in 24-well shallow plates the small volume i.e. 0.7 mL to 1 mL capacities could 
account for VCD calculation inconsistencies due to multiple sampling reducing the 
volume further, in addition to evaporation (Chaturvedi et al. 2014). 
 
 
 
 
	 188	
4.3 Validation of the sponge technology: Understanding the reason for ‘No 
phenotypic outcome’ 
 
With the aforementioned observations, we were interested in verifying whether the 
Let-7 sponge vector in the Let-7 sponge clones was effectively and specifically 
binding endogenous Let-7 or not. For this purpose, we transiently transfected two of 
our clones with Let-7 mimics and non-specific control miRNA mimics. We observed 
that the transient up-regulation of Let-7 induced further significant reduction in the 
GFP signal fluorescence in the Let-7 sponge expressing cells but not in the control 
cells. Therefore, these observations confirmed that Let-7 sponge was indeed 
specifically binding endogenous Let-7, thereby reducing the endogenous Let-7 levels 
available to bind to their mRNA targets. Both the tested Let-7 stable clones, upon 
exogenous Let-7 mimics introduction, displayed significantly reduced GFP signal 
fluorescence. Therefore, it was safe to say that theoretically all Let-7 clones had 
enough sponge transcript copies to fully sequester the endogenous Let-7 available. 
Similar to our study, this method of transfecting exogenous molecules for sponge 
validation have been performed in our laboratory previously by Sanchez et al. (2014), 
Kelly et al. (2015a) and Kelly et al. (2015b) for miR-7, miR-23b and miR-34, 
respectively. 
In order to further confirm that Let-7 is deflected from its usual function upon Let-7 
depletion by the Let-7 sponge in CHO cells, we conducted two separate real time 
qPCR experiments for the quantitation of Bcl2 gene and CDK6 gene expression 
levels. Both of these two genes are marked as predicted genes in 
www.chogenome.org database. We examined these two predicted and RT-qPCR 
validated targets of Let-7a due to their potential roles in a myriad of cell types and 
disease settings in regulation of cell-cycle pathways, in humans (Garzon et al. 2007, 
Johnson et al. 2005). The expression levels of both of these genes, in Let-7 sponge 
clones, were more or less similar to the controls.  
After the previous observations in the Let-7 mimic transfection experiment versus 
Bcl2 and CDK6 expression level quantitation, we were interested in characterising the 
manner of Let-7 sponge in sequestering the endogenous Let-7 in CHO cells. For this 
purpose, we quantified the amount of mature endogenous Let-7a expression in the 
stable Let-7 clones. To our surprise, we observed that the stable Let-7 sponge clones 
had virtually similar endogenous Let-7a levels as the NC stable sponge clones as 
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measured by RT-qPCR. Moreover, one of the clones showed only slightly increased, 
although statistically insignificant, endogenous Let-7 expression levels, in comparison 
to all NC stable sponge clones. Similar observations, wherein the endogenous mature 
miRNA expression levels in stable miRNA sponge expressing CHO cells were higher 
in contrast to control sponge expressing CHO cells was reported by (Yang et al. 
2012a, Sanchez et al. 2014, Kelly et al. 2015a, Kelly et al. 2015b) for Let-7, miR-7, 
miR-23b and miR-34, respectively. However, these findings of slightly higher or 
similar endogenous Let-7a levels in stable Let-7 clones seem inconsistent with the 
results of gain-of-function experiment using Let-7 mimics, which showed that the 
sponge was effective and specific to Let-7 binding in the stably expressing Let-7 
CHO clones. The somewhat increased or similar Let-7 levels in the Let-7 sponge 
expressing cells could also be explained by the fact that endogenous Let-7 are single-
stranded molecules bound to the Let-7 sponge, which could dissociate from the 
sponge during total RNA extraction process i.e. the sponge loses its sequestration 
capability outside the cellular context. Subsequently, during the RT step the specific 
Let-7a primer could bind to the now-released Let-7a miRNA resulting in an apparent 
slight up-regulation of Let-7a levels or similar Let-7a levels in Let-7 sponge clones, 
compared to control sponge clones (Sanchez et al. 2014). 
Recently, a phenomenon known as target-mediated miRNA protection (TMMP) has 
come to light. TMMP may enable miRNA targets to protect their cognate miRNAs 
against cytoplasmic nucleases such as exoribonuclease XRN-2 (in C.elegans) 
(Chatterjee et al. 2011) and XRN-1 (in humans) (Bail et al. 2010), hence leading to 
accumulation of mature target-bound miRNAs (Fig. 4.1). Briefly, miRNA turnover is 
regulated by the XRN-2 via TMMP. Due to mRNA target availability, the active 
turnover of miRNAs and consequently, the degradation of miRNA duplex 
components are prevented (Chatterjee and Großhans 2009, Chatterjee et al. 2011). 
This could be very well be the case with our study wherein the sponge was efficiently 
soaking-up and protecting endogenous Let-7, however, the cells were compensating 
for the lack of the endogenous Let-7 levels in order to maintain normal cellular 
homeostasis through the experimentally validated mechanism of TMMP. It has also 
been reported that target availability could enforce accumulation of certain miR 
passenger (miR*) strands through TMMP. This could mean that independent of the 
thermodynamic asymmetry of miR: miR* duplex, for certain miRNAs the bias 
between miR and miR* (Chatterjee and Großhans 2009, Chatterjee et al. 2011) can 
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occur after incorporation of Ago into RISC. This adds more complexity to the 
regulatory role of miRNAs whereby, depending on mRNA availability, could result in 
further expression of a miRNAs and/or the miR: miR* ratio is maybe altered 
(Chatterjee et al. 2011). From these observations, it would be interesting to quantitate 
Let-7 levels immediately (or after fixed time intervals) after endogenous Let-7 
sequestration by the Let-7 sponge to assess and evaluate the role of TMMP in 
protecting endogenous Let-7 levels and the generation of the mature form of Let-7. 
Such a study could allow for a better understanding of TMMP in influencing miRNA 
levels and at what magnitude and after what time post-sponge transfection.  
 
 
Figure 4.1: Outlines the process of normal miRNA regulation of their targets and the process of 
TMMP. (A) Shows the thermodynamically stable pre-miRNA (Let-7 in our case) duplex with 3’ 
nt overhangs. (B) Normally, the guide strand (Let-7 guide in our case) is loaded onto the 
Ago/RISC complex for the translational repression of their mRNA targets and the passgenger 
(miR*, or Let-7* strand in our case) is degraded through cytoplasmic exoribonuclease enzyme, 
XRN-2 (C.elegans) and/or XRN-1 (in humans) through its 5’à  3’ nuclease activity. However, (C) 
TMMP mechanism when the mRNA targets are available, then passenger strand accumulation 
prevents their decay by XRN-2 enzyme by abolishing XRN-2 activity. This image is reproduced 
from Thesis of Dr. Paul S Kelly 2013. 
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In addition to TMMP, there have been reports suggesting that for highly abundant 
miRNAs like the Let-7 family (12 members distributed across 8 loci in mouse), the 
genetic inactivation of miRNA results in very modest de-repression of its direct 
targets i.e. less than 2-fold. On many occasions, such modest de-repression of miRNA 
targets are well tolerated by cells, hence resulting in no obvious phenotypes. These 
observations sparks the idea that miRNAs act as rheostats to fine-tune the expression 
of hundreds of gene in order to reinforce cellular fates, rather than acting as genetic 
switches. As rheostats, miRNAs are able to buffer the cell against stochastic 
fluctuations that could perturb normal cellular homeostasis and provide robustness in 
spite of internal or external perturbations (Kitano 2004, Klein et al. 2007). We 
speculate that the miRNA buffering mechanism of cells (via feedback loops) against 
any environmental stress and/or miRNA manipulation (e.g. sponge-based miRNA 
depletion) includes the known and experimentally validated TMMP mechanism 
(Bartel and Chen 2004, Hornstein and Shomron 2006, Baek et al. 2008, Mu et al. 
2009, Ebert and Sharp 2012). 
In contrast to our results of no significant change in growth profile with CHO cells 
expressing the stable Let-7 sponge transcript, Greenlees et al. (2014) have reported 
improved CHO cell phenotypes, as mentioned above, using anti-Let-7a synthetic 
molecules (Greenlees et al. 2014). However, reports have suggested that ectopic 
expression studies through the use of inhibitors molecules, often lead to supra-
physiological levels of miRNA and therefore, stronger repression of its targets and 
sometimes repression of mRNAs that might not even be their biological targets (Baek 
et al. 2008, Selbach et al. 2008, Guo et al. 2010, Ebert and Sharp 2012).  
 
4.4 Let-7 as a potential candidate for CHO cell engineering 
 
Although our study to stably knockdown Let-7 in CHO cells did not induce enhanced 
growth and/or productivity characteristics, it did improve cell viability. However, 
enhanced viability could not be replicated in the scale-up studies. In the absence of 
SEAP expression data, we could not test whether Let-7 stable knockdown impacted 
productivity. There are studies reporting that knocking down Let-7 family members 
resulted in > 60 % improved antibody specific productivity in two different CHO cell-
lines, and improved cell viability during the later stages of culture (Greenlees et al. 
2014). Moreover, the manipulation of Let-7 using sponge decoy vector has been 
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reported to increase cell survival in carcinoma cell lines (Yang et al. 2012b). We 
believe that the productivity data would have allowed us to pick clones that maybe 
performed better in contrast to control clones. However, due to epigenetic gene 
silencing of the SEAP transgene, we were unable to examine this. As mentioned 
above, Let-7 is the most highly studied miRNA and plays a vital role in various 
cellular pathways such as cell division, cell proliferation and induction of apoptosis 
(Johnson et al. 2007). Moreover, we feel that Let-7 manipulation by means of other 
genome modifying techniques such as CRISPR-Cas9 to knock out Let-7 locus could 
be interesting to explore. In contrast to stable Let-7 depletion, the knock out approach 
differs in that the gene is knocked out in the subsequent generations in the particular 
cell line and could provide an effective alternative to stable miRNA-based depletion, 
which has the drawback of compensation for the depletion of miRNA through 
TMMP. 
Keeping this in mind, in the second part of this project we employed a novel genome 
editing system to manipulate a widely published miRNA with a proven track record in 
CHO cells to improve CHO cell growth and productivity characteristics. 
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Figure 4.2: Outlines the impact of Let-7a alterations in effecting multiple potentially important 
cellular pathways by regulating an array of genes involved in these pathways in two antibody 
producing CHO cell lines. Image reproduced from an article by Greenlees et al. 2014. 
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4.5 Exploring the CRISPR-Cas9 system for CHO cell engineering 
 
In contrast to other genome editing techniques such as ZFNs, TALENs and various 
other nuclease-based techniques, CRISPR-Cas9 stands out as the latest ‘go-to’ gene-
editing tool. This is essentially due to its greater specificity, efficiency, time and cost 
economy and less cytotoxic effects when applied to mammalian cell lines. CRISPR-
Cas9 also allows for multiplex genome engineering to induce functional gene 
knockouts in the genome at multiple sites by using an all-in-one CRISPR-Cas9 
system, which is a tedious, expensive and time-consuming process with ZFNs and 
TALENs. All these points make CRISPR-Cas9 the method of choice for the next 
generation of genome editing in mammalian cells (Cong et al. 2013, Mali et al. 
2013b, Sakuma et al. 2014), and in regard to this project, for CHO cell engineering 
specifically. CRISPR-Cas9 technology is beginning to be explored in CHO cells in 
order to improve bioprocess-related and therapeutic protein quality related 
characteristics. Working towards this goal, we aimed to implement the CRISPR-Cas9 
technology in CHO cells in this project, firstly, in a test CHO cell line (CHO-eGFP 
cell line), then finally to induce miR-7a-5p gene locus knockout in industrially 
relevant CHO cel lines with a view to improve CHO cell growth and productivity 
characteristics. 
 
4.5.1 Implementation of CRISPR-Cas9 system in CHO-eGFP cell line  
 
For the proof-of-concept, we employed CRISPR-Cas9 to attempt eGFP gene 
knockout in the CHO-eGFP cell line (or eGFP cell line). This cell line has very high 
levels of GFP expression and contains one or more copies of eGFP gene, possibly 
integrated into rare transcriptional “hot spot” in the genome. It expresses stable eGFP 
invariably as confirmed by our 5-day mean GFP expression analysis. 
Initially, we used two 20 nt long sgRNAs designed to target eGFP gene at 5’- and 3’-
end, respectively, cloned into a pCas9 CRISPR vector separately. We transfected the 
eGFP cells with these two eGFP targeting CRISPR systems, however, we did not 
observe satisfactory reduction in mean GFP expression in either of the wells 
transfected with eGFP 1 and eGFP 2 CRISPR system. We conducted a transient co-
transfection experiment, in which we found that the eGFP CRISPR was efficient in 
knocking out the eGFP gene sequence of peGFP plasmid. However, similar 
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satisfactory reduction in mean GFP expression could not be achieved in eGFP cells. 
We believe that whilst designing the sgRNA sequences 20 nt long according to the 
manufacturer’s guidelines we appended an extra ‘G’ nt at 3-end of the guide sequence 
(in addition to appending an extra ‘G’ at the 5’-end of the guide sequence), making 
the sgRNA guide length 21 nt long. The sgRNAs with 21 nt long sequence has been 
reported to be far less effective than 20 nt sgRNA CRISPR systems (Ren et al. 2014). 
Moreover, even after appending extra ‘G’ nt at the 5’-end of the guide sequence as 
preferential and efficient U6 transcription start site, certain sgRNAs are reported not 
functioning on rare occasions for unknown reasons. 
 
4.5.2 Opening up the prospects for the generation of isogenic CHO cell lines via 
CRISPR-Cas9 technology 
 
In relation to this project, it was imperative for us to demonstrate CRISPR-Cas9 
genome technology can be implemented for the task of knocking out the eGFP gene 
in CHO cells. We used a different CRIPSR-Cas9 expression vector system to induce 
eGFP gene knockouts in the cells. We designed four eGFP targeting sgRNAs i.e. 
sgGFP 1A, sgGFP 1B, sgGFP 2A and sgGFP 2B and cloned into the px459 vector.  
With these eGFP CRISPRs we demonstrated high eGFP knock out efficiency as mean 
GFP expression was reduced by more than 25-fold in eGFP CRISPR-treated samples. 
We also reported indels frequency in the range of 40-50 %. Moreover, from 
sequencing results we observed that the majority of eGFP CRISPRs induced 
deletions, as opposed to insertions. Ronda et al. (2014) reported similar percentage of 
indels frequencies (i.e. 47 %) in the COSMC gene in CHO cells. The sgGFP 19 nt 
long demonstrated highest ~ 50 % indel frequencies and with more than 60 % of the 
TOPO samples with indels in double-digit numbers, as opposed to sgGFP 20 nt long, 
which mostly generated indels of sizes 1 or 2 bp. The sgRNAs that Ronda et al. 
(2014) used also generated single base pair insertions, in the two targeted genes, more 
frequently than big indels (Ronda et al. 2014). From these findings we infer that the 
length of sgRNA used did not impact the performance of sgRNAs to a great deal. 
However, the location of the genomic site to be targeted was critical since we 
observed marginally higher eGFP CRISPR targeting efficiency with the eGFP 1 
CRISPRs targeting the 5’-end of the eGFP gene. This could be due to the fact that 
sgGFP 1A and sgGFP 1B were designed to target the 5’end of the eGFP gene, where 
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a frameshift mutation is more likely to result downstream effect. On the other hand, 
eGFP 2 CRISPRs targets the 3’-end of the eGFP gene, wherein, for instance, in case 
of a single bp indels a part of the eGFP sequence would still be transcribed and could 
result in a functional GFP (Lawhorn, Ferreira and Wang 2014). It has been reported 
that mutations such as indels in the ORF of GFP gene differentially reduce the GFP 
mRNA transcription rate, translation efficiency due to protein instability but still 
allows expression of very faint GFP (Sacchetti et al. 2001). Additionally, sequence 
surrounding the translation start site (i.e. near the 5’-end) such as the Kozak motif if 
disrupted could directly affect its transcription and translation abilities (Kozak 1991, 
Afshar-Kharghan et al. 1999). With the successful implementation of CRISPR-Cas9 
to specifically target the stably integrated eGFP gene in CHO-eGFP cell line, we 
demonstrated that the CRISPR-Cas9 system could efficiently target genes in CHO 
cells. Moreover, another spin-off project from this proof-of-concept study could be 
the use of eGFP CRISPR to induce eGFP functional knockout in CHO-eGFP cell line, 
followed by high fidelity HDR-based transgene insertion with donor DNA (encoding 
another GOI) (Smith et al. 2008, Chu et al. 2015, Lee et al. 2015, Maruyama et al. 
2015). Therefore, making CRISPR-Cas9 as an attractive option for the generation of a 
‘truly hyperproducing’ isogenic CHO cell line that has homogenous and sustained 
expression of the introduced GOI into a transcriptionally ‘active zone’ of the CHO 
genome. This could also save time and labor by facilitating generation of isogenic 
recombinant CHO cell lines without using the traditional DHFR or GS-based 
selection and amplification system. 
 
4.5.3 CRISPR-Cas9 genome editing technology to manipulate miR-7 for 
improved CHO cell phenotypes 
 
In the first half of the project, we employed sponge technology to stably deplete 
endogenous Let-7 levels in CHO-K1 SEAP expressing cells. However, due to 
possible compensation via TMMP for the depletion of endogenous Let-7 levels, we 
were not able to observe any significantly improved growth and/or productivity 
phenotypes. For this reason, we chose to employ CRISPR-Cas9 system to completely 
knockout a previously well-characterised miRNA i.e. miR-7, in industrially relevant 
CHO cell line. As opposed to miR-7 sponge stable depletion (which already has been 
reported in our laboratory), we were interested in completely knocking out the miR-
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7a-5p locus in CHO cells using CRISPR-Cas9. miR-7 is reported to be one of the key 
regulators of cell processes such as cell proliferation/division and apoptosis. 
Numerous reports have suggested miR-7 role as tumour suppressor in cancer of 
different types (Webster et al. 2009, Giles et al. 2013, Liu et al. 2013). However, very 
recently, miR-7 has also been reported as an oncogene since its up-regulated in renal 
carcinoma. These reports demonstrate cell- and organ-specificity of miR-7 action 
(Gu, Huang and Tian 2015b). 
From the biotechnological point of view, the importance of miR-7 as a potential 
candidate for CHO cell engineering has been widely published due to the fact that it is 
an important cell cycle regulator miRNA. As reported by Sanchez et al. (2013) miR-7 
triggers CHO cell cycle arrest by targeting a multitude of cell cycle regulator 
components such as S-phase kinase-associated protein-2 (Skp2), myc and p27KIP1 for 
temporary growth arrest by down-regulating pro-apoptotic factors, DNA repair 
factors, as well by up-regulating anti-apoptotic factors (Sanchez et al. 2013). These 
findings demonstrated what a critically important role miR-7 plays in the regulation 
of cell cycle. Barron et al. (2011) transiently overexpressed miR-7 to induce cell cycle 
growth arrest and observed the temperature shift phenotype, resulting in increased 
normalised productivity (Barron et al. 2011b). These findings are further supported 
from miR-7 sponge work by Sanchez et al. (2014), who reported 3-fold improved cell 
proliferation and 2-fold increase in protein productivity by stably depleting 
endogenous miR-7 levels in CHO cells (Sanchez et al. 2014). Therefore, for this half 
of the project we were interested in applying a different gene engineering strategy to 
knockout the miR-7a alleles altogether. The reason for choosing miR-7a to be 
knocked out, and not miR-7b, also stems from the data published by Hackl et al. 
(2011) in CHO cell lines. Their next generation sequencing data reported stronger 
expression of miR-7a in comparison to miR-7b in CHO cell lines (Hackl et al. 2011a). 
In order to cause miR-7a-5p locus knock out in CHO-K1 1.14 cells, we designed four 
sgRNAs CRISPR-Cas9 systems targeting the miR-7a-5p sequence. Keeping in mind 
that targeting an ORF of a protein gene is easier since only one bp knock out is 
enough to disrupt the reading frame e.g. in the case of eGFP. For miR-7 (with two 
alleles located on two different chromosomal loci), where there are possibly four 
copies of the gene with functional redundancy due to paralogs, we assumed that it 
would be a harder task to knock out all the four copies of a non-coding gene. 
Moreover, in order to render miRNAs functionless, we required significant deletions 
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in the mature miR-7a-5p sequence as opposed to single base indels. Therefore, we 
were interested in knocking out the mature or loop sequence in the miR-7a-5p 
sequence so that subsequently it would not be recognised by the Dicer complex for 
processing. No miR-7 would be available to bind to its target mRNAs once the mature 
sequence or loop structure is disrupted, and such a disruption would make it 
functionless. miR-7 is a mirtronic non-coding RNA molecule, whose pre-mir-like 
transcripts by-pass Drosha processing (Berezikov et al. 2007). The four miR7 
CRISPR-Cas9 systems, when transfected into 1.14 cells, resulted in 35-40 % targeting 
efficiency. Inexplicably, the location of the target site showed preferentially higher 
CRISPR activity since sgmiR7(s) 20 nt in length targeting downstream of the mature 
miR-7a-5p sequence demonstrated highest indel frequencies, and were marginally 
better than the sgmiR7(s) targeting upstream of the mature miR-7a-5p sequence. 
Reports have suggested that the 20-nt sgRNA CRISPR systems work better in most 
cases. However, many studies have also shown the importance of certain major 
parameters such as the number, position and distribution of nucleotide mismatches 
between the sgRNAs and genomic DNA in mammalian cells, can impact the targeting 
efficiency significantly (Fu et al. 2013, Hsu et al. 2013, Mali et al. 2013a, Pattanayak 
et al. 2013, Wu et al. 2014). For instance, Fu et al. (2014) reported that truncated 18 nt 
long sgRNAs showed similar targeting efficiency as 19 or 20 nt truncated sgRNAs 
(Fu Y. et al. 2014). 
Here as well, sequencing results reported that majority of the indels generated by all 
the four CRISPRs were single base pair insertions, as observed for protein coding 
COSMC gene in CHO cells by Ronda et al. (2014). From this study, the knowledge 
and further detailed analyses of the types of indels induced by these four sgmiR7 
based CRISPRs could allow for the design of better (maybe multiplex) CRISPR 
systems in future, and such systems could be used to induce bigger deletions of the 
mature miR-7a-5p sequence. 
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4.5.4 Picking the population for the isolation of potential single cell CHO clone/s 
 
We were interested in picking clones that contained large indels in the mature miR-7 
and/or loop sequence from the mix of these four 1.14 cell populations transfected 
separately with the four aforementioned CRISPRs. We believed that in order to have 
a functional knockout of miR-7, we needed clones that showed a large part of the 
mature miR-7a-5p sequence mutagenized and/or deleted due to indels induced by the 
CRISPR-Cas9 system. In these clones, the altered sequence (with the seed region 
deleted or random bp inserted) would not act as Dicer substrates and would not be 
processed, and hence would not lead to translational repression of their biological 
targets. The sgmiR7 2B CRISPR with 40% indel frequencies and 30 % of the TOPO 
sequencing samples demonstrating large miR-7a-5p sequence deletions, was the 1.14 
mixed pool of cells chosen to be analyzed further due to higher probability of finding 
a clone that had a part or the whole of mature miR-7a-5p sequence knocked out. 
 
4.5.5 Partially down regulated miR-7 expression in single cell clones 
 
Following limited dilution cloning, we screened 38 single clones for endogenous 
mature miR-7a expression levels. Encouragingly, we observed a range of single cell 
clones demonstrating 5-fold and more down-regulation in endogenous mature miR-7a 
expression levels. A few of the clones showed more than 10-fold down regulation of 
mature miR-7a expression levels. However, for a few selected clones the mature miR-
7a expression levels were re-analysed as a rigorous validation step using fresh total 
RNA samples. Upon re-analysis, the mature miR-7a levels were less down regulated 
for three of the clones (i.e. Clone 6, Clone 14 and Clone 30), however, the levels in 
Clone 25, Clone 34 and Clone 36 remained unchanged, in comparison to levels in the 
control cells. This change in mature expression level could be potentially due to 
timing of the total RNA extraction. Nevertheless, theoretically we were expecting to 
observe significant down regulation of mature miR-7a in these clones, as opposed to 
partial or no change of mature miR-7a expression levels. From the studies by Sanchez 
et al. (2014), Kelly et al. (2015a and 2015b) on the stable depletion of miR-7, miR-
23b and miR-34, respectively, they observed compensation (via TMMP) in response 
to the depletion of these miRNAs, whilst using specific miRNA sponge for their 
studies. (Sanchez et al. 2014, Kelly et al. 2015a, Kelly et al. 2015b). We speculated 
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that due to miR-7a knockout or disruption by the CRISPR-Cas9, the cells were 
perhaps compensating for the perceived lack of miR-7a by increasing the 
transcriptional rate of other alleles. This speculation is true for many miRNAs as they 
are vital for the normal functioning in the cell and can sense any internal or external 
perturbations that can have a large downstream effect. miRNAs (e.g. here miR-7) 
regulate many critical cell cycle related processes and confer cells with phenotypic 
robustness by buffering the cell against any cell-to-cell variability arising from any 
stochastic fluctuations in gene transcription through unknown feedback or feed 
forward loop mechanisms (Bartel 2004a, Hornstein and Shomron 2006, Klein et al. 
2007, Ebert and Sharp 2012). Moreover, we hypothesized that the compensation 
might be contributed by miR-7 paralogs i.e. miR-7b. The presence of these paralogs 
with high degree of sequence homology could compensate for the knockout of a miR-
7a allele since miR-7b is a functional paralog for miR-7a and has the same seed 
region with similar affinities for miR-7 target mRNAs. The presence of miRNAs with 
redundant functions, in certain scenarios, means that several members of the family 
need to be deleted in order to observe any phenotypic consequence. For instance, in 
vertebrate multiciliated cells, six miRNAs comprising the conserved miR-34/449 
family encoded by miR-34a, miR-34b/c, and miR-449a/b/c- can coordinately repress 
cp110 expression during ciliogenesis. Animals with deleted single genes of miR-
34/449 family were viable and phenotypically normal, however, deletion of all three 
loci leads to animals’ survival with defective ciliogenesis (Bao et al. 2012, Song et al. 
2014). We also quantitated the nascent transcript of miR-7 paralog i.e. pre-mir-7b 
expression levels in a few selected clones. Based on next generation sequencing data 
from Hackl et al. (2011), we understood that miR-7a-5p is more strongly expressed in 
comparison to miR-7b-5p across seven CHO cell lines (Hackl et al. 2011b) and 
expected that this latter speculation about miR-7b to not be responsible for the 
compensation of loss of miR-7a. 
We did not observe any significant differences in the expression of pre-mir-7a and 
pre-mir-7b in Clone 14 and Clone 34, in comparison to levels in the control cells. 
Clone 34 showed slightly increased levels of pre-mir-7b, although insignificant. 
Therefore, the speculation of possible compensation of miR-7a and/or miR-7b 
through increased pre-mir-7a and/or pre-mir-7b transcriptional rates through some 
feedback mechanism was unfounded.  
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4.5.6 Heterozygous deletion of miR-7a  
 
The miR-7a-5p sequence region for a few selected clones (i.e, Clone 6, 14, 25, 30, 34 
and 36) was analysed by Sanger sequencing. Of the 6 clones, we found that Clone 14 
contained the wild-type miR-7a-5p sequence, while Clone 34 contained a 
heterozygous deletion of miR-7a. The increased mature miR-7a expression levels in 
Clone 34 was rather surprising since even after heterozygous deletion of miR-7a, the 
mature miR-7a was expressed in abundance. One possible explanation for this could 
be that the deleted miR-7a copy was silent due to gene imprinting phenomenon 
(McGrath and Solter 1984, Bartolomei and Ferguson-Smith 2011). We also speculate 
that even if we were able to induce a homozygous deletion of miR-7a alleles, we 
believe such a deletion was lethal to cells and these cells with homozygous miR-7a 
deletions never survived, hence never analysed. This could be true in the case of miR-
7, as it plays a critical role in cellular and many other pathways (Sanchez et al. 2013). 
Hence, maybe an absolute requirement for cells to survive. The another possible, 
however, less likely explanation could be the fact that the levels of pre-mir-7b were 
slightly high in Clone 34, although insignificant, as a compensation mechanism by 
cells to cater for the loss of one miR-7a copy in order to buffer the cell against any 
internal/external cellular perturbations and providing robustnessto cell (Bao et al. 
2012, Ebert and Sharp 2012, Song et al. 2014). 
For Clone 14, the presence of wild-type miR-7a-5p sequence was rather surprising 
since we observed ~ 5-fold down regulation in the mature miR-7a expression levels. 
In order to address the anomaly between the sequencing and qPCR data for Clone 14, 
we performed a validation study to quantitate the expression levels of Psme3 and 
Rad54L as two potential miR-7 downstream targets, previously validated in our 
laboratory (Sanchez et al. 2013). In theory, Clone 14 would result in increased levels 
of expression of Rad54L and Psme3 compared to Clone 34 (if the qPCR data was not 
a false positive). Since Clone 14 had 5-fold less mature miR-7a expression than Clone 
34, in which the mature miR-7a expression levels were insignificantly down 
regulated. The down-regulated expression of both the genes in Clone 14, in 
comparison to control confirmed that it contains mature miR-7a-5p sequence intact 
and the RT-qPCR result for partial down regulation of mature miR-7a was a false 
positive. For Clone 34, the slightly increased levels of Rad54L and the sequencing 
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results further suggest the fact that it contains a heterozygous deletion in one of the 
miR-7a copy while the other was still expressed due to which the overexpression of 
both of these genes was not to a greater magnitude. However, we also believe that 
some genes require more than one miRNA to bind to regulate them. Perhaps the 
reduction in miR-7 via knockout strategy was not enough to observe upregulation of 
these two target genes.  Moreover, these genes were validated using mimic molecules, 
which could often lead to supra-physiological levels of miRNA and therefore, 
stronger repression of its targets, in contrast to stable depletion via miR-7 sponge or in 
our case of knocking miR-7a out (Baek et al. 2008, Selbach et al. 2008, Guo et al. 
2010, Ebert and Sharp 2012). 
We strongly believe that more questions regarding the nature and number of miR-7a 
copies knocked out, in the Clone 34 and rest of the 32, clones will be answered 
through next generation sequencing, which was beyond the scope of this project. As 
for future work, we believe it would be interesting to evaluate Clone 34 phenotype in 
a batch culture study. PCR and/or Sanger sequencing analysis of the rest of the 32 
clones would allow us perhaps to find more interesting clones. We also believe that 
increasing the number of single cell clones, from the mixed CHO 1.14 population 
chosen here, to be analyzed using RT-qPCR, PCR, and Sanger as well as maybe next 
generation sequencing would increase the probability of isolating clone/s containing a 
homozygous miR-7a knockout. If this is proved unsuccessful it may suggest that 
homozygous miR-7a deletion is lethal, and cannot be tolerated by cells. 
 
4.6 Multiplex CRISPR-Cas9 tools for the generation of isogenic CHO cell lines 
 
In addition to single guide CRISPR-Cas9 systems, we designed duplex CRISPR-Cas9 
system- GFP Duplex CRISPR containing sgGFP 1B and sgmiR7 2B guides. We 
achieved a range of indel efficiencies with the two-guide CRISPR-Cas9 system in-
one, i.e. one guide resulting in 35-40 %, while the other yielded ~ 20 % targeting 
efficiency. As mentioned earlier targeting an ORF of a protein gene is easier since 
only one bp knock out is enough to disrupt the reading frame of e.g. in the case of 
eGFP gene. For non-coding genes such as in the case of miR-7 (with two alleles 
located on two different chromosomal loci), where there are possibly four copies of 
the gene, we infer that it was a harder task to knock out all the four copies, hence, 
resulted in low indel efficiency of the second guide. We believe that multiplexing 
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CRISPR-Cas9 systems with further improvement in designing strategy could be an 
attractive tool to target other relevant miRNAs or any gene in one-go (Cong et al. 
2013). From our single guide miR7 CRISPR systems, we believe it is necessary to 
target miR-7a-5p sequence to introduce significant indels with greater frequency since 
single indels might not be enough to impact miRNA expression, hence, to render 
them functionless. For miRNA knockout we believe multiplex CRISPR-Cas9 
technology could, particularly be useful in deleting whole mature miRNA sequence in 
CHO cells. When these CHO cells with large knockouts are evaluated for bioprocess-
related phenotypes could yield interesting phenotypes in terms of growth and protein 
productivity. 
Irrespective of the technology used, miRNA manipulation to improve CHO cell 
phenotypes is a very promising tool to be further examined. Their striking ability to 
regulate hundreds of genes involved in complex cellular pathways such as cell cycle, 
metabolism, secretion and apoptosis, without imposing any burden on the cell’s 
translational machinery, make them attractive tools for the CHO cell engineering. 
Rightly so, investigators are continuing the process of evaluating miRNA roles in 
CHO cell cultures through the analysis of up/down regulation of endogenous miRNAs 
in CHO production cultures. Several groups have also successfully implemented the 
use of ectopic expression of miRs (mimics) or anti-miRs (inhibitors) synthetic 
molecules in CHO cells to improved bioprocess-related phenotypes (Greenlees et al. 
2014). However, until recently the lack of publically available CHO genomic data, as 
well as miRNA seriously stymied the progress of using miRNA for CHO cell 
engineering. We hope that with the availability of CHO genomic data and with novel 
genome-editing technology to manipulate miRNA in CHO cells we could achieve this 
objective. 
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Conclusions 
Study I: Stable depletion of endogenous Let-7 miRNA in CHO-K1 SEAP cells 
using sponge “decoy” vectors 
 
• Stable depletion of endogenous Let-7 levels was achieved and validated in 
CHO-K1 SEAP cells using a Let-7 sponge vector. 
• Let-7 depletion did not enhance growth characteristics in CHO-K1 SEAP 
clones though there was some evidence of improved viability and SEAP 
productivity in mixed population before cloning. 
• Impact of productivity could not be evaluated due to loss of SEAP transgene 
expression in CHO-K1 SEAP cells. 
 
Study II: CRISPR-Cas9 genome editing technology to knockout miR-7a-5p 
sequence in industrially relevant CHO cell line 
 
• 50 % targeting efficiency could be achieved using CRISPR-Cas9 to target a 
stably integrated eGFP gene in CHO-K1 cells. 
• 40 % targeting efficiency could be achieved using CRISPR-Cas9 to target 
miR-7a-5p locus in mAb-producing CHO cell line. 
• The length of sgRNA (19 or 20 nt) did not have a big impact on the nature and 
extent indels efficiency. 
• The location of target site (i.e. 5’ or 3’end of gene) did have an impact, with 
5’-end targeting resulting in marginally better targeting efficiency. 
• Isolated a clone containing heterozygous deletion of miR-7a. 
• ~ 30 % targeting efficiency could be achieved with a Duplex CRISPR-Cas9 
system in CHO-eGFP cell line. 
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Future Work 
 
• Analyse the impact of stable Let-7 depletion in other industrially relevant 
protein producing CHO cell lines. 
• Explore the potential of TMMP: By quantitating Let-7 levels immediately (or 
after fixed time intervals) after endogenous Let-7 sequestration by the Let-7 
sponge to assess and evaluate the role of TMMP in protecting endogenous 
Let-7 levels and the generation of the mature form of Let-7. This study could 
allow for a better understanding of TMMP in influencing miRNA levels and at 
what magnitude and after what time post-sponge transfection. 
• Use CRISPR-Cas9 system to knockout mature Let-7a sequence and/or other 
Let-7 family members in other relevant CHO cell lines using an efficient 
multiplex CRISPR-Cas9 system. Following this, studying the impact such 
knockout on CHO cell phenotypes in Batch and Fed-Batch mode of culture. 
• Use the CRISPR-Cas9 system to target the eGFP, and subsequently, in 
conjunction with HDR introduce a GOI (another protein encoding gene) at 
that target site in CHO-eGFP cell line to establish a targetable hyperproducing 
CHO cell line. 
• Evaluate the Clone 34 for growth and productivity characteristics. 
• Analyse the rest of the 32 single cell clones using PCR and Sanger as well as 
next generation sequencing to study the number and type of miR-7a indels 
observed. 
• Analyse more single cell clones from CHO 1.14 sgmiR7 2B mixed population 
using RT-qPCR, PCR, and next generation sequencing for the isolation of 
clone/s containing homozygous miR-7a knockout. 
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(A)                                                                          (B)   
 
Figure A1: PCR optimization for Surveyor Assay. (A) Gel image showing plasmid G and plasmid 
C from the Surveyor kit’s Internal control plasmids used to form amplicon of size 623 bp and 
px459 wt or reference eGFP, eGFP 1A and eGFP 1B PCR amplicons of size 800 bp from the 
genomic DNA extracted from px459 empty vector only plasmid DNA, eGFP 1A and eGFP 1B 
CRISPR transfected eGFP cells, respectively (B) Gel image showing eGFP 2A and eGFP 2B PCR 
amplicons of size 800 bp from the genomic DNA extracted from eGFP 2A and eGFP 2B CRISPR 
transfected eGFP cells, respectively. 
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(C) 
 
Figure A2: PCR optimization for Surveyor Assay. (C) Gel image showing miR-7 1A, miR-7 1B, 
miR-7 2A and miR-7 2B PCR amplicons of size 854 bp from the genomic DNA extracted from 
px459 empty vector only plasmid DNA, miR-7 1A, miR-7 1B, miR-7 2A and miR-7 2B CRISPR 
transfected 1.14 cells, respectively. 
 
 
 
 
 
 
 
	 242	
 
 
 
 
(A)                                                               (B) 
 
Figure A3: Diagnostic gels for eGFP 1B and miR-7 1B plasmid CRISPR DNA linearization. (A) 
eGFP 1B plasmid doubly digested with XbaI + Kpn I to linearize and generating ~ 9 Kb eGFP 1B 
backbone vector (B) miR-7 1B plasmid doubly digested with XbaI + Kpn I to linearize and 
generating ~ 9 Kb miR-7 1B backbone vector. 
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(C) 
 
Figure A4: Diagnostic gels for eGFP and miR-7 duplex CRISPR plasmid DNA preparation. (C) 
Left hand side of the gel image showing three positive eGFP duplex CRISPR samples with 450 
bp miR-7 2B guide RNA and U6 promoter sequence ligated along with XbaI + KpnI recognition 
sites, while right hand side of the image showing two positive miR-7 duplex CRISPR samples 
with 450 bp miR-7 2B guide RNA and U6 promoter sequence ligated along with XbaI + KpnI 
recognition sites. 
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Table A1: List of all the primers and oligo sequences used in this project 
Primer & Oligos 
Name 
Type Sequence (5’à3’ direction) 
 GFP_Cas1s Sense sequence 
for cloning 
GATCGAGGGCGAGGAGCTGTTCACCG 
GFP_Cas1as Sequence for 
cloning 
AAAACGGTGAACAGCTCCTCGCCCTC 
GFP_Cas2s Sequence for 
cloning 
GATCGGCGCGATCACATGGTCCTGCG 
GFP_Cas2as Sequence for 
cloning 
AAAACGCAGGACCATGTGATCGCGCC 
GFP1F GFP sequence 
primers 
GACTCCACGGAGTACCGG 
GFP1R GFP sequence 
primers 
GTGGGCCATGATATAGACGTT 
GFP2F GFP sequence 
primers 
GCGCACCATCTTCTTCAAG 
GFP2R GFP sequence 
primers 
GCTGAGCCTGGTCATGCAT 
px459_R640 Duplex 
CRISPR for 
sequencing 
GCCATTTACCGTCATTGACGTC 
px459_R423_K Duplex 
CRISPR for 
sequencing 
GGGGTACCTTGTCTGCAGAATTGGCGCACG 
px459_F1_Xba Duplex 
CRISPR for 
sequencing 
GCTCTAGAGAGGGCCTATTTCCCATGATTC 
miR7_F_a459 miR7 sequence 
primers 
CCTGTCCATGCAATTAGAGGC 
miR7_R_a1520 miR7 sequence 
primers 
CAGACATTGCAGACCATCCAG 
miR7_F_b586 miR7 sequence 
primers 
AGCTATGGGTTATGCGCTCT 
miR_7_R_b1440 miR7 sequence 
primers 
TGTTACCTGCCCTCCATGAG 
miR7_F_131 upstr miR7 sequence 
primers 
CAAGGAGTTTTGGGGTGTGG 
miR7_R_seed seq miR7 sequence CAACAAAATCACTAGTCTTCC 
	 245	
primers 
miR7_CRIS_R miR7 sequence 
primers 
CTCCCATACCTCCCCCTGATG 
miR7_Loop_R miR7 sequence 
primers 
TGAGTATAGAGAGACAACAAC 
Cgr-premir7a_F Premir7a 
sequence 
primer 
CCACAGGAGGTGGTTAGCAA 
Cgr-premir7a_R Premir7a 
sequence 
primer 
ATCCAGAAATGGTGCTCCCA 
Cgr-premir7b_F Premir7b 
sequence 
primer 
TGAGCGTGTGAGCCAGTGCTAT 
Cgr-premir7b_R Premir7b 
sequence 
primer 
GGAGAAAGGTGAAAGGAGTCCAC 
Cgr-miR7b_F miR7b 
sequence 
primer 
TCCTCCTGCCTCTACTTCCT 
Cgr-miR7b_R miR7b 
sequence 
primer 
CGTTGACTTTGCCAGACTCC 
CDC7_F CDC7 gene 
primer 
CATCTGACCTTCCCTCCAAA 
CDC7_R CDC7 gene 
primer 
GATACGGCATGGCAATAACC 
Rad54_F Rad54L gene 
primer 
CCATTAAGAAGCGAGCCAAG 
Rad54_R Rad54L gene 
primer 
GGGTTCCAGTCAGGATCAAA 
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wt eGFP sequence 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG  
 
wt eGFP sequence reverse complement 
 
CTACTTGTACAGCTCGTCCATGCCGAGAGTGATCCCGGCGGCGGTCA
CGAACTCCAGCAGGACCATGTGATCGCGCTTCTCGTTGGGGTCTTTG
CTCAGGGCGGACTGGGTGCTCAGGTAGTGGTTGTCGGGCAGCAGCAC
GGGGCCGTCGCCGATGGGGGTGTTCTGCTGGTAGTGGTCGGCGAGC
TGCACGCTGCCGTCCTCGATGTTGTGGCGGATCTTGAAGTTCACCTT
GATGCCGTTCTTCTGCTTGTCGGCCATGATATAGACGTTGTGGCTGTT
GTAGTTGTACTCCAGCTTGTGCCCCAGGATGTTGCCGTCCTCCTTGAA
GTCGATGCCCTTCAGCTCGATGCGGTTCACCAGGGTGTCGCCCTCGA
ACTTCACCTCGGCGCGGGTCTTGTAGTTGCCGTCGTCCTTGAAGAAG
ATGGTGCGCTCCTGGACGTAGCCTTCGGGCATGGCGGACTTGAAGAA
GTCGTGCTGCTTCATGTGGTCGGGGTAGCGGCTGAAGCACTGCACGC
CGTAGGTCAGGGTGGTCACGAGGGTGGGCCAGGGCACGGGCAGCTT
GCCGGTGGTGCAGATGAACTTCAGGGTCAGCTTGCCGTAGGTGGCAT
CGCCCTCGCCCTCGCCGGACACGCTGAACTTGTGGCCGTTTACGTCG
CCGTCCAGCTCGACCAGGATGGGCACCACCCCGGTGAACAGCTCCTC
GCCCTTGCTCACCAT 
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GFP 1A2- 1 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1A3- 3 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1A4- 15 bp deletion + 204 bp eGFP sequence insertion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
	 248	
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1A6- 4 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG  
 
GFP 1A7- 4 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1A9- 27 bp deletion  
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ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1A12- 4 bp deletion + 69 bp insertion  
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1A13- 1 bp deletion Exactly the same as GFP 1A2. 
 
GFP 1A14- 3 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
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CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1A15- 12 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
GFP 1B1- 18 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1B4- 27 bp deletion     
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ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1B6- 19 bp deletion    
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1B9- 18 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
	 252	
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1B12- 13 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
GFP 1B11- 2 bp insertion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 1B7- 27 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
	 253	
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
 
GFP 1B8- 15bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
GFP 2A1- 1 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
	 254	
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
GFP 2A2- 1 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP 2A3- 1 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG  
 
GFP2A4- 15 bp insertion & 118 bp deletion = 132 indels 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
	 255	
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTC…………………TT
GGCATGGACGAGCTGTACAAGTAG 
 
GFP2A5- 7 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP2A6- 26 bp deletion- randomly 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
	 256	
GFP2A7 & 2A8-  No indels detected. 
 
GFP2A9- 1 bp insertion + sequence not good enough 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTTGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP2A10- No indels detected. 
 
GFP2A11- 1 bp insertion  
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGAGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP2B3- 1 bp insertion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
	 257	
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
CCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP2B4- BAD Sequence 
 
GFP2B5- 1 bp insertion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
CCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
 
GFP2B6- 1 bp insertion off-target & 102 bp deletion on target, however, deletion 
downstream of eGFP target sequence as well. 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACTCCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
	 258	
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
GFP2B7- no indels detected. 
 
 
GFP2B8 – 2 bp insertion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
GFP2B9- 3 bp deletion 
 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
GFP2B10- no indels detected. 
	 259	
 
 
GFP2B11- 12 bp insertion & 19 bp deletion = 31 bp indels 
 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCATCTAGAAGCGCGATCACATGG
CCCACATGGAGTTCAAGTTCGCCGCCGGGCTCACTCTTGGCATGGAC
GAGCTGTACAAGTAG 
 
 
GFP2B12- 1 bp deletion 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
GFP2B13- no indels detected 
 
GFP2B14- Sequence not good enough. 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
	 260	
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCT
GGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTC
ATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGAC
CACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACA
TGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTC
CAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCG
CGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAG
CTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAA
GCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCG
AGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCC
ATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCAC
CCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGG
TCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGAC
GAGCTGTACAAGTAG 
 
 
 
Cgr-miR-7 CRISPR sequencing results 
 
cgr-miR-7a-5p locus sense 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
Protospacer 
Cleavage site 
Mature miR-7 
Loop 
	 261	
Star Strand 
 
 
miR-7a flanking sequence ~2.224 kb 
 
>gi|351515069:117788-120011 Cricetulus griseus unplaced genomic scaffold, 
CriGri_1.0 scaffold4923, whole genome shotgun sequence 
 
AAAAGTATCAACTGTTCCTACTACCCACTTTTGGCTCAGCAGCCCAGT
TAGACTTGTTCTTTAGCATACA 
CTGAAGTCGATCCTCACAGTGGTCCTGGGTTAGAACTGGGGACGTAC
CTTGCATCCTCCACAAAGCGCTT 
TTTAGAGTGTAGAACTGTGCCCCATCCCAGGCTCTGGGCTATGAAAG
GGTTGGACTGAGAGGCCTTCCCC 
ACCCCATTTGTCGATGACTTTCTCCATGTCCAGGCAAGCCCTTCCCCA
GTCTAGATGAACAGAACAAATC 
AAAGGATGGAGGAGGGGTGGGGCAAAGAGAATGAGCTAGCAATTAA
AAGGCAAAAGAATTAAAAGCACCA 
ATCAGGAAGGGTAATAATCCTTCAGCTGCTGCAGAAATACAATTAGA
GCCATGCGCTCTTGGAGTTGCCA 
GGATATTGTGGCTTTTCCTAATTAAGGAGCGGATGTGCCCTGTCCATG
CAATTAGAGGCTGGCTCAGGCA 
GTGGGGGCCCTGCCTACCTTTTATCAACGTACTACAAGGGGAATTAA
CCAACAATACAGCCTATGTCCCC 
TGCCTAGTAGTCCCACTTGACTCTGAGCTATGGGTTATGCGCTCTGG
GAAGATGTTCACCTTGGGTTCTG 
GGGACCCTTGGGAAGGGGAGAAGAGGCCTGGGGTAGGCACTACTTG
GAGCTTTTTCTTTTATCTATTCTC 
TGTGGTAGTGCAGGGTTTTATGATACCTGAAGAAAATATGGAGACAT
GAGCTGCCCACCTGCTTTCCATG 
AGAAATAAGATTCCCCTAAGATTAAAGGAAGCGTCTTCACTGTGGAA
AATAGGAGGAGAAAAAAAAGGGG 
ATTTCTCCTCCATTTGGAGCCAGAGACTCCAAGGAGTTTTGGGGTGT
GGGGGGTACATGGGGCGGGGAGG 
TGTATGGGGTGGTGCAGTGGAGAACATAAGGAAAGTAGAGGGCATG
GGGAAAGACGCTGGCCTCCCCACA 
GGAGTATCCAGATGATAACAGGTGGTGGCCAAGGCCCAGAGGAGGT
GGTTAGCAAGGCCATGGACAGGCC 
AGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCA
ACAACAAGTCCCAGTCTACCAC 
ACGGTGCGGGTCCTCTGAGCATCAGGGGGAGGTATGGGAGCACCATT
TCTGGATGTATTTTCTCTGCCTT 
CTATGTTCCCTAGCAAACTACCAAAATATTCCTCTAAGGCCTGGGCTG
AAGACACCTCAGGGGGACTCCT 
CCAGAAACGAGTACACTGAATCTAGAGTGGGGCAGGGGACAGGATGT
CTGTCCTCAGGGAATGGTGAGCG 
ACTCTGCATCCACACACCCTCCCATGGGCTTATTCATTCACCCTGCAA
GCTCCTCCTTGGTGAGAGACAC 
CACAGGGCCAACACACAGGGCTCATGGAGGGCAGGTAACAGTGTGTA
CTAGCACAGGCACATGTCCCTAT 
	 262	
CACCTTTTGGGCAAGTGGGCCACCCGATCCTGGATGGTCTGCAATGT
CTGTGCCTGCCTGTGGGGCATAA 
TGATATAGAAAAAAACTCCTCACTGCCAATAAATGGAATTTTGGAAGC
CCTGTCTGCTGCCTGTGCTTGG 
AGGCCCCCTCAATGGCAGAAGTAGTCATTTCCCCACAAATGTGGCAG
CATATGCCTTTAATTCCATCACT 
CAGTAAGGCTTCTGTGTGTAAACCTGTCTTAAAAGGGGAAGGAAGGA
AGGAAGGAAGGAAGGAAGGAAGG 
AAGGAAGGAAGGAAGGAAGGAAAGAAGGAAAGAAGGAAAGAAGGAA
GGAAGGAAGGAAACCCTTCACAGC 
CCTCCATCCTTTCTGGGTGTCATGTAGCCCAGGCTGGTCTTCAGTTAC
CTACACAGCTCTCCATCCTTTC 
TGGGTGTCATGTAGCCCAGGCTGGTCTTCAGTTACCTATGTAGCTGA
GGATGATCCTGAACTCTGTTCTT 
CCTGCTTCTGCCCCAAATGCTGGAATTACAGGCATGTGCAATCATACT
CGGTTTATGCAGTGCTGGGGCA 
CAAACCCAAGGCTTCACACAAGAGAAGCAAGCACTCTACCACTTGAG
TCCTTCAGCCCTTCTCTTTGCTT 
CTCTTCTTTTCCTCCTCTCCCACTCCCTCCATCCTGACATTCATTCATT
CATTTGCACTACTGGAAATAG 
AACCTAGGGTTCTGTGCTCTCTTCTTTTCCTCCTCTCCCACTCCCTCC
TTCCTG 
 
 
 
 
 
 
 
 
miR-7 1B1: 177 bp deletion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC--------- 
 
miR-7 1B2: Non-specific PCR product into TOPO-TA vector 
 
miR-7 1B3: Incomplete sequence. 
 
miR-7 1B4: 2 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCA
ACAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGG
GAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCC
CTAGCAAACTACCAAAATATTCCTC 
 
	 263	
miR-7 1B5: 1 bp deletion 
 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 1B6: Incomplete sequence. 
 
 
miR-7 1B7: 1 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 1B8: 1 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 1B9: 1 bp insertion 
 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 1B10: Non-specific PCR product into TOPO-TA vector 
 
3652440 order 
 
miR-7 1B7: negative 
 
miR-7 1B8: 1 bp mismatch mutation +  1 bp insertion + 4 bp deletion 
 
GGTGGTGGCCAAGGCCCAGGGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATGTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
	 264	
 
 
 
miR-7 1B9: 1 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 1B10 & 11: 5 bp deletion same for both the samples. 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 1B12:  25 bp deletion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 1B13: 6 bp mismatch mutations 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCCCTCTACACTCAA
CAACAAGTCCCAGCCGACCACACGGAGCGGGTCCACTGAGCATCAGGGG
GAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCC
CTAGCAAACTACCAAAATATTCCTC 
 
 
 
 
miR-7 2B1: 127 bp deletion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 2B2: 8 bp deletion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
	 265	
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 2B3: 16 bp deletion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 2B4: Incomplete sequence 
 
miR-7 2B5: 2 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCACATCAGGGG
GAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCC
CTAGCAAACTACCAAAATATTCCTC 
 
 
 
miR-7 2B6: 7 bp mismatch mutations + possibility for more, however could not 
observe due incomplete amplification of sequencing results. 
 
GGTGGTGGCCAAGGCCTGGAGGAGGTGGTCCGTAGGGCTATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
 
miR-7 2B7: 1 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCAATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
 
miR-7 2B8: 17 bp mismatch mutations and 1bp insertion 
 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTATGTATACTCAAC
AACAAGTTCCATTTTACCTCAACAACAAGTTCCTGTGTGCCACCAGGGGG
	 266	
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 2B9: DID NOT ALIGNà BAD 
 
 
miR-7 2B10: 89 bp and 160 bp deletion downstream of miR-7a sequence deletion  
 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC………………..160 bp downstream miR-7a 
sequence…. 
 
 
miR-7 2B11: 1 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCAATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
 
miR-7 2B12: 240 bp deletion : 169 bp in the miR-7a sequence + 71 bp upstream of 
the miR-7 sequence. 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
 
 
 
 
 
 
miR-7 1A1: 1 bp insertion + 6 bp deletion + 18 bp mismatch and 1 bp insertion, 9 bp 
deletion and 16 bp mismatch mutations + just few bp upstream of the sequence 
 
upstrmidm…….GGTAGTATCCAAGGATGATAACAGGTGGTGGCCAAGGCCC
AGAGGCAGGCCTGGTCAGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTC
TATACTCAACAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGC
ATCAGGGGGAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTC
TATGTTCCCTAGCAAACTACCAAAATATTCCTC 
 
	 267	
 
miR-7 1A2: 1 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 1A3: Incomplete sequence. 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
Order 3652440 
 
miR-7 1A3: 5 bp deletion + 1 bp mismatch mutation 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCGCCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 1A4: 1bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 1A5: 1bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 1A6: 1bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
	 268	
miR-7 1A7: 1bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 1A8: 1bp insertion + 1 bp mismatch mutation 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCGCCTGGAAGACTAGTGATTTCGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 1A9: 64 bp deletion + 32 bp upstream of miR-7a sequence 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 1A10: 2bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCA
ACAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGG
GAGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCC
CTAGCAAACTACCAAAATATTCCTC 
 
miR-7 1A11: 18 bp deletion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
 
 
miR-7 2A1: 3 bp deletion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
	 269	
 
miR-7 2A2: 1 bp deletion + 1 bp insertion and possibility for more, however, 
incomplete sequence further downstream….. 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAGAGGCCATGGACAGG
CCAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAA
CAACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
 
miR-7 2A3: 1 bp insertion 
 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCAATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
 
miR-7 2A4: 1 bp insertion same as above 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 2A5: 1 bp insertion same as above 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
 
miR-7 2A6: 6 bp deletion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
miR-7 2A7: 5bp mismatch + 1 bp deletion and possibility for more, however, 
downstream seq info incomplete. 
 
 
	 270	
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGAAAGGCTCTGGACAGGT
CAGCCCTGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
 
miR-7 2A8: 1 bp mismatch, however, possibility for more incomplete sequence 
downstream  
 
 
GGTGGTGGCCAAGGCGCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCATCAGGGGGA
GGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCTA
GCAAACTACCAAAATATTCCTC 
 
 
miR-7 2A9: 1 bp deletion + 1 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCAATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
miR-7 2A10: 1 bp insertion 
 
GGTGGTGGCCAAGGCCCAGAGGAGGTGGTTAGCAAGGCCATGGACAGGC
CAGCCCCGCCTGGAAGACTAGTGATTTTGTTGTTGTCTCTCTATACTCAAC
AACAAGTCCCAGTCTACCACACGGTGCGGGTCCTCTGAGCAATCAGGGGG
AGGTATGGGAGCACCATTTCTGGATGTATTTTCTCTGCCTTCTATGTTCCCT
AGCAAACTACCAAAATATTCCTC 
 
 
 
 
 
 
 
 
 
 
 
 
	 271	
 
 
